

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

18th July 2025

To,

Listing Compliance Department Metropolitan Stock Exchange of India Ltd. Building A, Unit 205A, 2nd Floor, Piramal Agastya Corporate Park, L.B.S Road, Kurla West, MUMBAI - 400 070

Dear Sir,

<u>Sub: Submission of Notice of 102nd Annual General Meeting (AGM) and Annual Report for the</u> <u>Financial Year 2024-2025</u>

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Notice of 102nd Annual General Meeting (AGM) of the Company to be held on Monday, 11th August, 2025 at 4.00 pm, at Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeswanthpur, Bengaluru- 560022.

In accordance with Ministry of Corporate Affairs General Circular nos. 20/2020, 14/2020, 17/2020, 02/2021 and Securities and Exchange Board of India ('SEBI') vide its Circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 and SEBI/HO/CFD/CMD2/CIR/P/2021/11, Notice is being sent only through electronic mode to members of the Company, whose email ID is registered. Further, the notice is also uploaded on website of the Company at <u>www.afdil.com</u>

As per provisions of Section 108 of the Companies Act, 2013 and Rule 20 of Companies (Management and Administration) Rules, 2014, the Company is availing e-voting services of NSDL for providing remote e-voting facility to its Members.



Contd ... 2.

Registered Office: Plot No.4, Phase II, Peenya Industrial Area, Peenya, BENGALURU-560058 Tel: 080-41170134, E-Mail:contact@afdil.com, Website: <u>www.afdil.com</u> CIN No.: L24230KA1923PLC010205, GST No.: 29AAACA9756E1Z



ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

-2-

The Schedule of events for e-voting are as follows:

:	Monday. 4 th August 2025	
:	Monday, 4 th August 2025	
:	Tuesday, 5th August 2025 to	
	Monday, 11 th August 2025 (Both days inclusive)	
:	Friday, 8 th August 2025	
:	9:00 am	
:	Sunday, 10 th August 2025	
:	5:00 pm	

Kindly take the above information on your records.

Thanking you,

Yours faithfully, For Anglo-French Drugs & Industries Ltd.,

Sriee Aneetha.M **Company Secretary & Compliance Officer**

Encl:a.a

102nd **АЛЛИАЦ ВЕРОВТ** 2024-25



Board of Directors:

Mr. Abhay Kanoria Mr. Uddhav Abhay Kanoria Mr. Nirbhay Abhay Kanoria Mr. Rakesh Parmeshwar Kanyadi Mr. Rohit Choraria Mrs.Rani Shokeen Mr. Srinivasan Krishnan Mr. Pradeep Joshi Mrs. Jayashree V.Ranade Mr. Ahmedali Nalagath

Chief Financial Officer

Mr. Nirbhay Abhay Kanoria (upto 12-08-2024) Mr. Manik Kumar Singh (w.e.f 29-07-2024)

Secretarial Auditors

M/s. Raghavendra Naveen BK, **Practicing Company Secretary**

Bankers

HDFC Bank Limited YES Bank Limited

Registered Office

Anglo-French Drugs & Industries Limited CIN:L24230KA1923PLC010205 Plot No.4, Phase-II, Peenya Industrial Area, Peenya, Bengaluru - 560058 Tel Nos. 080-23154770 / 23156757

Chairman & Managing Director (upto 20-03-2025) and re-designated to Chairman (w.e.f 20-03-2025) President & Whole-Time Director (upto 20-03-2025) and re-designated to Managing Director (w.e.f 20-03-2025) President & Whole-Time Director (upto 20-03-2025) and re-designated to Managing Director (w.e.f 20-03-2025) Non-Executive & Non-Independent Director (upto 07-11-2024) Non-Executive & Non-Independent Director Independent Director (w.e.f 28-05-2024) Independent Director Independent Director Nominee Director (upto 30-04-2024) Independent Director (upto 12-08-2024)

Statutory Auditors

Internal Auditors

M/s. KAMG & Associates

M/s. B. Choraria & Mates

Chartered Accountants

Chartered Accountants

Company Secretary

Mrs. Sriee Aneetha. M

Cost Auditors

M/s. Sandhya P & Co., **Cost Accountants**

Factory / Plant Address

Plot No.4, Phase-II, Peenya Industrial Area, Peenya, Bengaluru - 560058.

Registrars & Share Transfer Agents

New RTA w.e.f 06-12-2024 Integrated Registry Management Services Private Limited, 30, Ramana Residency 4th Cross, Sampige Road, Malleswaram, Bangalore - 560 003 Tel: +91-80-23460815-818 | Fax: +91-80-23460819 Email: irg@integratedindia.in

Old RTA upto 06-12-2024 Canbank Computer Services Limited J P Royale, 1st Floor, No.218, 2nd Main, Sampige Road, (Near 14th Cross), Malleswaram, Bengaluru - 560003 Tel Nos. :080-23469661/62/64/65 Fax No. 080-23469667 Email: Canbankrta@ccsl.co.in

Stock Exchange

Metropolitan Stock Exchange of India Limited (MSE)

Investor Grievance Contact

Email Id: Compliance@afdil.com Tel No. 080-23156757

Contents	Page Nos
Notice	2
Board's Report	13
Corporate Governance Report	28
Management Discussion and Analysis Report	36
Independent Auditor's Report	40
Statement of Assets and Liabilities	47
Statement of Profit and Loss	48
Cash Flow Statement	49
Notes to Financial Statements	52

1

Anglo-French Drugs & Industries Limited

Registered Office: Plot no.4, Phase II, Peenya Industrial Area, Peenya, Bengaluru 560058.

CIN:L24230KA1923PLC010205 Websie:www.afdil.com

NOTICE CONVENING 102nd ANNUAL GENERAL MEETING

NOTICE is hereby given that the 102nd Annual General Meeting of the Members of Anglo-French Drugs & Industries Limited ("Company") will be held on Monday, the 11th August 2025 at 4.00 pm at Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeshwanthpur, Bengaluru- 560022 Karnataka to transact the following business;

ORDINARY BUSINESS:

- 1. To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended 31st March 2025 together with the Report of the Board of Directors and Auditors thereon.
- 2. To declare final dividend on equity shares for the financial year ended 31st March 2025.
- To appoint a Director in place of Mr. Rohit Choraria, DIN: 07003583, who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

4. Appointment and ratification of remuneration of Secretarial Auditors of the Company

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**

RESOLVED THAT, pursuant to Section 204 of the Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 24(A)(1) of SEBI LODR (as amended) and based on the recommendation of the Board of Directors of the Company M/s. Rao and Associates, Partner Mr. Raghavendra Naveen B K, Practicing Company Secretary M.No.59814 CP No.23728, be and are hereby appointed as the Secretarial Auditor of the Company to hold office for first term of 5 years from the conclusion of the 102nd AGM until the conclusion of the 107th AGM, on such remuneration as may be decided by the Board of Directors of the Company.

5. Appointment and ratification of remuneration of Cost Auditors of the Company for the Financial Year 2025-26

To consider and if thought fit, to pass the following resolution as an **Ordinary Resolution**

RESOLVED THAT pursuant to the provisions of Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013, Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), the appointment of M/s. Sandhya P & Co., Cost Accountants Firm Registration No. 004755 as Cost Auditors of the Company and as approved by the Board on the recommendation of the Audit Committee, to conduct the audit of Cost records of the Company for the Financial year 2025-26 and ratification of remuneration payable to them amounting to Rs.70,000/- pa (Rupees Seventy Thousand Only) plus taxes and reimbursement of out of pocket expenses in connection with the aforesaid audit be and is hereby ratified and confirmed.

6. Advancing/granting any loan, giving any guarantee and/or providing any security to all such person specified under

section 185 and 186 of the Companies Act, 2013 up to an aggregate limit of Rs.300 crores

To consider and, if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution**

RESOLVED THAT pursuant to Section 185, 186 and other applicable provisions if any, of the Companies Act, 2013 and relevant rules made thereto (including any statutory modification(s) or re-enactments thereof, for the time being in force) and subject to such approvals and permissions as may be necessary, approval of the members be and is hereby accorded to the Board of Directors of the Company (hereinafter referred to as the "Board" which term shall include any Committee constituted by the Board or any person(s) authorized by the Board to exercise its powers, including the powers conferred by this Resolution), to advance any loan(s) in one or more tranches including loan represented by way of book debt and/or to give any guarantee(s) and/or to provide any security(ies) in connection with any financial assistance/ loan taken/to be taken/availed/to be availed by any entity which is a Subsidiary/ Associate/Joint Venture or such other entity/person as specified under Section 185 and 186 of the Companies Act, 2013 and more specifically to such other entity/person as the Board of the Directors in its absolute discretion deems fit and beneficial and in the best interest of the Company (hereinafter commonly known as the Entities); all together with in whom or in which any of the Director of the Company from time to time is interested or deemed to be interested; provided that the aggregate limit of advancing loan and/or giving guarantee and/or providing any security to the entities shall not at any time exceed Rs.300 crores (Rupees Three hundred crores only).

RESOLVED FURTHER THAT the aforementioned loan(s) and/or guarantee(s) and/or security(ies) shall only be utilized by the borrower(s) for the purpose of its principal business activities.

RESOLVED FURTHER THAT the Board of Directors or Company Secretary of the Company be and is hereby authorized to do all such acts, deeds, things and execute all such documents, instruments, writings, in its absolute discretion, as may be considered necessary, expedient or desirable, in order to give effect to all the above resolutions or otherwise as considered by the Board to be in the best interest of the Company as it may deem fit."

> By Order of the Board of Directors For Anglo-French Drugs & Industries Limited

Date: 02nd May 2025 Place: Bengaluru

> Sriee Aneetha. M Company Secretary & Compliance Officer

Registered Address:

Plot No.4, Phase – II, Peenya Industrial Area, Peenya, Bengaluru – 560058.

Notes:

- 1. In view of the continuing COVID-19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide its General Circular nos. 20/2020, 14/2020, 17/2020, 02/2021 and Securities and Exchange Board of India ('SEBI') vide its Circular no. SEBI/ HO/CFD/CMD1/CIR/P/2020/79 and SEBI/HO/CFD/CMD2/ CIR/P/2021/11 (hereinafter collectively referred to as "the Circulars"), has permitted that Notice of the AGM along with the Annual Report 2024-25 be sent through electronic mode. In view of this, Notice along with Annual report is being sent only through electronic mode to those Members whose e-mail addresses are registered with the Company or RTA or CDSL / NSDL ("Depositories"). Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website www.afdil.com and website of the Stock Exchange - MSEI Limited at www.msei.in
- The relative explanatory statement pursuant to Section 102 of the Companies Act, 2013, and Rules made thereunder in respect of the Special Business set out in the notice, Secretarial Standards on General Meeting (SS-2), whenever applicable, and SEBI(LODR) Regulations, 2015 whenever applicable, is annexed hereto.
- 3. IN TERMS OF SECTION 105 OF THE COMPANIES ACT, 2013 A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER AND THE PROXY FORM, TO BE EFFECTIVE, MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY AT LEAST 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.
- 4. Proxies submitted on behalf of the Companies, Societies etc., must be supported by an appropriate resolution/authority, as applicable. Members, Proxies and Authorized Representatives are requested to bring to the meeting the enclosed Attendance Slip duly completed and signed, mentioning therein details of their DP ID and Client ID/ Folio No.
- Corporate Members intending to attend the AGM through their authorized representatives are requested to send a certified copy of the board resolution authorizing their representative to attend and vote on their behalf at the meeting.
- 6. Notice of the said Meeting along with Annual Report, Attendance Slip, Proxy Form and Route map for venue of the Meeting are being sent by electronic mode to all those members whose e-mail addresses are registered with the Company/RTA or Depositories for communication purposes unless any member has requested for a hard copy of the same.
- 7. Green Initiative: To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their DPs in case the shares are held by them in electronic form and with the Registrar & Transfer Agents, M/s. Integrated Registry Management Services Private Limited in case the shares are held by them in physical form.
- 8. In compliance with the aforesaid MCA Circulars and SEBI Circular, the Notice of the 102nd AGM and other documents are being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. Therefore, those Members, whose email address is not registered with the Company or with their respective Depository Participant/s, and who wish to receive the Notice of the 102nd AGM and the Annual Report for the year 2024-25 and all other communication sent by the Company, from time to time, can get their email address registered by following the steps as given below:-

Anglo-French Drugs & Industries Limited

- a) For Members holding shares in physical form, please send scanned copy of a signed request letter mentioning your folio number, complete address, email address to be registered along with scanned self- attested copy of the PAN and any document (such as Driving License, Passport, Bank Statement, AADHAR) supporting the registered address of the Member, by email to the Company's email address at: compliance@afdil.com
- For the Members holding shares in demat form, please update your email address through your respective Depository Participant/s.

9. Dividend related information:

The final dividend of ₹1.50 per fully paid-up Equity share of ₹10/- each @15% for the Financial year 2024-25 as recommended by Board of Directors, if approved by the Members at the AGM, will be paid subject to deduction of income-tax at source ('TDS') on or after Thursday, 14th August 2025 to those members whose names appear on the Register of Members as on Monday, 4th August 2025.

- Members holding shares in electronic form are hereby informed that bank particulars registered with their respective Depository Participants (DP), with whom they maintain their demat accounts, will be used by the Company for payment of dividend.
- 11. Members holding shares in physical/electronic form are required to submit their bank account details, if not already registered, as mandated by SEBI.
- 12. Shareholders holding shares in dematerialized mode are requested to register complete bank account details with the Depository Participant(s).
- 13. SEBI, vide its circular dated 3rd November, 2021 (subsequently amended by circulars) mandated that the security holders (holding securities in physical form), whose folio(s) do not have PAN or Choice of Nomination or Contact Details or Mobile Number or Bank Account Details or Specimen Signature updated, shall be eligible for any dividend payment in respect of such folios, only through electronic mode with effect from 1 April, 2024, only upon furnishing the PAN, choice of nomination, contact details including mobile number, bank account details and specimen signature.

Further, relevant FAQs published by SEBI on its website can be viewed at the following link : https://www.sebi.gov.in/ sebi_data/faqfiles/jan-2024/1704433843359.pdf

- 14. Members may note that as per the Income Tax Act, 1961, as amended by the Finance Act, 2020, dividends paid or distributed by the Company after 1st April 2020, shall be taxable in the hands of the shareholders and the Company shall be required to deduct tax at source (TDS) at the prescribed rates from the dividend to be paid to shareholders, subject to approval of shareholders in the ensuing AGM. The TDS rate would vary depending on the residential status of the shareholder and the documents submitted by them and accepted by the Company.
 - All Shareholders are requested to ensure that the below information & details are completed and/or updated, as applicable, in their respective demat account(s) maintained with the Depository Participant(s);

Please note that the following information & details, if already registered with RTA and Depositories, as the case may be, will be relied upon by the Company, for the purpose of complying with the applicable TDS provisions:

I. Valid Permanent Account Number (PAN)*

Annual Report 2024-25

- II. Residential status as per the Income Tax Act i.e. Resident or Non-Resident for FY 2024-25.
- III. Category of the Shareholder viz. Mutual Fund, Insurance Company, Alternate Investment Fund (AIF) Category I and II, AIF Category III, Government (Central/State Government), Foreign Portfolio Investor (FPI)/Foreign Institutional Investor (FII): Foreign Company, FPI/FII: Others (being Individual, Firm, Trust, Artificial Juridical Person, etc.), Individual, Hindu Undivided Family (HUF), Firm, Limited Liability Partnership (LLP), Association of Persons (AOP), Body of Individuals (BOI) or Artificial Juridical Person, Trust, Domestic Company, Foreign Company, Overseas Corporate Bodies, etc.
- IV. Email Address.
- V. Residential Address.

*If the PAN is not as per the database of the Income-tax Portal, it would be considered as invalid PAN. Further as per the Notification of Central Board of Direct Taxes, individual shareholders are requested to link their Aadhaar number with PAN.

b. For Resident Shareholders, TDS is required to be deducted at the rate of 10% under Section 194 of the Income TaxAct, 1961 on the amount of dividend declared and paid by the Company in the financial year 2025-26 provided valid PAN is registered by the Shareholder. If the valid PAN is not registered, the TDS is required to be deducted at the rate of 20% under Section 206AA of the Income TaxAct, 1961.

However, in case the dividend is not exceeding ₹ 5,000 in a fiscal year to resident individual shareholder then no tax will be deducted from the dividend. If any resident individual shareholder is in receipt of Dividend exceeding ₹ 5,000 in a fiscal year, entire dividend will be subject to TDS @ 10%.

Even in the cases where the shareholder provides valid Form 15G (for individuals, with no tax liability on total income and income not exceeding maximum amount which is not chargeable to tax) or Form 15H (for individual above the age of 60 years with no tax liability on total income), no TDS shall be deducted.

c. For Non-resident shareholders [Including Foreign Institutional Investors (FIIs)/Foreign Portfolio Investors (FPIs)], the TDS is required to be deducted at the rate of 20% (plus applicable surcharge and cess) under Section 195 or 196D of the Income Tax Act, 1961, as the case may be. Further, as per Section 90 of the Income Tax Act, 1961, the non-resident shareholder has the option to be governed by the provisions of the Double Tax Avoidance Treaty between India and the country of tax residence of the shareholder, if they are more beneficial to them.

For this purpose, i.e. to avail Tax Treaty benefits, the non-resident shareholders will have to provide the following:

- I. Self-attested copy of the PAN allotted by the Indian Income Tax authorities;
- Self-attested copy of valid Tax Residency Certificate obtained from the tax authorities of the country of which the shareholder is a resident;
- III. Self-declaration in Form 10F; and

- IV. Self-declaration in the attached format certifying:
- Shareholder is and will continue to remain a tax resident of the country of its residence during the Financial Year 2024-25;
 - Shareholder is eligible to claim the beneficial Double Taxation Avoidance Agreement (DTAA) rate for the purposes of tax withholding on dividend declared by the Company;
 - Shareholder has no reason to believe that its claim for the benefits of the DTAA is impaired in any manner;
 - Shareholder is the ultimate beneficial owner of its shareholding in the Company and dividend receivable from the Company; and
 - Shareholder does not have a taxable presence or a permanent establishment in India during the Financial Year 2024-25.
- The draft of the aforementioned documents may also be accessed from the Company's website at www.afdil.com.
- e) Submission of tax related documents: Resident Shareholders

The aforesaid documents such as Form 15G/15H, documents under Sections 196, 197A, etc. can be uploaded on the link https://ipostatus. integratedregistry.in/TaxExemptionRegistration. aspx on or before **Friday**, **01st August 2025** to enable the Company to determine the appropriate TDS/withholding tax rate applicable. Any communication on the tax determination/ deduction received post **Friday**, **01st August 2025** shall not be considered.

Shareholders can also send the scanned copies of the documents mentioned above at the email id mentioned below:

Email ID: irg@integratedindia.in	Email ID:	irg@integratedindia.in
----------------------------------	-----------	------------------------

Non-Resident Shareholders

Shareholders are requested to send the scanned copies of the documents mentioned above at the email id mentioned below:

Email ID:	irg@integratedindia.in
-----------	------------------------

These documents should reach us on or before **Friday, 01st August 2025** in order to enable the Company to determine and deduct appropriate TDS/withholding tax rate. No communication on the tax determination/deduction shall be entertained post **Friday, 01st August 2025**.

f) It may be further noted that in case the tax on dividend is deducted at a higher rate in absence of receipt of the aforementioned details/documents, there would still be an option available with the shareholder to file the return of income and claim an appropriate refund, if eligible. No claim shall lie against the Company for such taxes deducted.

15. Share Transfer permitted only in Demat: As per Regulation 40 of SEBI Listing Regulations, as amended, securities of

listed Companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition of securities.

- 16. **Nomination:** Members holding shares in single name are advised to avail the facility of nomination in respect of shares held by them pursuant to the provisions of Section 72 of the Act.
- 17. Submission of PAN: SEBI has mandated the submission of PAN by every participant in the securities market. Accordingly, members holding shares in electronic form are requested to submit their PAN to the Depository Participants with whom they maintain their demat accounts. Members holding shares in physical form should submit their PAN to the Company. Members may please note that SEBI has also made it mandatory for submission of PAN in the following cases, viz. (i) Deletion of name of the deceased shareholder(s) (ii) Transmission of shares to the legal heir(s) and (iii) Transposition of shares.
- 18. Members holding shares in physical form, in identical order of names, in more than one folio are requested to send to the Company or Integrated Registry Management Services Private Limited, the details of such folios together with the share certificates for consolidating their holdings in one folio. A consolidated share certificate will be issued to such Members after making requisite changes.
- 19. The Company has established the Electronic Connectivity with NSDL and CDSL to facilitate holding and transfer of shares in de-materialized form. The International Securities Identification Number (ISIN) allotted to the Company's equity is INE570E01016. The shareholders may get their holding into de-materialized form.
- In case of joint holders attending the AGM, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote.
- 21. Relevant documents referred to in the Notice and the explanatory statement are open for inspection by the members at the Registered Office of the Company during the normal business hours on all working days (i.e., except Saturdays, Sundays and Public Holidays) up to the date of AGM. The aforesaid documents will also be available for inspection by the members at the meeting.
- 22. **Shareholders' Communication:** Members who wish to claim dividends, which remain unclaimed, are requested to either correspond with the Secretarial Department at the Company's Registered Office or the Company's Registrars and Share Transfer Agents M/s. Integrated Registry Management Services Private Limited.
- 23. The Register of Members and the Share Transfer Books of the Company will remain closed from Tuesday, 05th August 2025 to Monday, 11th August 2025 (both days inclusive).
- 24. The route map showing directions to reach the venue of the 102nd Annual General Meeting is annexed to this notice.
- 25. In compliance with Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Circulars issued by MCA and SEBI, the Company has provided a facility of casting the votes by the Members using an electronic voting system from a place other than venue of AGM ("remote e-Voting") through the electronic voting service facility arranged by National Securities Depository Limited (NSDL).

26. Furnishing of PAN, KYC details and Nomination by holders of physical securities

SEBI has mandated the submission of the Permanent Account Number (PAN) by every participant in the securities market. Shareholders holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participant(s).

Further, SEBI vide their Circular dated November 3, 2021 and December 14, 2021 has mandated furnishing of PAN, email address, mobile number, bank account details and nomination by holders of physical securities. Effective January 1, 2022, RTA/ Company shall consider any service request such as transfer, transmission, issue of duplicate share certificates, renewal/ exchange of share certificates, consolidation of folios etc., only upon registration of the PAN, Bank details and Nomination.

- 27. SEBI vide Circular no. SEBI/HO/OIAE/OIAE_IAD-1/P/ CIR/2023/131 dated 31 July, 2023 (updated as on 4 August, 2023) has specified that a shareholder shall first take up his/ her/their grievance with the listed entity by lodging a complaint directly with the concerned listed entity and if the grievance is not redressed satisfactorily, the shareholder may, in accordance with the SCORES guidelines, escalate the same through the SCORES Portal in accordance with the process laid out therein. Only after exhausting all available options for resolution of the grievance, if the shareholder is not satisfied with the outcome, he/she/ they can initiate dispute resolution through the Online Dispute Resolution ("ODR") Portal. Shareholders are requested to take note of the same.
- 28. The remote e-voting period begins on Friday, 08th August 2025 at 09.00 am and ends on Sunday, 10th August, 2025 at 05.00 pm. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. Monday, 04th August 2025 may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Monday, 04th August 2025.

The facility for voting, either through electronic voting system or ballot paper shall also be made available at the meeting and Members attending the meeting who have not cast their votes by remote e-voting shall be able to exercise their right at the meeting.

The Members who have cast their vote by remote e-voting prior to the meeting may also attend the meeting but shall not be entitled to cast their vote again.

A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting as well as voting at the meeting.

Mr. Raghavendra Naveen BK, Practicing Company Secretary, has been appointed as the Scrutinizer to scrutinize the remote e-voting process as well as voting at the meeting, in a fair and transparent manner.

The Scrutinizer shall, immediately after the conclusion of voting at the AGM, count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and make, not later than two days of conclusion of the meeting, a consolidated Scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing who shall countersign the same.



The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.afdil.com immediately after the results are declared and the same shall be communicated to Metropolitan Stock Exchange of India Limited, where the shares of the Company are listed.

Electronic Copy of the Annual report for 2024-25 is being sent, inter alia, indicating the process and manner of e-voting along with Attendance Slip and Proxy Form to all members whose email ids are registered with the Company/Depository Participants for communication purposes unless any member has requested for a hard copy of the same.

29. The instructions for e-voting are as follows:

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A). Login method for e-Voting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Тур	Type of shareholders : Individual Shareholders holding securities in demat mode with NSDL.		
	Login Method		
1.	For OTP based login you can click on <u>https://eservices.nsdl.com/SecureWeb/evoting/ evotinglogin.jsp</u> . You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.		
2.	Existing IDeAS user can visit the e-Services website of NSDL Viz. <u>https://eservices.nsdl.com</u> either on a Personal Computer or on a mobile. On the e-Services home page click on the " Beneficial Owner " icon under " Login " which is available under ' IDeAS ' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on " Access to e-Voting " under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period.		
3.	If you are not registered for IDeAS e-Services, option to register is available at <u>https://eservices.nsdl.com</u> . Select "Register Online for IDeAS Portal" or click at <u>https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</u>		
4.	Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <u>https://www.evoting.nsdl.com/</u> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.		
5.	Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience. NSDL Mobile App Is available on App Store Google Play		
Indi	dividual Shareholders holding securities in demat mode with CDSL		
1.	Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password.		

- 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.
- 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option.
- 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on <u>www.cdslindia.com</u> home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders (holding securities in demat mode) login through their depository participants

You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSD	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <u>helpdesk.evoting@cdslindia.com</u> or contact at toll free no. 1800-21-09911

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

- 1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
- 2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section.
- 3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

	ner of holding shares i.e. Demat (NSDL or CDSL) hysical	Your User ID is:
a)	For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12*****.
b)	For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************************************
c)	For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***



- 5. Password details for shareholders other than Individual shareholders are given below:
 - a. If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
 - b. If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
 - c. How to retrieve your 'initial password'?
 - i. If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - ii. If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered
- 6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a. Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - <u>Physical User Reset Password?</u>" (If you are holding shares in physical mode) option available on <u>www.evoting.nsdl.</u> <u>com</u>.
 - c. If you are still unable to get the password by aforesaid two options, you can send a request at <u>evoting@nsdl.com</u> mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d. Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
- 7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
- 8. Now, you will have to click on "Login" button.
- 9. After you click on the "Login" button, Home page of eNow, you will have to click on "Login" button.-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

- 1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle
- 2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period.
- 3. Now you are ready for e-Voting as the Voting page opens.
- 4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted
- 5. Upon confirmation, the message "Vote cast successfully" will be displayed.
- 6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
- 7. Once you confirm your vote on the Resolutions, you will not be allowed to modify your vote.

General Guidelines for shareholders

- Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolutions/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to support@raoandassociates.co.in with a copy marked to <u>evoting@nsdl.com</u>. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
- 2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.
- In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of <u>www.evoting.nsdl.com</u> or call on : 022 - 4886 7000 or send a request to Mr. Falguni Chakraborty, Asst.Manager at <u>evoting@nsdl.com</u>

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the Resolutions set out in this notice:

- In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to compliance@afdil.com.
- 2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to compliance@afdil.com. If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting for Individual shareholders holding securities in demat mode.
- Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.
- 4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 (1) OF THE COMPANIES ACT, 2013.

ITEM NO.4

The Securities and Exchange Board of India (SEBI), vide its Notification No. SEBI/LAD-NRO/GN/2024/218 dated 12th December 2024, has introduced certain amendments to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which came into effect from 13th December 2024. One of the key amendments under Regulation 24A(1) pertains to the appointment, eligibility, qualifications, and disqualifications of the Secretarial Auditor of a listed entity.

In compliance with the above-stated amended regulations, the Board of Directors of the Company, on the recommendation of the Audit Committee, has approved the appointment of M/s. Rao and Associates, having Mr. Raghavendra Naveen B K, Practicing Company Secretary (Membership No. 59814, CP No. 23728), a Peer Reviewed Company Secretary, as the Secretarial Auditor of the Company for a first term of five consecutive years commencing from the conclusion of the 102nd Annual General Meeting (AGM) until the conclusion of the 107th AGM.

Mr. Raghavendra Naveen B K meets the eligibility criteria as prescribed under the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 (as amended), and has confirmed that he is not disgualified under any of the applicable provisions.

The Board recommends the resolution as set out in Item No.4 of the Notice for approval of the Members by way of an Ordinary resolution.

ITEM NO.5

On recommendation of the Audit Committee, the Board of Directors of the Company at their meeting held on 02nd May 2025 approved the appointment of M/s. Sandhya P & Co, Cost Accountants, Firm Registration No.004755, as Cost Auditor of the Company, to conduct the audit of Cost records relating to Pharmaceutical Formulations for the Financial Year 2024-25 at a remuneration of ₹70,000/- (Rupees Seventy Thousand Only) per annum, plus taxes and reimbursement of out of pocket expenses incurred by them in connection with the aforesaid audit.

In accordance with the provision of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, Companies (Cost Audit & Records) Rules, 2014, the remuneration payable to the Cost Auditors as recommended by the Audit Committee and approved by the Board has to be ratified by the Members of the Company.

The Board recommends the resolution in relation to appointment of Cost Auditors and ratification of remuneration of cost auditor set out in Item No.5 of the Notice for approval of the Members by way of an Ordinary resolution.

ITEM NO.6

During the course of business, the Company may have to provide financial support by way of providing loan, guarantee or security from its internal resources/accruals and/or any other appropriate sources, as permitted, for the business activities, including working capital requirements and capital expenditure, of its subsidiary companies or associates or group entities or any other entity in whom any of the Director of the Company is interested or deemed to be interested (hereinafter collectively referred to as the "Entities") from time to time.

Pursuant to the provisions of Section 185 and 186 of the Companies Act, 2013 read with the Companies (Meeting of Board and its Powers) Rules, 2014 (the "Rules") (as amended from time to time), no company shall, directly or indirectly, advance any loan, including any loan represented by a book debt to, or give any guarantee or provide any security in connection with any loan taken by (a) any director of company, or of a company which is its holding company or any partner or relative of any such director; or (b) any firm in which any such director or relative is a partner. However, a company may advance any loan including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any person in whom any of the director of the company is interested, subject to the condition that (a) a special resolution is passed by the company in general meeting and the loans are utilized by the borrowing company for its principal business activities.

Accordingly, the Board of Directors in its meeting held on 02nd May 2025 has considered and decided to seek shareholders' approval by way of a special resolution for advancing any loan, giving any guarantee or providing any security to all such Entities specified under Section 185 and 186 of the Companies Act, 2013 and more specifically such other entity/person as the Board of the Directors in its absolute discretion deems fit and beneficial and in the best interest of the Company, provided that the aggregate limit shall not at any time exceed Rs.300 crores. Further, the said loan(s) and/or guarantee(s) and/or security (ies) shall only be utilized by the Borrower for the purpose of its principal business activities and that keeping the best interest of the Company.



It may be noted that the Company had earlier obtained shareholders' approval by way of a special resolution under Section 186 through a postal ballot dated 22nd March 2022, authorizing it to grant loans, provide guarantees or securities, or acquire securities of other body corporates up to an aggregate limit of INR 300 crores. However, separate approval under Section 185 is required for certain transactions covered therein. Hence, this resolution is being proposed for compliance and clarity.

The Board of Directors recommends resolution as set out in item No. 6 for approval of the members of the Company by way of passing a Special Resolution.

None of the Directors or any KMPs of the Company or their respective relatives are either directly or indirectly concerned or interested, financially or otherwise, in this Resolution except to the extent of their directorships and shareholding in the Company (if any).

By Order of the Board of Directors For Anglo-French Drugs & Industries Limited

Date: 02nd May 2025 Place: Bengaluru


-/Sd Sriee Aneetha. M Company Secretary & Compliance Officer

Registered Address: Plot No.4, Phase - II, Peenya Industrial Area, Peenya, Bengaluru - 560058.

Route Map for 102nd Annual General Meeting Venue

Venue: Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeswanthpur, Bengaluru- 560022.

Date: Monday, 11th August 2025 at 4.00 p.m





Anglo-French Drugs & Industries Limited

Registered Office: Plot no.4, Phase II, Peenya Industrial Area, Peenya, Bengaluru 560058.

CIN:L24230KA1923PLC010205 Websie:www.afdil.com

ATTENDANCE SLIP

I hereby record my presence at the 102nd Annual General Meeting held on Monday, 11th August 2025, at 4.00 p.m. at Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeswanthpur, Bengaluru-560022, Karnataka.

Folio No. / DP ID-Client ID	
Full Name of the Shareholder in Block Letters	
No. of Shares held	
Name of Proxy (if any) in Block Letters	

Note: 1. A proxy attending on behalf of Shareholder(s) should write the name of the Shareholder(s) from whom he holds Proxy.

2. Members will be provided with a copy of Annual Report at the Meeting.

Signature of the Shareholder/Proxy



Anglo-French Drugs & Industries Limited

Registered Office: Plot no.4, Phase II, Peenya Industrial Area, Peenya, Bengaluru 560058.

CIN:L24230KA1923PLC010205 Websie:www.afdil.com

PROXY FORM

(Form No.MGT-11)

[Pursuant to Section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration Rules, 2014)

CIN	L24230KA	1923PLC010205	
Name of the Company	Anglo-Fre	nch Drugs & Industries Ltd.	
Registered Office	Plot no,4,	Phase II, Peenya Industrial Area, Peenya Bengaluru -	560058.
Name of the Member(s):			
Registered Address:			
E-mail ID :			
Folio No./Client ID or DP ID :			
I/We, being the member(s) of	,	shares of the above named Company hereby appoint:	
1)	of	having e-mail ID	or failing him/her
2)	of	_having e-mail ID	or failing him/her
3)	of	having e-mail ID	or failing him/her

and whose signature(s) are appended below as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual General Meeting of the Company, to be held on Monday, 11th August 2025, at 4.00 p.m. at Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeswanthpur, Bengaluru- 560022, Karnataka, and at any adjournment thereof in respect of such resolutions as are indicated below:

* I/We appoint my / our above Proxy to vote in the manner as indicated in the box below:

Resolution No.	Description	I assent to the Resolution	l dissent to the Resolution
1	To receive, consider and adopt the Audited Financial Statements of the Company, for the financial year ended 31st March, 2025 together with the Report of the Board of Directors and Auditors thereon.		
2	To declare final dividend on equity shares for the Financial Year ended 31st March 2025.		
3	To appoint a Director in place of Mr. Rohit Choraria, DIN: 07003583, who retires by rotation and being eligible, offers himself for re-appointment.		
4	Appointment and ratification of remuneration of Secretarial Auditors of the Company for first term of 5 years from the conclusion of the 102nd AGM until the conclusion of the 107th AGM.		
5	Appointment and ratification of remuneration of Cost Auditors of the Company for the Financial Year 2025-26		
6	Approval to advance any loan/give guarantee/provide security u/s 185 and 186		

Signed this day of August, 2025.

Affix Revenue Stamp of not less than ₹ 1/-

Signature of Shareholder

Signature of Proxy holder (s)

Notes:

Please complete all details of Member(s) before submission.

This form of Proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

BOARD'S REPORT

To the Members,

Your Directors are pleased to present the 102nd Annual Report of the Company and the Audited Financial Statements for the year ended 31st March 2025.

1. FINANCIAL HIGHLIGHTS

(All figures are Rs. in Lakhs)

Particulars	Financial yea 2024-25	-
Revenue from Operations	8779	9520
Other Income	3020	464
Profit before Depreciation, Tax and Exceptional item	1120	-914
Depreciation and Amortisation	327	315
Exceptional Item	(0
Provision for Tax (including deferred Tax)	7	12
Profit / (Loss) for the year	722	-1,234

2. SHARE CAPITAL

- a. Authorized Share Capital- The authorised share capital of the Company as on 31st March, 2025 is Rs.2,00,00,000/- (Rupees Two Crores Only) divided into 20,00,000 equity shares of Rs.10 /- (Rupees Ten Only) each. During the financial year under review, there is no change in the authorised share capital of the Company.
- b. Issued, Subscribed and Paid-up Share Capital -

Buyback:2023-24 - The issued, subscribed and paid-up share capital of the Company as at 31st March 2024 is Rs.1,23,33,820/- (Rupees One Crore Twenty Three Lacs Thirty-three Thousand Eight Hundred and Twenty Only) comprising of 12,33,382 equity shares of ₹ 10/- (Rupees Ten Only) each.

As at 31st March, 2023 Share Capital was ₹1,29,15,000/-(Rupees One Crore Twenty Nine Lacs Fifteen Thousand Only) comprising of 12,91,500 equity shares of ₹ 10/- (Rupees Ten Only) each.

During the financial year 2023-24, Board of Directors of the Company in the Meeting held on 14th July 2023, approved the buyback of shares proposed by the Company at Rs.3,100 per share. A total of 58,118 equity shares have been bought back by the company in the second quarter of FY 2023-24 (face value Rs.10/- per share and Share premium of Rs.30 per share). The offer size of the buy-back was 4.5% of the total issued and paidup Equity Share capital of the Company, as on 31st March 2023.

The total value of such buyback was Rs.18,01,65,800/-, and the total amount available for distribution after deduction of costs was Rs.17,78,41,080/-. The settlement payment of buyback consideration was made on 14th August 2023 and the shares were extinguished on 17th August 2023.

Buyback:2024-25 – As of March 31, 2025, the issued, subscribed, and paid-up share capital of the Company stood at ₹1,12,68,820/- (Rupees One Crore Twelve Lakhs Sixty-Eight Thousand Eight Hundred and Twenty Only), comprising 11,26,882 equity shares of ₹10/- (Rupees Ten Only) each. In comparison, the paid-up share capital as of March 31, 2024, was ₹1,23,33,820/- (Rupees One Crore Twenty-Three Lakhs Thirty-Three Thousand Eight Hundred and Twenty Only), consisting of 12,33,382 equity shares of ₹10/- each.

During the financial year 2024-25, the Board of Directors, at its meeting held on July 29, 2024, approved and recommended

a buyback of 1,06,500 equity shares at a price of ₹4,000/-(Rupees Four Thousand Only) per share. This represented approximately 8.63% of the total number of equity shares in the paid-up equity capital of the Company as on March 31, 2024. The aggregate buyback consideration amounted to ₹42,60,00,000/- (Rupees Forty-Two Crores Sixty Lakhs Only), representing 25% of the aggregate of the Company's paid-up capital and free reserves as per the audited financial statements for the financial year ended March 31, 2024.

Shareholders' approval for the buyback was obtained through an Extraordinary General Meeting held on August 21, 2024, conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM).

The total value of the buyback was ₹42.60 crores, and after deduction of applicable costs, the total amount available for distribution stood at ₹42,00,76,240/-. The buyback consideration was settled on September 23, 2024, and the extinguishment of the bought-back shares was completed on October 1, 2024.

3. COMPANY'S PERFORMANCE

Your Company's revenue from sales and operating income is Rs. 8,779 Lakhs (Rs.9,520 Lakhs last year). Your Company's Other Income through investment have increased, Net Profit for the year is Rs. 722 Lakhs (Pr. Year Loss of Rs. -1,234 Lakhs).

Corporate Updates;

a. Cessation of Share Transfer Agent – Canbank Computer Services Limited (CCSL)

Canbank Computer Services Limited (CCSL), via communication dated September 23, 2024, informed the Company of its decision to cease operations as Registrar and Transfer Agent (RTA). CCSL has advised the Company to appoint a new RTA.

b. Appointment of New Share Transfer Agent - The Company entered into a tripartite agreement on December 6, 2024, with M/s Integrated Registry Management Services Private Limited, Bangalore, appointing them as the new Registrar and Share Transfer Agent, replacing CCSL.

Pursuant to SEBI (LODR) Regulation 7(c) & (d) the change in the Share Transfer Agent duly intimated to Stock Exchange.



- c. Shifting of Registered Office The Company have shifted its Registered Office from No.41, 3rd Cross, V Block, SSI Area, Rajajinagar, Bengaluru 560010 to Factory Premises Plot No.4, Phase-II, Peenya Industrial Area, Peenya, Bengaluru – 560058 wef. 01st March 2024
- d. Shifting of Registered Office The Board, in its meeting held on May 2, 2025, approved the shifting of the Company's registered office from Karnataka: Plot No.4, Phase II, Peenya Industrial Area, Peenya, Bangalore – 560058 to Maharashtra: Unit No.T6C, 5th Floor, C Wing, Phoenix House, Senapati Bapat Marg, Lower Parel (West), Mumbai – 400013.

The shift aims to enhance operational efficiency and does not adversely impact employees, creditors, or debtors. All business operations will continue uninterrupted.

As a consequence, Clause II of the Memorandum of Association (MOA) was amended. This change was approved by members through Postal Ballot on June 5, 2025.

e. Adoption of New Memorandum of Association - In the same Board Meeting dated May 2, 2025, the Company resolved to adopt a new set of MOA to align with the Companies Act, 2013, replacing the version based on the erstwhile Companies Act, 1956. The object clause was revised in accordance with Table A of Schedule I of the new Act, with no changes to the main objects. The revised MOA was approved by members via Postal Ballot on June 5, 2025.

4. DIVIDEND

The Directors of your Company recommend a dividend of Rs.1.50 per equity share of Rs.10/- each, @15% for the Financial year ended 31st March 2025, subject to the approval of the members, payable to those shareholders whose names appear in the Register of Members as on the Record date.

5. TRANSFER TO GENERAL RESERVE

Your Directors do not propose to transfer any amount to the reserves.

6. SUBSIDIARY COMPANY

Your Company do not have any subsidiary as on date 31st March 2025.

7. DIRECTORS & KEY MANAGERIAL PERSONNEL

The composition of the Board is in accordance with the provisions of Section 149 of the Act and the SEBI Listing Regulations, with an appropriate combination of Executive, Non-Executive Directors and Independent Directors.

As on March 31, 2025, the Company has 7 (Seven) Directors with an optimum combination of Executive and Non-Executive Directors including one women director.

The Board comprises of 3 (Three) Executive Directors and 4 (Four) Non-Executive Directors, out of which 1 (One) Women Director.

During the year;

Pursuant to section 149(11) of the Companies Act 2013, the two term of Independent Director Mr. N. Ahmedali DIN: 00704341 concluded on the 101st AGM dated:12th August 2024. Consequently, retired from Board as Independent Director and from Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee as Chairman.

Mr. Nirbhay Abhay Kanoria (DIN: 02558300) served as the Chief Financial Officer of the Company from January 18, 2024. He was re-designated as Vice President and Whole-Time Director effective August 12, 2024.

Subsequently, Mr. Manik Kumar Singh was appointed as the Chief Financial Officer with effect from July 29, 2024.

Based on the recommendation of Nomination and Remuneration Committee, Mrs. Rani Shokeen (DIN:10634071) was appointed as Additional Director by the Board at its Meeting held on 28th May 2024 and regularized in 101st AGM as Independent Non-Executive Director.

Based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at their meeting held on 13th February 2025, decided to reschedule the designations of Executive directors.

Accordingly, on 20th March 2025, shareholders approved, via postal ballot, three Special Resolutions concerning changes in the designations of key company executives. The first resolution approved the re-designation of Mr. Abhay Kanoria (DIN: 00108894) from Chairman & Managing Director to Chairman of the Company, with no changes to his remuneration, tenure, or other terms of appointment, as previously approved at the 100th Annual General Meeting held on 3rd August 2023.

The second resolution approved the re-designation of Mr. Uddhav Abhay Kanoria (DIN: 00108909) from President & Whole-Time Director to Managing Director, with all existing terms remaining unchanged, as approved at the 101st Annual General Meeting held on 12th August 2024.

The third resolution involved the re-designation of Mr. Nirbhay Abhay Kanoria (DIN: 02558300) from President & Whole-Time Director to Managing Director, also without any variation in terms, as approved at the 100th Annual General Meeting held on 3rd August 2023.

Non-Executive Director Mr. Rakesh Kanyadi, (DIN:08532438) resigned on 7th November 2024. Board placed on record their appreciation for the duties and responsibilities during his tenure as Director of the Company.

The Company has received necessary declaration from each independent director under Section 149(7) of the Companies Act, 2013 (the "Act") that they meet the criteria of independence laid down in Section 149(6) of the Act and Regulation 25 of the SEBI (LODR) Regulations, 2015.

The Company has obtained a Certificate from M/s. Raghavendra Naveen BK, Practicing Company Secretaries, pursuant to Regulation 34(3) read with Schedule V of SEBI(LODR) Regulations 2015, that none of the Directors on the Board of the Company were debarred or disqualified from being appointed or continuing as a Director on the Board.

As per the provisions of the Act, Mr. Rohit Choraria retires by rotation at the ensuing Annual General Meeting and, being eligible, has offered himself for re-appointment. The Board recommends his re-appointment.

During the year, Non-Executive directors of the Company did not have any pecuniary relationship or transactions with the Company, other than sitting fees with related expenses incurred for attending meetings of the Company.

Pursuant to the provisions of Section 203 of the Act, Mr. Abhay Kanoria Chairman, Mr. Uddhav Abhay Kanoria - Managing Director, Mr. Nirbhay Abhay Kanoria - Managing Director, Mr.Manik Kumar Singh - Chief Financial Officer and Mrs. Sriee Aneetha M Company Secretary are the Key Managerial Personnel of the Company as on March 31, 2025.

8. DIRECTORS RESPONSIBILITY STATEMENT

Pursuant to the provisions of Section 134(5) of the Act, the Directors' Responsibility Statement is given hereunder:

- In the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures if any;
- ii The Directors have, in the selection of the accounting policies, consulted the statutory auditors and have applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;
- iii The Directors have taken proper and sufficient care, for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- iv The Directors have prepared the annual accounts on a going concern basis;
- The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively;
- vi The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

9. BOARD EVALUATION

SEBI Listing Regulations mandates that the Board shall monitor and review the Board evaluation framework. The structure includes the evaluation of directors on various parameters such as board dynamics and relationships, information flow, decision making, relationship with stakeholders, company performance, tracking board and committees' effectiveness, and peer evaluation.

As per the provisions of the Act including Schedule IV, the evaluation of all the directors and the Board as a whole was conducted based on the criteria and framework adopted by the Board. The Board approved the evaluation results as collated by the nomination and remuneration committee.

In a separate meeting of Independent Directors held on 13th February 2025, performance of Non-Independent directors, performance of the Board as a whole and performance of the Chairperson of the Company was evaluated.

10. POLICY ON DIRECTORS' APPOINTMENT AND REMUNERATION

The Board of Directors has framed a policy for selection and appointment of Directors including determining qualifications and independence of a Director, Key Managerial Personnel (KMP), senior management personnel and their remuneration as part of its role and other matters provided under Section 178(3) of the Companies Act, 2013 and Listing Regulations.

Pursuant to Section 134(3) of the Companies Act, 2013, the nomination and remuneration policy of the Company which lays down the criteria for determining qualifications, competencies, positive attributes and independence for appointment of Directors and policies of the Company relating to remuneration of Directors, KMP and other employees was amended and adopted by the Board of Directors at their meeting held on 14th June, 2021. The Policy is available on the website of the

Company at https://www.afdil.com.

11. CODE OF CONDUCT

The Company has adopted the Code of Conduct for its Board Members and Senior Management of the Company. All the Board members and Senior Management personnel have affirmed compliance with the applicable Code of Conduct.

12. MANAGEMENT DISCUSSIONS AND ANALYSIS REPORT

A separate section on Management Discussion and Analysis Report (MDAR) which forms a part of the Director's report is included as required under Regulation 34(2) (e) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

13. BOARD MEETINGS:

During the Financial year 2024-25, Company held 5 Board Meetings on 28th May 2024, 29th July 2024, 12th August 2024, 07th November 2024 and 13th February 2025.

During the Financial year 2024-25;

EGM - held on 21st August 2024 via Video Conference or Other Audio-Visual means at 12:00 Noon, Approved Buyback of Equity Shares of the Company.

POSTAL BALLOT :

- a. Details of Resolutions passed by Postal Ballot : the Company had sought approval of its shareholders by way of Postal Ballot through remote e-Voting process, vide Notice dated 13th February 2025, on the following Resolution(s):
 - Change in designation of Mr.Abhay Kanoria DIN:00108894 from Chairman & Managing Director of the Company to Chairman
 - Change in designation of Mr Uddhav Abhay Kanoria DIN:00108909 from President & Whole Time Director to Managing Director
 - Change in designation of Mr. Nirbhay Abhay Kanoria DIN:02558300 from President & Whole Time Director to Managing Director

Proper notices were given and the proceedings were properly recorded and signed in the Minutes Book. The necessary of capturing Assent and dissent were recorded and quorum was present at all the meetings.

14. AUDIT COMMITTEE: The details pertaining to the composition of the Audit Committee are included in the Corporate Governance Report, which is a part of this report.

AUDITORS

a. Statutory Auditors:

In compliance with the Companies (Audit and Auditors) Rules 2014, M/s KAMG & Associates, Chartered Accountants (FRN:311027E) were re-appointed as the Statutory Auditors of the Company, at the 99th AGM held on 10th August, 2022 for a period of five years till the conclusion of 104th Annual General Meeting of Company.

M/s. KAMG & Associates, have consented to the said reappointment, and confirmed that their reappointment, if made, would be within the limits specified under Section 141(3)(g) of the Act. They have further confirmed that they are not disqualified to be reappointed as statutory auditor in terms of the provisions of the Act, and the

Annual Report 2024-25

provisions of the Companies (Audit and Auditors) Rules, 2014, as amended from time to time. The audit report does not contain any adverse remark or qualifications.

b. Cost Auditor:

Pursuant to the provisions of Section 148 of the Companies Act, 2013 and as per the Companies (Cost Records and Audit) Rules, 2014 and amendments thereof, the Board, at its meeting held on 02nd May 2025, has approved the appointment of _Sandhya .P & Co, Cost Accountants, Bengaluru (Firm Registration No. 004755) as the Cost Auditors of the Company to conduct cost audit of the accounts maintained by the Company, in respect of the Formulation products for the Financial Year 2025-2026.

c. Secretarial Auditor:

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors on the recommendation of the Audit Committee, at its meeting held on 02nd May 2025 have appointed Mr. Raghavendra Naveen B K, Practicing Company Secretary M.No.59814 CP No.23728, for conducting the Secretarial Audit of the Company for a period of five Years from Financial Year 2025-2026.

The Secretarial Audit report issued by M/s. Raghavendra Naveen B K, Practising Company Secretary for the financial year ended 31st March, 2025 does not contain any adverse remark or qualifications and is annexed as Annexure V to this report.

d. Internal Auditor:

M/s B Choraria & Mates., Chartered Accountants, were appointed as the Internal Auditors of the Company for the Financial Year 2025-26.

During the year under review, M/s B Choraria & Mates., Chartered Accountants, Bengaluru carried out the internal audit exercise and submitted their report for Financial Year 2024-2025.

14. CORPORATE GOVERNANCE

The Corporate Governance Report applicable from the Financial year 2023-24 to the Company in accordance with SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015. The Corporate Governance Report for the Financial year 2024-25 forms part of this report as per Annexure - VI

15. VIGIL MECHANISM/ WHISTLE BLOWER POLICY

The Company has established a vigil mechanism/framed a whistle blower policy. The policy enables the employees and other stakeholders to report to the management instances of unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or ethics policy. No personnel have been denied access to the Audit Committee. The provisions of this policy are in line with the provisions of Section 177 (9) of Companies Act, 2013. The policy is available on the website of the company at www.afdil.com

16. INTERNAL FINANCIAL CONTROL (IFC) SYSTEM AND THEIR ADEQUACY

As per the provisions of the Companies Act, 2013, the Directors have the responsibility for ensuring that the company has implemented robust system / framework for IFCs to provide them with reasonable assurance regarding the adequacy and operating effectiveness of controls to enable the Directors to meet with their responsibility.

The Company has in place a sound financial control system and framework in place to ensure:

- The orderly and efficient conduct of its business,
- Safeguarding of its assets,
- The prevention and detection of frauds and errors,
- The accuracy and completeness of the accounting records and
- The timely preparation of reliable financial information

17. QUALITY

The quality function at AFDIL has been at the forefront when it comes to healthcare. The products manufactured are of the highest quality, safest and effective. Our commitment to quality is managed by current and validated technology, the best resources, effective GMP, efficient and trained personnel, excellent production design and continuous in process monitoring.

18. PARTICULARS OF CONTRACTS & ARRANGEMENTS WITH RELATED PARTIES

All related party transactions that were entered into during the financial year were on arm's length basis and were in ordinary course of business. There are no materially significant related party transactions made by the Company which may have potential conflict with the interest of the Company.

There are no material related party transactions which are not in ordinary course of business or which are not on arm's length basis and hence there is no information to be provided as required under Section 134(3) (h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014.

Pursuant to the provisions of Section 188(1) of the Companies Act, 2013 read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Rule 8(2) of the Companies (Accounts) Rules, 2014, particulars of contracts and arrangements entered between the Company and the Related Parties, in the prescribed Form AOC-2, are as per Annexure -I.

The Company has formulated a Related Party Transactions Policy which is available on the website of the Company www. afdil.com

19. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186

The loans, Guarantees and investments under Section 186 of the Act form a part of Financial Statements. Details of ICD given to related party on arm's length basis are in Annexure-1 Form AOC-2. The particulars of Loans and Advances entered u/s.185 between the Company and the Related Parties are given in Notes No.14.

Your Company has obtained member's approval by way of Special Resolution through Postal Ballot on 22nd March 2022, to give any loan to any person or body corporate, give any guarantee or provide security in connection with a loan to any other body corporate or person, and acquire by way of subscription, purchase or otherwise, the securities of any other body corporate on such terms and conditions up to the limit aggregating to and not exceeding INR 300 crores (Rupees Three Hundred Crores Only).

20. PARTICULARS OF EMPLOYEES AND REMUNERATION

The total number of employees of the company as on 31st March, 2025 was 172 as against 211 as on 31st March, 2024.

The information required pursuant to the provisions of Section 197(12) of Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 have been appended as Annexure II to this Report.

The Board of Directors affirms that the remuneration paid to the employees of the Company is as per the Policy on Directors' appointment and remuneration for Directors, KMPs and other employees and is in accordance with the requirements of the Act and SEBI Listing Regulations.

21. DEPOSITS FROM PUBLIC

During the year under review, your Company neither accepted any deposits nor there were any amounts outstanding at the beginning of the year which were classified as 'Deposits' in terms of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposit) Rules, 2014 and hence, the requirement for furnishing of details of deposits which are not in compliance with the Chapter V of the Companies Act, 2013 is not applicable.

22. DISCLOSURE ON MATERIAL CHANGE UNDER SECTION 134(3)(L) OF THE COMPANIES ACT, 2013

Except as disclosed elsewhere in the Report, no material changes and commitments which could affect the financial position of the Company have occurred between the end of the financial year of the Company to which the financial statements relate and the date of this Report.

23. SIGNIFICANT AND MATERIAL ORDERS PASSED BY REGULATORS OR COURTS

There are no significant and material orders passed by any Regulator/ Court that would impact the 'going concern' status of the Company and its future operations.

24. RISK MANAGEMENT POLICY

The Company has implemented a risk management policy for the Company including identification therein of elements of risk, if any, and the same has been inserted in the website of the Company. The policy is available on the website of the Company at www.afdil.com

25. COMPLIANCE WITH SECRETARIAL STANDARDS

The Company has complied with the Secretarial Standards issued by The Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.

26. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS & OUTGO

The Information required under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is given in Annexure III to the Report and forms a part of this Report.

27. EXTRACTS OF ANNUAL RETURN

The extract of the Annual Return required pursuant to Section 92 (3) of the Companies Act, 2013 read with Rule 12(1) of the Companies (Management and Administration)

Rules 2014, will be made available on the website of the Company at www.afdil.com

28. INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of section 124 (5) of the Companies Act, 2013 read with the IEPF Rules,

There are no unclaimed and unpaid dividends/shares to be transferred as per the requirements of the IEPF rules, during the year.

Details of Nodal Officer:

Name & Designation: Mrs.Sriee Aneetha.M – Company Secretary and Compliance Officer

Address: Plot 4, Phase II, Peenya Industrial Area, Peenya, Bengaluru – 560 058.

Email:Compliance@afdil.com

29. COMPLIANCE UNDER THE SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has a robust mechanism in place to redress complaints reported under it. The Company has in place a policy for prevention, prohibition and redressal of sexual harassment and for matters connected or incidental thereto, with the objective of providing a safe working environment. Further, the Company has also constituted an Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, where employees can register and redress complaints pertaining to sexual harassment. During the year ended 31st March, 2025, no cases of sexual harassment were reported in your Company.

30. DISCLOSURE OF ACCOUNTING TREATMENT

The Company has prepared the Financial Statements in accordance with the Indian Accounting Standards (IND AS) to comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the relevant provisions of the Act, as applicable.

31. DETAILS OF NON COMPLIANCE

There have been no instances of non-compliance on any matter as regards the rules and regulations prescribed by the Stock Exchange, SEBI or any statutory authority relating to capital markets during the last three years. No penalties or strictures have been imposed by them on the Company.

32. DISCLOSURES ON DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

The Company does not have any unclaimed shares and hence there are no disclosures to be made pursuant to Regulation 39(4) of the SEBI Listing Regulations.

33. CORPORATE SOCIAL RESPONSIBILITY (CSR)

The Committee has formulated Corporate Social Responsibility Policy which recommends the social activities to be undertaken by the Company, as specified in Schedule VII of the Companies Act, 2013. A copy of the said Policy is available on Company's website at www.afdil.com

Annual Report on CSR for the Financial Year ended 31st March 2025, is annexed herewith as Annexure IV.



34. GREEN INITIATIVES

Electronic copies of the Annual Report 2024-2025 and the notice of the 102nd Annual General Meeting are being sent to all members whose e-mail addresses are registered with the Company/Depository Participants.

35. ACKNOWLEDGEMENTS

Your Directors acknowledge with gratitude the continued support, patronage and co-operation received from the Medical Professionals, Trade, Banks, other Business Associates, the Central and State Governments and the Shareholders.

Your Directors also place on record their appreciation of all the employees of the company for their valuable contribution and dedicated service.

On behalf of the Board,

Place: Bengaluru Date: 02nd May 2025 Nirbhay Abhay Kanoria Managing Director (DIN: 02558300)

ANNEXURE - I

FORM No. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis.

There were no contracts or arrangements or transactions entered into during the year ended 31st March 2025, which were not at arm's length basis.

2. Details of contracts or arrangements or transactions at Arm's length basis.

The details of material contracts or arrangements or transactions entered into during the year ended 31st March 2025, which are at arm's length basis are as follows.

Sr. No.	Particulars	Details
-		
1.	Name (s) of the related party & nature of relationship	Mr. Abhay Kanoria/Mrs. Pallavi Kanoria
2.	Nature of contracts/ arrangements/ transaction	Payment of monthly rent for the Flat located at Bengaluru leased to the Company.
3.	Duration of the contracts/ arrangements/ transaction	Agreement renewed from 27th February 2024
4.	5	Rent Mr. Abhay Kanoria – ₹14 Lakhs pa
	transaction including the value, if any	Rent Mrs. Pallavi Kanoria- ₹ 14 Lakhs pa
5.	Date of approval by the Board	28th May 2024
6.	Amount paid as advances, if any	Nil

Sr. No.	Particulars	Details		
1.	Name (s) of the related party & nature of relationship	Dormirbien Pvt. Ltd. – Related Party u/s.185		
2.	Nature of contracts/ arrangements/ transaction	Payment of monthly rent for the Godown located at Bengaluru.		
3.	Duration of the contracts/ arrangements/ transaction	Co-Working Space Agreement dated:03rd May 2024		
4.	Salient terms of the contracts or arrangements or transaction including the value, if any	Godown Rent – ₹ 0.54 Lakh pa		
5.	Date of approval by the Board	28th May 2024		
6.	Amount paid as advances, if any	Nil		

Sr. No.	Particulars	Details				
1.	Name (s) of the related party & nature of relationship	Dormirbien Pvt. Ltd. – Related Party				
2.	Nature of contracts/ arrangements/ transaction	Loan given for working capital. Members approval u/s.186 throug Special Resolution dated 22nd March 2022.				
3.	Duration of the contracts/ arrangements/ transaction	ICD Agreement as on 28th May 2024				
4.	Salient terms of the contracts or arrangements or transaction including the value, if any	ICD given ₹ 752 Lakhs.				
5.	Date of approval by the Board	28th May 2024				
6.	Amount paid as advances, if any	Nil				

On behalf of the Board of Directors,

Place: Bengaluru Date: 02nd May 2025 Nirbhay Abhay Kanoria Managing Director DIN: 02558300



ANNEXURE II

Information required under Section 197 (12) of the Act read with Rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial year 2024-25 and the percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the Financial year 2024-25.

Name of the Director and Key Managerial Personnel	Designation	Ratio of remuneration of each Director to median remuneration of employees	Increase/(Decrease) in remuneration in FY 2024- 2025
Directors			
Mr. Abhay Kanoria	CMD upto 20-03-2025 and re-designated to Chairman w.e.f 20-03-2025	18.44	0.20%
Mr. Uddhav Kanoria	President & Whole-Time Director and re- designated to Managing Director w.e.f 20-03- 2025	12.59	0.16%
Mr. Nirbhay Kanoria	President & Whole-Time Director and re- designated to Managing Director w.e.f 20-03- 2025	10.22	0.19%
Mr. Rakesh Parmeshwar Kanyadi	Non-Executive Director (upto 07-11-2024)	5.52	Nil
Mr.Pradeep V Joshi	Independent Non-Executive Director	Nil	Nil
Mr.S.Krishnan	Independent Non-Executive Director	Nil	Nil
Mrs. Rani Shokeen	Independent Non-Executive Director (w.e.f 28-05-2024)	Nil	Nil
Mr.Rohit Choraria	Non-Executive Director	Nil	Nil
Key Managerial Personnel			
Mr. Manik Kumar Singh	Chief Financial Officer	3.95	Nil*
	(w.e.f 29-07-2024)		
Mrs. Sriee Aneetha M	Company Secretary & Compliance Officer	3.07	7.17%

Remuneration does not include commission for the financial year 2024-2025.

* Mr. Manik Kumar Singh CFO was appointed on 29th July 2024 and hence the remuneration received in FY 2024-25 is not comparable with previous year and therefore the percentage is not stated.

Notes:

- 1. The Independent Directors paid only Sitting Fees for attending the Board /Committee Meetings.
- 2. For the purpose of calculation of median remuneration, employees who have worked for part of the year were not considered.
- 3. The percentage increase in the median remuneration of employees in the financial year was 6.74%. For said calculation, employees who have worked for part of the year in FY 2024-25 were not considered to ensure comparability.
- 4. The number of permanent employees on the rolls of Company as on 31st March, 2025 was 172.
- 5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration: There were no change in the Managerial Remuneration for the Financial year 2024-25.
- 6. The average annual increase in the salaries of the employees during the year was 6% whereas increase in managerial remuneration for the year was Nil.
- 7. Affirmation that the remuneration is as per the remuneration policy of the Company:

The Company affirms remuneration is as per the remuneration policy of the Company.

ANNEXURE III

The Information required under Section 134(3) (m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and forming part of the Directors' Report for the year ended 31st March 2025.

A. CONSERVATION OF ENERGY:

- a) Energy conservation measures taken
- b) Additional investments and proposals, if Any, being implemented for reduction of Consumption of energy.
- c) Impact of the measures at (a) and (b) For reduction of energy consumption and consequent impact on the cost of Production of goods.
- Total energy consumption and energy Consumption per unit of production.

The Company is constantly Concerned about energy conservation, but having regard to the present level of consumption and the nature of activities, which are not energy Intensive, the need for taking special energy conservation measures has above not been immediately felt.

Please refer Form A hereunder.

FORM A

[See Rule 2]

Form for disclosure of particulars with respect to conservation of energy.

Α. **Power and Fuel consumption: Current Year Previous year** 1. Electricity a) Purchased: Units 1377089 1153755 Total Amount [₹ in Lacs] 124 114 9 01 9 90 Rate/Unit [₹] **Own Generation:** b) I. **Through Diesel Generator** 2927 I Inits 3210 Units per Ltr. of Diesel Oil 2.72 2.29 Cost/Unit [₹] 32.59 37.78 П. **Through Steam Turbine/Generator** Units Nil Units per Ltr. of Fuel Oil/Gas Nil Cost/Unit [₹] 2. Coal Quantity (tonnes) Total Cost [₹] Nil Nil 3. **Furnace Oil Current Year Previous Year** Quantity (Kilts) Nil Nil Nil Nil Total Amount [₹ in 'Lacs] Average Rate [₹ per Ltrs] Nil Nil 4. Others/internal generation Quantity Total Cost Nil Nil Rate/Unit

B. Consumption per unit of Production:

Particulars

Products (with details) Units Electricity Furnace Oil Coal Others

Standard [if any]

Taking into account the number of formulations manufactured by the Company and having regard to the records and other books maintained, it is not possible to apportion the consumption of utilities unit wise at this stage.



B. TECHNOLOGY ABSORPTION:

Efforts made in technology absorption. Please refer Form B hereunder.

FORM B

[See Rule 2]

Form for disclosure of particulars with respect to Technology Absorption

Rese	arch a	and Development [R&D].				
1.		Specific areas in which R&D carried out by the Company.		:	Formulations: Development of new for new dosage forms, sub imports by indigenous r improvement in process	stitution of
2.		efits derived as a result of the re R&D		:	Launching of new produin the shelf life and reduction	
3.	Futu	re plan of action		:	Continuous development formulations.	nt of new
4.	Expe	enditure on R & D			Current Year	Previous Year
(a)	Capi	tal [₹ in Lacs]			Nil	Nil
(b)	Recu	ırring [₹ in 'Lacs]			53	28
(c)	Total	[₹ in 'Lacs]			53	28
(d)	Total	R&D expenditure as a percentage of total turnover			0.60%	0.29%
Tech	nolog	y absorption, adaptation and innovation				
1.		ts in brief made towards technology rption, adaptation and innovation		:	Regular absorption of u technical information.	pdated
2.	Benefits derived as a result of the above efforts e .g. product improvement, cost reduction, product development, import substitution, etc.			:	Improved processes an efficiencies, cost reduct	
3.	durin the b	se of imported technology (imports ig the last 5 years reckoned from leginning of the financial year) wing information may be furnished.				
	a)	Technology imported		:	Not Applicable	
	b)	Year of Import				
	c)	Has technology been fully absorbed				
	d)	If not fully absorbed, areas where this has not taken place, reasons therefore and future plans of action.				
С.	FOR	EIGN EXCHANGE EARNINGS AND OUTGO				
	a)	Activities relating to exports, initiatives taken to increase exports, development of new export markets for products and services and export plans.		:	Continuous efforts are r increase exports and de new export markets.	
					Current Year	Previous Year
b)	Total	foreign exchange used (₹ in lacs)		:	45	73
	Total	foreign exchange earned (₹ in lacs)		:	282	1139
					On	behalf of the Board of Directors,

Date: 2nd May, 2025 Place: Bengaluru Nirbhay Abhay Kanoria Managing Director

Managing Director DIN:02558300

ANNEXURE-IV

Annual Report on CSR Activities for the financial year ended 31st March 2025

1. Brief outline on CSR Policy of the Company- CSR Philosophy

The Company's CSR policy is in adherence to the Provisions of Section 135 of the Act read with rules thereunder and provides for carrying out CSR activities in the area of Health including preventive healthcare either directly or through 'Non-Profit Organisations'.

The CSR activities of the Company are aligned with the activities specified in Schedule VII of the Companies Act, 2013. During the FY 2024-25, the meeting of CSR Committee was held on 13th February 2025.

2. Composition of CSR Committee:

7.

SI. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year	
1	Mr. S.Krishnan	Chairperson, Independent Director	1	1	
2	Mr. Uddhav Kanoria	Member, Director	1	1	
3	Mr. Nirbhay Kanoria	Member, Director	1	1	

- 3. The web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company https://www.afdil.com/investor-relations.html#
- 4. The details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report). Not Applicable

In accordance with the provisions of Rules 8(3) of the Companies (Corporate Social Responsibility Policy) Rule, 2014 notified w.e.f. 22nd January 2021, the Company in not required to carry out impact assessment for CSR Projects.

- 5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any: **Not Applicable**
- 6. Average net profit of the company as per section 135(5) Rs.(3,707) Lakhs
 - (a) Two percent of average net profit of the company as per section 135(5)- Rs. (74) Lakhs
 - (b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years. Nil
 - (c) Amount required to be set off for the financial year, if any Nil
 - (d) Total CSR obligation for the financial year (7a+7b-7c) Nil
- 8. (a) CSR amount spent or unspent for the financial year 2024-25: Nil

Total Amount Spent	Amount unspent (in Rs.)						
for the Financial Year. (in Rs.)	CSR Account as	nsferred to Unspent per sub-section (6) tion 135.	Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135.				
	Amount.	Date of transfer	Name of the Fund	Amount.	Date of transfer.		
Nil	Nil			Nil			

- (b) Details of CSR amount spent against ongoing projects for the financial year: Not Applicable
- (c) Details of CSR amount spent against other than ongoing projects for the financial year: Nil

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
SI No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/ No)		on of the oject District	Project duration	Amount allocated for the project (in Rs.)	Amount spent in the current financial year (in Rs.)	Amount transferred to unspent CSR account for the project as per Section 135(6) (in Rs.)	Mode of implementation – Direct (Yes/ No)	through	nplementation- Implementing gency CSR Registration number
	Nil											

- (d) Amount spent in Administrative Overheads: Nil
- (e) Amount spent on Impact Assessment, if applicable: Nil



- Annual Report 2024-25
- (f) Total amount spent for the Financial Year (8b+8c+8d+8e): Nil
- (g) Excess amount for set off, if any: Nil
- 9. (a) Details of Unspent CSR amount for the preceding three financial years: Nil
 - (b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s): Not Applicable
- 10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year-(asset-wise details).
 - (a) Date of creation or acquisition of the capital asset(s): Not Applicable
 - (b) Amount of CSR spent for creation or acquisition of capital asset: Not Applicable
 - (c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: Not Applicable
 - (d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset): Not Applicable
- 11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5): Not Applicable

For and on behalf of the Committee and the Board of Directors,

Srinivasan Krishnan Chairperson of CSR Committee DIN:08709528

Date: 02nd May 2025 Place: Bengaluru Nirbhay Abhay Kanoria Managing Director DIN: 02558300

ANNEXURE - V

FORM NO. MR-3

SECRETARIAL AUDIT REPORT FOR THE FINANCIAL YEAR ENDED MARCH 31, 2025

(Pursuant to section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and remuneration of Managerial Personnel) Rules, 2014)

To, The Members, **Anglo-French Drugs & Industries Limited** CIN: L24230KA1923PLC010205 Registered Office: Plot No.4, Phase II, Peenya Industrial Area, Peenya, Peenya Small Industries, Bangalore, Bangalore North, Karnataka, India, 560058

I have conducted the secretarial audit of the compliance of applicable statutory provisions and adherence to good corporate practices by M/s. Anglo-French Drugs and Industries Limited, (herein after referred to as "Company"). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in our opinion, the company has, during the audit period covering the financial year ended on 31st March 2025 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance- mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March 2025 according to the provisions of:

- The Companies Act, 2013, (the Act) and the Rules made thereunder;
- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
- (iii) The Depositories Act, 1996 and the Regulations and By-laws framed thereunder;
- Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- The following Regulations are applicable, as amended from time to time and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act');
 - The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
 - c. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with stakeholders; and
 - The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - The Securities and Exchange Board of India (Issue of Capital and Disclosures Requirements) Regulations, 2018;

- f. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;
- (vi) The following Regulations, as amended from time to time and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'), are not applicable for the period under review;
 - The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; as the Company has not issued any shares to employees during the year under review;
 - b) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; as the Company has not issued any debt securities during the year under review;
 - c) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2022; as the Company has not opted for delisting process during the year under review;
- (vii) Employees Provident Fund and Miscellaneous Provisions Act, 1952
- (viii) Employees State Insurance Act, 1948
- (ix) Environment Protection Act, 1986 and other applicable environmental laws
- (x) Indian Contract Act, 1872
- (xi) Income Tax Act, 1961, Goods and Service Tax Act, 2017 and other related laws
- (xii) Payment of Bonus Act, 1965
- (xiii) Payment of Gratuity Act, 1972 and such other applicable labour laws.
- (xiv) Trade Marks Act, 1999

Further, the sectoral laws applicable to the company were as under:

- (i) The Drugs and Cosmetics Act, 1940
- (ii) The Narcotic Drugs and Psychotropic Substances Act, 1985
- (iii) The Drugs Price Control Order, 2016
- (iv) The Factories Act, 1948
- (v) The Air (Prevention and Control of Pollution) Act- 1981 and relevant rules.
- (vi) The Water (Prevention and Control of Pollution) Act- 1974 and relevant rules.
- (vii) The Environment (Protection) Act-1986 and relevant rules.
- (viii) Bio-Medical Waste (Management and Handling) Rules, 1998.
- (ix) Chemical Accidents (Emergency Planning Preparedness and Response) Rules, 1996.
- (x) Hazardous and other waste Management and transboundary Movement Rules, 2016

Annual Report 2024-25

I have relied on the representation made by the Company and its Officers for systems and mechanism formed by the Company for compliances under other applicable Acts, Laws, Rules and Regulations to the Company. I have also examined compliance with the applicable clauses of the following:

- Secretarial Standards with respect to Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India;
- ii) Guidance note on ICSI Auditing Standards CSAS 1 to CSAS 4;
- iii) Listing Agreement entered into with the Metropolitan Stock Exchange of India Limited.

I further report that:

- The Board of Directors of the Company is duly constituted with proper composition of Executive Directors, Non-Executive Directors and Independent Directors including Women Directors.
- (ii) Adequate notice is given to all directors to schedule the Board, Committee meetings and Postal Ballot. Agenda and detailed notes on agenda were sent in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- (iii) Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.
- (iv) There are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- (v) During the audit period the company has no major decisions taken by the members in pursuance to section 180 of the Companies Act, 2013, having major bearing on the company's affairs in pursuance of the above referred laws, rules,

regulations, guidelines, standards etc.

- (vi) We further report that during the review period, significant transactions have been placed before the shareholders through postal ballot and the same is approved by them. These following transactions are having a significant impact on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.:
 - a) Buy-back of Equity Shares from the existing Shareholders of the Company.
 - b) Conducted postal ballot for
 - Re-designation of Mr. Abhay Kanoria DIN:00108894 from Chairman & Managing Director to Chairman
 - Re-designation of Mr Uddhav Abhay Kanoria DIN:00108909 President & Whole Time Director as Managing Director
 - Re-designation of Mr. Nirbhay Abhay Kanoria DIN:02558300 President & Whole Time Director as Managing Director.

This Report is to be read with our letter of even date which is annexed as Annexure A and forms an integral part of this report.

CS Raghavendra Naveen B K

Practicing Company Secretary Membership No.: 59814 CP No.: 23728 UDIN: A059814G000218060 ICSI Unique Code: I2020KR2098300 Peer Review Certificate No:6511/2025

Place: Bengaluru Date: 28/04/2025

Annexure - A to MR-3

To, The Members, Anglo-French Drugs & Industries Limited CIN: L24230KA1923PLC010205 Registered Office: Plot No.4, Phase II, Peenya Industrial Area, Peenya, Peenya Small Industries, Bangalore, Bangalore North, Karnataka, India, 560058

Our report of even date is to be read along with this letter.

Management's Responsibility

1. To maintain the Secretarial records, devise proper systems and to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor's Responsibility

- Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the Company with respect to secretarial compliances.
- 3. We have conducted the Audit as per the applicable Auditing Standards issued by the Institute of Company Secretaries of India.
- 4. We believe that audit evidence and information obtained from the Company's management is adequate and appropriate for us to provide a basis for our opinion.
- 5. Wherever required, we have obtained reasonable assurance whether the statements prepared, documents or Records, in relation to Secretarial Audit, maintained by the Company, are free from misstatement.
- 6. Wherever required, we have obtained the management's representation about the compliance of laws, rules and regulations and happening of events etc.

Disclaimer

- 7. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.
- 8. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

CS Raghavendra Naveen B K

Practicing Company Secretary Membership No.: 59814, CP No.: 23728 UDIN: A059814G000218060 ICSI Unique Code: I2020KR2098300 Peer Review Certificate No:6511/2025

Place: Bengaluru Date: 28/04/2025

ANNEXURE - VI

CORPORATE GOVERNANCE REPORT

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

Anglo-French Drugs & Industries Limited commenced its operations in India in 1923, by importing and selling pharmaceutical products. By the year 1955, Anglo-French was one of the most reputed pharmaceutical organizations, manufacturing and marketing Sulpha drugs, Vitamins, Anti-Asthmatics and other ethical specialties.

The Company has a strong legacy of believing in sound corporate practices, based on transparency, accountability and high level of integrity, which forms an essential part in the functioning of the Company and increasing the long-term enhancement of stakeholders' value & interest. The Company believes that its actions must result in enhancing corporate performance by maximizing stakeholders' value and also in motivating work force. We, as a Company, have always focused on 'best-in-class' Corporate Governance practices, which is a key driver for sustainable corporate growth and long-term value creation for our stakeholders. Through the Governance mechanism in the Company, the Board along with its Committees undertakes its fiduciary responsibilities towards all its stakeholders by ensuring transparency, fair play and independence in its decision making. The Company's Policies are an extension of its values and reflect its commitment to ethical business practices, integrity and regulatory compliances.

The Company has won Quality Excellence award three times from Indian Drug Manufacturers Association, Presently, the Company manufactures and markets a wide range of pharmaceutical products in the Therapeutic groups of Vitamins, Sleep inducing Agents, Anti-Malarial, Anti-epileptics, Antibiotics, Cardiac drugs, Cold Remedies, Anti-ulcer GRD (Gastoesophageal reflex disease) Hematinic (iron syrup) anti-fungal and oral hypoglycemic etc.,. The Company is also adding 4 to 6 new products every year.

2. BOARD OF DIRECTORS

As on 31st March 2025, the Company had 7 Directors, comprising 4 Non-Executive Directors, 3 Executive Directors.

The names and categories of the Directors on the Board, their attendance at Board Meetings held during the year and at the last Annual General Meeting, as also the number of Directorships and Committee Memberships held by them in other public companies as on 31st March 2025 are given herein below. Other Directorships do not include Alternate Directorships and directorships in private limited companies, foreign Companies and companies under Section 8 of the Act. Chairmanships / Memberships of Board Committees only include Audit Committee and Shareholders' Relationship Committee.

Name of the Director	Category	No. of Board Meetings	Attended Last AGM	No. of other Directorships and Committee positions held in other listed companies			
		Attended		Director	Committee Member	Committee Chairman	
Mr. Abhay Kanoria DIN: 00108894	Executive	5	Yes	-	-	-	
Mr. Uddhav Kanoria DIN:00108909	Executive	4	No	-	-	-	
Mr. Nirbhay Kanoria DIN:02558300	Executive	5	Yes	-	-	-	
Mr. Rakesh Kanyadi # DIN:08532438	Non-Executive	4	Yes	-	-	-	
Mr. Rohit Choraria DIN:'07003583	Non-Executive	5	Yes	-	-	-	
Mr.Pradeep Joshi DIN: 02713934	Independent Non-Executive	5	Yes	-	-	-	
Mr. Srinivasan Krishnan DIN: 10634071	Independent Non-Executive	5	Yes	-	-	-	
Mrs. Rani Shokeen DIN:10634071 @	Independent Non-Executive	3	No				
Mr. Ahmedali Nalagath DIN: 00704341 @@	Independent Non-Executive	3	No	-	-	-	
Mrs. Jayashree V Ranade DIN: 09320683 \$	Nominee Director	Nil	No	-	-	-	

@@ Pursuant to section 149(11) of the Companies Act 2013, the two term of Independent Director Mr. N. Ahmedali DIN: 00704341 concluded on the 101st AGM dated:12th August 2024. Consequently, retired from Board, Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee

@ Mrs.Rani Shokeen was appointed as Additional Director by the Board at its Meeting held on 28th May 2024 and regularized in 101st AGM as Independent Non-Executive Director.

Mr.Rakesh Kanyadi Non-Executive Director resigned on 7th November 2024 for his personal reason. He was not on Board of any other company.

\$ Mrs. Jayashree V Ranade Nominee Director retired on 30th April 2024.

None of the Directors on the Board hold directorships in more than eight public companies. Further none of them is a member of more than ten committees or chairman of more than five committees across all the public companies in which he is a Director.

Mr. Abhay Kanoria, Mr. Uddhav Kanoria and Mr. Nirbhay Kanoria are the Directors on the Board who are related to each other.

During the Financial year 2024-25, Company held 5 Board Meetings on 28th May 2024, 29th July 2024, 12th August 2024, 07th November 2024 and 13th February 2025. The information and declarations as required in terms of Listing Regulations is being regularly placed before the Board.

As on 31st March 2025, Non-Executive Directors Mr.Rohit Choraria holds 348 Equity Shares of the Company. None of the other Non-Executive Directors hold shares in the Company.

The details of the familiarization programs for Independent Directors are available on the website of the Company www.afdil.com.

Skills / Expertise / Competence identified by the of the Board of Directors:

The Board has identified the following skills/ expertise/ competencies as required for the effective functioning of the Company which are currently available with the Board:

Name of the Director	Area of skills / expertise / competence							
	Strategy	Finance	Leadership	Technical	HR	Governance	Business Development	
Mr. Abhay Kanoria	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	
Mr. Uddhav Kanoria	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	
Mr. Nirbhay Kanoria	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	
Mr. Ahmedali Nalagath	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	
Mr. Rakesh Kanyadi	\checkmark	-	\checkmark	\checkmark	-	\checkmark	-	
Mr. Rohit Choraria	\checkmark	\checkmark	\checkmark	\checkmark	-	\checkmark	-	
Mrs.Rani Shokeen	\checkmark	-	\checkmark	-	\checkmark	√	\checkmark	
Mr.Pradeep Joshi	\checkmark	\checkmark	\checkmark	\checkmark	-	\checkmark	\checkmark	
Mr.Srinivasan Krishnan	\checkmark	\checkmark	\checkmark	\checkmark	-	\checkmark		

3 AUDIT COMMITTEE

The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of SEBI Listing Regulations, read with Section 177 of the Act. The Audit Committee assists the board in the dissemination of financial information and in overseeing the financial and accounting processes in the company.

The terms of reference of the Audit Committee covers all matters specified in Regulation 18(3) Part C of SEBI Listing Regulations and in concurrence with Section 177 of the Act 2013. The terms of reference broadly include review of internal audit reports and action taken on reports, assessment of the efficacy of the internal control systems/ financial reporting systems and reviewing the adequacy of the financial policies and practices followed by the Company. The Audit Committee reviews the compliance with legal and statutory requirements, the quarterly and annual financial statements and related party transactions and reports its findings to the Board. The Committee also recommends the appointment of internal and statutory auditor. The Audit Committee takes note of any default in the payments to creditors and debtors. The Committee also looks into those matters specifically referred to it by the Board.

The Audit Committee invites such of the executives, as it considers appropriate (particularly the head of the finance function), representatives of the statutory auditors and representatives of the internal auditors to be present at its meetings. The Company Secretary acts as the Secretary to the Audit Committee.,

During the year 2024-25, Audit Committee had 4 meetings 28th May 2024, 12th August 2024, 07th November 2024 and 13th February 2025. The Audit Committee were re-constituted at the Board Meeting held on 12th August 2024. The composition of the Audit Committee and the details of meetings attended by its members are as follows:

Name of the Director	Category	No. of Meetings Attended
Mr.Pradeep V Joshi – Chairman - wef 12-08-2024	Independent Non-Executive	2
Mr.S.Krishnan - wef 12-08-2024	Independent Non-Executive	4
Mr.Nirbhay Abhay Kanoria - wef 12-08-2024	Executive	2
Mr. Ahmedali Nalagath – Chairman - Upto 12-08-2024	Independent Non-Executive	2
Mr. Abhay Kanoria – Upto 12-08-2024	Executive	2

Annual Report 2024-25

4 NOMINATION AND REMUNERATION COMMITTEE

The nomination and remuneration committee of the Company is constituted in line with the provisions of Regulation 19 of SEBI Listing Regulations, read with Section 178 of the Act.

The broad terms of reference of the Nomination and Remuneration Committee are to recommend to the Board the setup and composition of the Board and its committees, the appointment or reappointment of Directors, the appointment of KMP, and the remuneration payable to Directors, considering criteria such as industry benchmarks, financial performance of the Company, performance of the respective Director, etc..

During the year 2024-25, Nomination and Remuneration Committee had 2 meetings held on 28th May 2024 and 13th February 2025. The Nomination & Remuneration Committee were re-constituted at the Board Meeting held on 12th August 2024. The composition of the Nomination and Remuneration Committee and the details of meetings attended by its members are as follows:

Name of the Director	Category	No. of Meetings Attended
Mr.S.Krishnan – Chairman - wef 12-08-2024	Independent Non-Executive	1
Mr.Pradeep V Joshi –wef 12-08-2024	Independent Non-Executive	1
Mr.Rohit Choraria – wef 12-08-2024	Non-Executive	0
Mr. Ahmedali Nalagath – Chairman - Upto 12-08-2024	Independent Non-Executive	1
Mr. Abhay Kanoria – Upto 12-08-2024	Executive	1

Performance Evaluation criteria for Independent Directors:

The performance evaluation criteria for independent directors is determined by the Nomination and Remuneration Committee. An indicative list of factors that may be evaluated include participation and contribution by a Director, commitment, effective deployment of knowledge and expertise, effective management of relationship with stakeholders, integrity and maintenance of confidentiality and independence of performance and judgment. Independent Director meeting held on 13th February 2025.

5 STAKEHOLDERS' RELATIONSHIP COMMITTEE

The Stakeholders' Relationship Committee is constituted in line with the provisions of Regulation 20 of SEBI Listing Regulations read with Section 178 of the Act.

The broad terms of reference of the Stakeholders' Relationship Committee are to look into the redressal of investors' complaints in connection with transfer of shares, non-receipt of annual reports, non-receipt of declared dividends, etc. In addition, the Committee also looks into matters which can facilitate services and relations with the investors.

During the year 2024-25, the Stakeholders' Relationship Committee met one time 13th February 2025. The Stakeholders' Relationship Committee were re-constituted at the Board Meeting held on 12th August 2024. The composition of the Stakeholders' Relationship Committee and the details of meetings attended by its members are as follows:

Name of the Director	Category	No. of Meetings Attended
Mrs.Rani Shokeen – Chairman - wef 12-08-2024	Independent Non-Executive	1
Mr.Pradeep V Joshi –wef 12-08-2024	Independent Non-Executive	1
Mr.Uddhav Kanoria - Member	Executive	1
Mr. Nirbhay Kanoria - Member	Executive	1

Mrs. Sriee Aneetha M, Company Secretary, is the Compliance Officer of the Company, and shareholders may contact her for any clarification / complaint at the Registered Office of the Company.

There were no shareholders' complaints outstanding as on April 1, 2024 and as on March 31,2025. During the year all the requests for dematerializations were approved by the Company. No valid transfer / transmission of shares was pending as of 31st March 2025.

6 RISK MANAGEMENT COMMITTEE

In terms of Regulation 21 of SEBI (LODR) Regulations, 2015, the provision of the said Regulation 21(5) is not applicable to the company for the financial year 2024-25.

7 SENIOR MANAGEMENT

The particulars of senior management as per Regulation 16(1) (d) of the Listing Regulations during the Financial Year 2024-25 are as follows:

Mr.Abhay Kanoria	Chairman & Managing Director (upto 20-03-2025) and re-designated to Chairman (w.e.f 20-03-2025)		
Mr.Uddhav Kanoria	Jddhav Kanoria President & Whole-Time Director (upto 20-03-2025) and re-designated to Managing Director (w.e.f 20-03-20		
Mr.Nirbhay Kanoria	President & Whole-Time Director (upto 20-03-2025) and re-designated to Managing Director (w.e.f 20-03-2025		
Mr. Manik Kumar Singh	Chief Financial Officer – w.e.f 29-07-2024		
Mrs. Sriee Aneetha M	Company Secretary and Compliance Officer		

8 REMUNERATION OF DIRECTORS

Pursuant to the requirements of the Companies Act, 2013 and Part D(A)(1) of Schedule II to SEBI (LODR) Regulations 2015, the Board has, on the recommendation of the Nomination & Remuneration Committee, framed a Remuneration Policy for its Directors, considering particularly the following, amongst other things:

Remuneration to the Executive Directors:

The remuneration of the Managing / Whole-time / Executive Director(s) is decided by the Nomination & Remuneration Committee (NRC), based on the criteria such as industry benchmarks, Company's performance vis-à-vis Industry performance / track record of the Managing / Whole-time / Executive Director(s) and the same is recommended to the Board of Directors. The Company pays remuneration by way of salary, perquisites & allowances (fixed component), Performance Incentive, specifically computed for this purpose, as per the provisions of Section 198 of the Companies Act, 2013, to all / each of its Whole-time / Executive Director(s), as may be recommended by NRC and approved by the Board, such that the total remuneration (including commission / bonus, if any), as decided by the Board of Directors in its absolute discretion, does not exceed the limits prescribed under Section 197 and Schedule V to the Companies Act, 2013. In case of inadequate or no profits, remuneration is paid, subject to the provisions of the Act and / or approval of the shareholders.

Further, the annual increments are recommended by the Nomination & Remuneration Committee within the salary scale of each of the Executive Directors. The terms of remuneration are approved by the Shareholders at the Annual General Meeting and are effected in the individual Agreements, executed with the respective Executive Directors.

Remuneration to the Non-Executive Directors:

As required under Schedule V(C)(6)(b) to SEBI (LODR) Regulations 2015, the Company has uploaded the criteria for payment of Remuneration to the Non-Executive Directors onto the website of the Company, at the following web link:www.afdil.com/Investors

The summary of the remuneration paid / payable to all the Directors for FY 2024–25 is given below:

SI. No.	Name of the Director	Salary*	Benefits (Perquisites)	Commission	Sitting Fees	Total
1	Mr.Abhay Kanoria	47.23	29.50	-	-	76.73
2	Mr.Uddhav Kanoria	28.80	19.30	-	-	48.10
3	Mr.Nirbhay Kanoria	23.40	15.94	-	-	39.34
4	Mr. Ahmedali Nalagath	-	-	-	1.20	1.20
5	Mr.Rakesh Kanyadi	13.49	9.94	-	0.80	24.23
6	Mrs.Rani Shokeen	-	-	-	-	-
7	Mr.S.Krishnan	-	-	-	2.60	2.60
8	Mr. Pradeep V Joshi	-	-	-	2.20	2.20
9	Mr.Rohit Choraria	-	-	-	1.20	1.20

* Fixed Component

Notes:

- The Agreement with the Executive Directors is for a period of 03 (three) years. Either party to the Agreement is entitled to terminate the Agreement by giving 03 (three) months' notice to the other party, as mentioned in the Agreement.
- The Company does not have any stock option scheme for its Directors or employees.
- Severance fees: NIL

9 GENERAL BODY MEETINGS

Required details of last three Annual General Meetings (AGMs), are as below:

AGM/EGM	Date & Time	Venue	Special Resolution(s)
101st AGM	12th August 2024 at 4:00 pm	Hotel The Fern, President Hall, 6/1, Tumkur Main Road, Next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase-I, Yeshwanthpur, Bengaluru 560022.	 Re-appointment of Mr.Uddhav Abhay Kanoria, president and whole time director of the Company, together with revision of Remuneration.



AGM/EGM	Date & Time	Venue	Special Resolution(s)
EGM-2023-24	14th July 2023 at 4.00 pm	Peenya Industrial Area, Peenya,	To Adopt new Articles of Association in accordance with Companies Act, 2013.
100th AGM	03rd August 2023 at 4:30 pm	Bangalore 560058.	1. Re-appointment of Mr.Abhay Kanoria DIN:00108894 as Chairman and Managing Director of the Company, together with revision of Remuneration.
			2. Re-appointment of Mr.Nirbhay Abhay Kanoria DIN:02558300 as President and Whole Time Director of the Company, together with revision of Remuneration.
			 Revision of Remuneration to Mr. Uddhav Abhay Kanoria DIN:00108909 President and Whole Time Director of the Company.
99th AGM	10th August 2022 at 4:30 pm		No Special Resolution was passed in this meeting.

All the special resolutions, moved in the previous 03 (three) Annual General Meetings were passed by the majority of the Members present & voted at the Meeting / remotely e-voted before the Meeting.

During the Financial year 2024-25;

EGM - held on 21st August 2024 via Video Conference or Other Audio-Visual means at 12:00 Noon, Approved Buyback of Equity Shares of the Company.

POSTAL BALLOT :

- Details of Resolutions passed by Postal Ballot : the Company had sought approval of its shareholders by way of Postal Ballot а through remote e-Voting process, vide Notice dated 13th February 2025, on the following Resolution(s):
 - Change in designation of Mr.Abhay Kanoria DIN:00108894 from Chairman & Managing Director of the Company to Chairman
 - Change in designation of Mr Uddhav Abhay Kanoria DIN:00108909 from President & Whole Time Director to Managing Director
 - Change in designation of Mr. Nirbhay Abhay Kanoria DIN:02558300 from President & Whole Time Director to Managing Director

b. Details of e-voting:

Description of the Resolution	Votes in favour of the Resolution(s)		Votes against of the Resolution(s)		Invalid
	No. of votes cast	% of total valid votes cast	No. of votes cast	% of total valid votes cast	
Change in designation of Mr.Abhay Kanoria DIN:00108894 from Chairman & Managing Director of the Company to Chairman	751650	99.99%	60	00.01%	Nil
Change in designation of Mr. Uddhav Abhay Kanoria DIN:00108909 from President & Whole Time Director to Managing Director	751650	99.99%	60	00.01%	Nil
Change in designation of Mr. Nirbhay Abhay Kanoria DIN:02558300 from President & Whole Time Director to Managing Director	751650	99.99%	60	00.01%	Nil

The resolutions were passed with the requisite majority on 20th March 2025 (being the last date of remote e-Voting), and the results of which were announced on 20th March 2025.

C. Person who conducted the aforesaid postal ballot exercise:

The Board of Directors had appointed Mr. Raghavendra Naveen BK Practicing Company Secretary, (M No. 598147; CP 23728) as the Scrutinizer to conduct the Postal Ballot only through the remote e-Voting process and for scrutinizing the votes cast therein, in a fair and transparent manner.

Procedure for Postal Ballot: d

In compliance with the provisions of Sections 108 and Section 110 and other applicable provisions of the Act, read with the Rules framed thereunder and the General Circular Nos. 14/2020 dated 8th April 2020, 17/2020 dated 13th April 2020, 10/2021 dated 23rd June 2021, 03/2022 dated 5th May 2022, 11/2022 dated 28th December 2022, 09/2023 dated 25th September 2023 and other relevant circulars and notifications issued by the Ministry of Corporate Affairs, the Company provided only remote e-Voting facility to its Equity Shareholders to enable them to cast their votes electronically instead of submitting the Postal Ballot form. The Company engaged the services of NSDL for facilitating remote e-Voting to enable the Members to cast their votes electronically.

The Company sent the Postal Ballot Notice in electronic form only to those Equity Shareholders whose names appeared in the Register of Members/List of Beneficial Owners as received from NSDL and CDSL and whose e-mail addresses were available with the Company/Depositories/the Depository Participants/the Company's Registrar and Share Transfer Agent as on the cut-off date. Voting rights were reckoned on the paid-up value of the shares registered in the names of the Members as on the cut-off date i.e., Friday, 14th February 2025. Members who desired to exercise their votes by electronic mode were requested to vote before close of business hours on the last date of e-Voting.

The Scrutinizer, after the completion of scrutiny, submitted his report and the consolidated results of the Postal Ballot through remote e-Voting were announced by the Company Secretary on 20th March 2025. The results are displayed on the website of the Company, www.afdil.com besides being communicated to the stock exchange, depository and Registrar and Share Transfer Agent. The resolutions are deemed to have been passed on 20th March 2025, the last date specified for receipt of votes through remote e-Voting process.

e. Details of special resolution proposed to be conducted through postal ballot: Company proposes to take shareholders' approval for agenda no.1 Shifting of Registered office from the State of Karnataka to the State of Maharashtra and agenda no.2 Adoption of New set of Memorandum of Association of the Company as per the Companies Act 2013.

10 MEANS OF COMMUNICATIONS:

The Company regularly publishes its Quarterly / Half-yearly & Annual Financial Results in newspapers, viz. Financial Express (English) & Udayakala (Kannada) and simultaneously uploads them onto the website of the Company: https://www.afdil.com/. Hence, the financial results are not sent / posted to the shareholders.

The Annual Report is e-mailed to those Shareholders, whose e-mail IDs are registered with the Company / RTA / DP and posted / sent / couriered to balance / other shareholders, who either do not have e-mail IDs or whose e-mail IDs are not registered with the Company / RTA / DP, or who have specifically requested for a physical copy. The Company has a designated e-mail id: compliance@afdil.com exclusively for investor relation, and the same is prominently displayed on the Company's website www. afdil.com. A separate dedicated section under "Investors", on the Company's website gives information on unclaimed dividends, shareholding pattern, quarterly / half yearly results and other relevant information of interest to the investors / public.

11 GENERAL SHAREHOLDER INFORMATION:

а	Day, Date and Time and Venue of Annual General Meeting	11th August 2025 at 4:00 pm at Hotel The Fern Residency, President Hall, 6/1, Tumkur Main Road, next to Sparsh Hospital, Yeshwanthpur Industrial Area, Phase 1, Yeswanthpur, Bengaluru- 560022.		
b.	Financial Year (FY)	01st April 2024 – 31st March 2025		
C.	Book Closure Date	05th August 2025 to 11th August 2025		
		(Both days inclusive)		
d.	Dividend Payment date	On or after 14th August 2025 (within the statutory time limit of 30 days) subject to Shareholders' approval at the AGM.		
e.	Listing of Equity Shares on Stock Exchange and Listing fees	Metropolitan Stock Exchange of India Limited, Building A, Unit 205A, 2nd Floor, Piramal Agastya Corporate Park, L.B.S Road, Kurla West, Mumbai - 400 070		
		Listing fees as prescribed has been paid to the above stock exchange for the FY 2025-26.		
f.	Scrip Code ISIN	INE570E01016		
g.	Market Price data – high, low during each month in last Financial year.	Said Scrip is under Special Pre-Open Session(SPOS) Category as Price Not Discovered		
h.	Performance in Comparison	NA		
i.	In case the securities are suspended from trading.	Nil		
j	Registrar to an issue and share transfer agents	New RTA w.e.f 06-12-2024 Integrated Registry Management Services Private Limited, 30, Ramana Residency 4th Cross, Sampige Road, Malleswaram, Bangalore - 560 003		
		Old RTA upto 06-12-2024 Canbank Computer Services Limited J P Royale, 1st Floor, No.218, 2nd Main, Sampige Road, (Near 14th Cross), Malleswaram, Bengaluru – 560003		

k. Share Transfer System :

In terms of Regulation 40(1) of SEBI LODR, as amended from time to time, transfer, transmission and transposition of securities shall be effected only in dematerialised form.

Pursuant to SEBI Circular dated 25th January 2022, the listed companies shall issue the securities in dematerialised form only, for processing any service requests from shareholders viz., issue of duplicate share certificates, endorsement, transmission, transposition, etc. After processing the service request, a letter of confirmation will be issued to the Shareholders and shall be valid for a period of 120 days, within which the Shareholder shall make a request to the Depository Participant for dematerialising those shares. If the Shareholders fail to submit the dematerialisation request within 120 days, then the Company shall credit those shares in the Suspense Escrow Demat account held by the Company. As on date Company did not have any shares to transfer to Suspense Escrow account.

Shareholders can claim these shares transferred to Suspense Escrow Demat account on submission of necessary documentation.

I. Distribution of shareholding as on 31st March 2025:

Category (Shares)	Shareholders		Amo	ount
	Numbers	% to Total	In Rs.	% to Total
Up to 5,000	1287	97.80	892670	7.92
5,000 - 10,000	8	0.61	49600	0.44
10,001 - 20,000	5	0.38	75830	0.67
20,001 - 30,000	3	0.23	67640	0.60
30,001 - 40,000	4	0.30	138330	1.23
40,001 - 50,000	1	0.08	42000	0.37
50,001 - 1,00,000	0	0.00	0	0.00
1,00,001 and Above	8	0.61	10002750	88.76
TOTAL	1316	100.00	11268820	100.00

m. Dematerialization of Shares and Liquidity:

As on 31st March 2025, 95.92% of the Company's Equity Capital was held in dematerialised form with NSDL and CDSL. Trading in equity shares of the Company is permitted only in dematerialised form with effect from 15th February 1999 as per the notification issued by the Securities and Exchange Board of India. Further, effective 1st April 2019, SEBI has amended Regulation 40 of the SEBI LODR, which deals with the transfer or transmission or transposition of securities. According to this amendment, the requests for effecting the transfer of listed securities shall not be processed unless the securities are held in dematerialised form with a Depository. Therefore, for effecting any transfer, the securities shall mandatorily be required to be in demat form.

n.	Outstanding GDR/ADR	Nil
0.	Commodity price risk or Foreign exchange risk	Nil
p.	Plant Location	Plot No.4, Phase II, Peenya Industrial Area, Peenya, Bangalore 560058.
q.	Address for Correspondence	Plot No.4, Phase II, Peenya Industrial Area, Peenya, Bangalore 560058.
r.	List of credit ratings	NA

12 OTHER DISCLOSURES:

a. Related Party Transactions:

All transactions entered into with related parties as defined under the Act and Regulation 23 of SEBI Listing Regulations during the financial year were in the ordinary course of business. These have been approved by the Audit Committee. The Board has approved a policy for related party transactions which has been uploaded on the Company's website.

b. Disclosure of Accounting Treatment

The Company has prepared the Financial Statements in accordance with the Indian Accounting Standards (IND AS) to comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the relevant provisions of the Act, as applicable.

c. Disclosures on materially significant related party transactions:

During the year under review, besides the transactions reported in Note 41 forming part of the financial statements for the year ended 31st March 2025 in the Annual Report, there were no other material related party transactions of the Company with its Promoters, Directors or the Management or their relatives and subsidiaries, associate company and joint venture. These transactions do not have any potential conflict with the interest of the Company at large. All related party transactions are placed before the Audit Committee of the Board periodically and placed for Board's information if required. Further, there are no material individual transactions that are not in the normal course of business or not on an arm's length basis.

d. Details of Non-compliance :

There have been no instances of non-compliance on any matter as regards the rules and regulations prescribed by the Stock Exchange, SEBI or any statutory authority relating to capital markets during the last three years. No penalties or strictures have been imposed by them on the Company.

e. Details of establishment of vigil mechanism/whistle blower policy :

The Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism as defined under Regulation 22 of SEBI Listing Regulations for directors and employees to report concerns about unethical behaviour. No person has been denied access to the Chairman of the Audit Committee. The said policy has been also put up on the website of the Company.

f. Details of compliance with mandatory requirement and adoption of the non-mandatory requirements

The Company has complied with mandatory requirements and based on need basis, adopted non-mandatory requirements. The Company has fulfilled the following discretionary requirements:

- The auditors' report on statutory financial statements of the Company are unqualified.
- The Internal Auditors of the Company make presentations to the Audit Committee on their reports.
- Since the Financial Results are published in newspapers having wide circulation and simultaneously also uploaded on the website of the Company and Stock Exchange, only the Annual Reports for the financial year 2024-25 are sent through electronic mode to all the Members and to those Physical copy on request.

g. Disclosure on website Policy for determining 'material' subsidiaries -

The Policy for determining 'material' subsidiaries is posted on the website of the Company and can be accessed at www.afdil.com under Investor section.

h. Disclosure of Policy on dealing with Related Party Transaction:

The Policy on Related Party Transactions is posted on the website of the Company and can be accessed at www.afdil.com under Investor section.

i. Disclosure of Commodity Price Risk or Foreign Exchange Risk and Hedging Activities :

The Company's foreign exchange exposures are typically of short term in nature, and in some cases provide a natural hedge with respect to import and export payments. Given the typically short term nature of the Company's foreign exchange exposures, no hedging by way of derivative financial instruments has been used as the cost of such instruments has been found to be high compared with historical foreign exchange movements over such periods.

j. Details of utilisation of funds raised through preferential allotment or qualified institutions placement :

During the Financial year 2024-25, Company has not raised any funds through preferential allotment or qualified institutions placement.

k. Certificate from Practicing Company Secretary:

A certificate dated:28th April 2025 has been obtained from a Practicing Company Secretary confirming that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of companies by SEBI/Ministry of Corporate Affairs or any such statutory authority.

I. Disclosure of non-acceptance of any recommendation of any committee by the Board in the Financial Year 2024-25 and its reason:

There was no such instance during the Financial Year 2024-25 where the Board had not accepted any recommendation of any Committee of the Board.

m. Fees paid to Statutory Auditor:

A total fee of Rs.3.12 Lakhs was paid by the Company, on a consolidated basis, for all services by the Statutory Auditor and all entities in the network firm/network entity of which the statutory auditor is a part.

n. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

There were no Complaints filed during the year 2024-25 and there were no complaints pending as on end of the Financial year 2024-25.

o. Disclose by listed entity and its subsidiaries of Loans and advances:

The particulars of Loans and Advances entered between the Company and the Related Parties are given in Notes No.41.

p. The Company do not have any Material Subsidiaries.

On behalf of the Board of Directors

Place: Bengaluru Date:02nd May 2025 Nirbhay Abhay Kanoria Managing Director DIN:02558300

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

INDUSTRY STRUCTURE AND DEVELOPMENTS

Anglo-French Drugs & Industries Limited (AFDIL) commenced its operations in 1923 by importing and selling pharmaceutical products.

A few years later, the Company established its own manufacturing facilities in Bombay. By the year 1955, Anglo-French was one of the most reputed pharmaceutical organizations, manufacturing and marketing Sulpha drugs, Vitamins, Anti-Asthmatics and other ethical specialities.

In 1959, Anglo-French became an associate of F-Hoffmann-La Roche, Basle, Switzerland. This association enabled Anglo-French to have an access to the molecules developed by F.Hoffmann-La Roche.

At the turn of the sixth decade, Anglo-French entered the field of manufacture of Injectable in India. The Company was the first to manufacture "Single Vitamin" injectable and a combination of B Complex Vitamins. Later on, once again, Anglo-French was the first to manufacture and market in India a combination of Vitamin B1 and Vitamin B12. With a view to modernizing its manufacturing facilities and preparing for further expansion, in 1972, the formulation manufacturing facilities of the Company were shifted from Bombay to Bangalore. In late 1970s, the Company established its multipurpose basic drugs manufacturing unit also at Bangalore. The Formulation facilities established in 1972 covered Tablets, Liquids, Capsules and Protein preparations.

In 1985, the controlling interest in the Company was acquired by the Kanoria group.

The Company has a well-equipped Quality Assurance Department, which thoroughly monitors quality of each and every product at every stage.

In 1996 a tableting only facility was established in Peenya Industrial Estate. In 2024 these facilities were upgraded to be PIC/S and EAEU compliant.

COMPANY AND DIVISION WISE PERFORMANCE

At AFDIL, we are committed to our Vision of "Reaching People and Touching Lives Globally as a Leading Provider of Valued Medicines." We strive to achieve this vision through a well-defined strategy that focuses on sustainable growth, cost leadership, business development, balanced investments and future profitability.

AFDIL is in the business of health care to mitigate human ailments so it is very important to maintain the quality standards. Your AFDIL, are committed to providing pharmaceutical products of global quality standards all over the world.

All our businesses are well-positioned, and we expect high-singledigit consolidated top line growth for FY25-26. The expansion of our global specialty business is expected to continue. As business operations have normalised globally, overall expenses are expected to increase. Our R&D spending is expected to be about 7-8% of sales in FY25-26 with an increasing share of spending expected on clinical trials for specialty/Generic products.

AFDIL currently has the following divisions:

- Manufacturing We are continuing to provide world-class tablet manufacturing and are contract manufacturing for many other companies.
- **Hospicare** Hospicare products are focused on Orthopaedic doctors and general health, the division uses established channels of the institutional and surgical business to synergistically grow into a preferred partner for doctors.

Export – AFDIL initiated exports in 1997 with registrations of products in Russia. Over the past decade, we have gained experience to meet & exceed our international customer expectations.

Currently we have our presence in 16 countries across Eastern Europe, South East Asia & Africa. From a pure trading oriented approach in the early years of our export operations, we are significantly shifting our focus to operate as marketers in most operating countries. In 2024 with the upgraded plant we will also be selling to PIC/S and EAEU countries.

- Optima Optima division ensures that no one in India falls short of AFD's medicines. More than 350 products in various therapeutic segments are sold across India at affordable prices.
- Franchisees Targeting smaller towns and harder to reach places AFDIL has franchised out some of its brands to independent distributors and sellers. This business is expected to grow at over 100% year on year.

Plant Upgradation

In line with our ongoing commitment to enhance operational efficiency, product quality, and regulatory compliance, your Company Anglo-French Drugs & Industries Limited has undertaken a significant upgradation of its manufacturing facility during the year. These improvements are focused on aligning with current Good Manufacturing Practices (cGMP), ensuring operational reliability, and expanding our production capabilities. Key highlights of the upgradation includes:

To enhance operational efficiency and maintain compliance with cGMP standards, several key upgrades have been implemented across the facility. Air Handling Units (AHUs) have been improved by replacing with HEPA filters to terminal positions at individual supply grills, enhancing air quality control in critical manufacturing areas. A 150 TR air-cooled chiller has been installed on the terrace as a backup to ensure uninterrupted HVAC functionality. Manufacturing equipment has been retrofitted with PLCs to strengthen data integrity and reduce manual interventions. In packaging, a new Alu-Alu blister packing machine has been installed to expand the product portfolio and increase productivity, along with a new auto-labelling machine to improve accuracy. A 61-station B tooling compression machine has been added in Compression Bay-1 to support cGMP compliance, and a 36" conventional coating pan has been commissioned in Coating Area Bay-1 to optimize validation batch processing. Additional equipment-including a planetary mixer, turbojet stirrer, and paste preparation vessel-has been introduced in both production bays to support enhanced formulation processes. Furthermore, a dust collector system has been installed to reduce filter clogging in AHUs, thereby improving air quality and equipment life.

These strategic enhancements are expected to significantly improve the plant's operational efficiency, regulatory compliance, and production scalability. The company remains committed to investing in technological advancements that strengthen product quality and safety for our stakeholders.

All of the above has resulted in a Eurasian Economic Union approval from Belarus. The expectation is to further get PIC/S approval from Thailand, wherein 1st stage of the audit is complete.

INDUSTRY OVERVIEW AND DEVELOPMENTS

The pharmaceutical industry remains a critical pillar of the global healthcare ecosystem, focused on the discovery, development, production, and marketing of medicines that prevent, treat, and cure

a wide range of diseases. Over the past few decades, the industry has witnessed significant transformation, driven by technological advancements, increased healthcare awareness, improved diagnostic capabilities, and growing global demand for high-quality medical treatments.

Your Company is committed to establishing itself as a globally competitive organization, distinguished by innovation, quality, and brand value. With a strong focus on aligning with international quality standards, we strive to create a lasting impact through excellence in our business practices and offerings.

Key trends shaping the pharmaceutical industry include an increased emphasis on research and development to drive innovation, and the integration of advanced technologies such as Artificial Intelligence (AI). The use of AI is transforming drug development by enabling faster, more accurate, and reproducible outcomes through automated algorithms.

While the industry continues to grow, it also faces challenges such as pricing pressures and competition from generic drug manufacturers. Despite these hurdles, the outlook remains positive. Global demand for healthcare is on the rise, particularly in emerging markets, supported by continued investment in R&D and the development of novel therapies.

Your Company is well-positioned to capitalize on these developments, leveraging its expanding capabilities and strategic direction to contribute meaningfully to the evolving pharmaceutical landscape.

OPPORTUNITIES AND CHALLENGES

The pharmaceutical sector continues to present a dynamic mix of opportunities and challenges. Favourable macroeconomic conditions in India and other emerging markets are expected to drive steady volume growth for pharmaceutical products over the long term. Additionally, developed markets are experiencing a sustained shift toward specialty products, which now constitute a growing share of overall pharmaceutical spending. Your Company has already commercialised several specialty products in these regions and is well-positioned to capitalize on this ongoing trend.

Emerging markets such as Cambodia and Zimbabwe are witnessing increased penetration of generic medicines, while the recent opening of the South African market presents a promising opportunity for Indian pharmaceutical companies, including AFDIL, to expand their global footprint and strengthen their market presence.

However, the global operating environment remains uncertain due to ongoing geopolitical tensions, which continue to disrupt supply chains, contribute to inflationary pressures, and affect overall economic stability. The U.S. generics market, in particular, poses challenges with a highly competitive pricing environment driven by customer consolidation and an accelerated pace of generic drug approvals by the USFDA, as well as tariff-related headwinds.

Foreign exchange volatility, especially in emerging markets, poses another significant risk. Even as these markets register real growth in local currency terms, fluctuations in exchange rates may impact reported performance. Additionally, fiscal constraints in several countries could lead to increased regulatory intervention, including government-imposed price controls on pharmaceutical products.

Your company is targeting about 5 numbers of new wholesale clients and around 15 numbers of new countries, developing a robust specialty pipeline remains a strategic priority for long-term value creation. However, this requires substantial upfront investments, which may affect short-term profitability. Despite these challenges, your Company remains committed to building a sustainable, innovation-led business model, capable of navigating risks and unlocking value in high-growth segments of the pharmaceutical industry.

OUTLOOK

The new financial year presents fresh challenges and opportunities for growth. As a pharmaceutical company, we remain optimistic about the industry's long-term prospects. The global pharmaceutical market is poised for continued expansion, driven by factors such as an aging population, the rising prevalence of chronic diseases, and increasing healthcare expenditures worldwide. In this evolving landscape, we are committed to sustained investments in innovation and research & development, aimed at launching new, differentiated products and reinforcing our competitive advantage.

We see promising growth potential in emerging markets, where increasing incomes, expanding populations, and greater healthcare awareness are creating robust demand for quality healthcare solutions. Additionally, we recognize the growing impact of digital health technologies and are actively exploring ways to integrate these innovations into our business model to enhance operational efficiency and patient outcomes.

Looking ahead, your Company is focused on strengthening its presence both in the domestic and international markets, with special emphasis on Contract Research and Manufacturing Services (CRAMS), a key strategic growth area. We are also guided by a strong commitment to ethical business practices and ecological sustainability, ensuring that our growth is responsible and inclusive.

Our diversified portfolio of services and products enables us to effectively manage risk and avoid overdependence on any single segment or market. With significant ongoing investments in R&D and a future-ready approach, the Company is well-positioned to sustain its growth momentum and deliver long-term value to its stakeholders.

RISKS AND CONCERNS

As a pharmaceutical company operating in a highly dynamic and regulated environment, we recognize the various risks and concerns inherent to our industry. Key challenges include evolving regulatory landscapes, patent expirations, intense pricing pressures, and heightened competition from generic alternatives. Additionally, there is increasing global scrutiny on drug pricing and marketing practices, which continues to influence both policy and public perception.

Legal and regulatory risks remain a significant area of concern. The pharmaceutical industry is governed by stringent guidelines pertaining to drug development, manufacturing, and marketing. Non-compliance with these regulations can lead to substantial penalties, legal liabilities, and reputational damage. Furthermore, litigation related to drug efficacy, safety, and side effects poses a potential financial risk, given the possibility of high legal expenses and settlements.

We continuously monitor policy shifts and industry developments to proactively address emerging challenges. Our strategic approach focuses on transparency, compliance, and resilience, ensuring we uphold our commitment to delivering innovative and effective healthcare solutions.

In addition to managing external risks, we are equally focused on enhancing internal efficiencies. Our ongoing initiatives emphasize sustainable cost reduction through the adoption of technology and process optimization. Efforts are also directed toward minimizing working capital deployment, improving manufacturing efficiencies, optimizing our manufacturing footprint, and lowering overall fixed costs. These measures collectively aim to strengthen our operational resilience and long-term competitiveness.

INTERNAL CONTROL SYSTEMS AND ADEQUACY

We believe the Company has a proper and adequate internal control system commensurate with the size and scale of its operations to in place to ensure that all activities and transactions are monitored, authorized, recorded and reported correctly. An Internal Audit system is in place to conduct a regular check and review of accounting



methodologies with a view to improving the control systems. The Audit Committee of the Board of Directors has appraised the adequacy of internal controls.

HUMAN RESOURCES

Human Resources (HR) remained a key focus area for your Company during the year under review. Various HR initiatives are taken to align the HR policies to the requirement of the business. The Company provides employees with a fair and equitable work environment and support to develop their capabilities. We are also focused on bringing in new talent and competencies to aid the Company's growth strategy.

KEY FINANCIAL RATIOS

The details of significant changes in key financial ratios, along with detailed explanations form part of the Financial Statement Note No.49.

Debtors Turnover Ratio: For the FY24-25 is 2.38 with Variance 25.96% Changes were due to slower collections from Customers and increased credit sales.

Inventory Turnover Ratio: For the FY24-25 is 5.91 with Variance (13.03%) Changes due efforts to reduce overstocking and improve working capital.

Current Ratio (in times): For the FY24-25 is 2.85 with Variance (48.23)% changes on account of utilisation of funds from investment for various activities (buyback, Dividend & Tax thereon); Use of Short term Borrowings for Operational purpose.

Debt Equity Ratio (in times) : For the FY24-25 is 0.15 with Variance 188.67% use of Short term Borrowings for Operational purpose and utilization of Equity Funds towards Buyback and incidental Expenses.

Net Profit Margin (%):For the FY24-25 is 0.06 with Variance (147.51)% Profit Earned during the year.

CAUTIONARY STATEMENT

Statement in the Management Discussion and Analysis describing the Company's objectives, projections, expectations and estimates regarding future performance may be 'forward-looking statements' and are bases on the currently available information. The management believes these to be true to the best of its knowledge at the time of preparation of this report. However, these statements are subject to certain future events and uncertainties, which could cause actual results to differ materially from those, which may be indicated in such statements.

INDEPENDENT COMPANY SECRETARY'S COMPLIANCE CERTIFICATE

For the Financial Year Ended 31st March 2025

To,

The Members, Anglo-French Drugs & Industries Limited

We have examined:

- (a) all the documents and records made available to us and the explanations provided by Anglo-French Drugs & Industries Limited ("the Company"),
- (b) the filings/submissions made by the Company to the stock exchanges,
- (c) the website of the Company, and
- (d) any other document/file as may be relevant,

for the year ended 31st March 2025 ("Review Period"), in respect of compliance with the provisions of:

- 1. Regulations 17 to 27, clauses (b) to (i) of Regulation 46(2), and paragraphs C and D of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").
- 2. The compliance of the conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.
- 3. We have examined the relevant records of the Company in accordance with the Generally Accepted Auditing Standards in India, to the extent applicable, and the Guidance Note on Certification of Corporate Governance issued by the Institute of Chartered Accountants of India.
- 4. In our opinion and to the best of our information and according to the explanations given to us and the representations made by the Directors and the Management, we certify that the Company has complied with the conditions of Corporate Governance as specified in the aforesaid SEBI Listing Regulations.

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

CS Raghavendra Naveen B K

Practicing Company Secretary Membership No.: 59814, CP No.: 23728 UDIN: A059814G000217840 ICSI Unique Code: I2020KR2098300 Peer Review Certificate No:6511/2025

Place: Bengaluru Date: 28/04/2025

DECLARATION BY THE MANAGING DIRECTOR UNDER SEBI (LODR) REGULATIONS, 2015

REGARDING COMPLIANCE WITH CODE OF CONDUCT

In accordance with Schedule V, Para D of the SEBI (LODR) Regulations, 2015 as amended from time to time, I the Managing Director of the Company hereby confirm that, all the Directors and the Senior Management personnel of the Company have affirmed compliance with the Code of Conduct, as applicable to them, for the financial year ended 31st March 2025.

Nirbhay Abhay Kanoria Managing Director DIN:02558300

Place: Bengaluru Date: 02nd May 2025

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,

The Members, Anglo-French Drugs & Industries Limited

I have examined the relevant documents, registers, records, forms, returns and disclosures received under Section 164 and 184 of the Companies Act, 2013, from the Directors of **Anglo-French Drugs & Industries Limited** having **CIN L24230KA1923PLC010205** and having registered office at Plot No.4, Phase II, Peenya Industrial Area, Peenya, Peenya Small Industries, Bangalore, Bangalore North, Karnataka, India, 560058 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as a disclosure in its Corporate Governance Report of the Financial Year ended 31st March 2025. I have considered non-disgualification status to include non-debarment by Regulatory or Statutory Authorities.

In my opinion and to the best of information made available to me and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31, 2025 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

SI. No	Name of the Director	DIN	Date of Appointment in the Company *	Date of Cessation*
1.	Abhay Kanoria	00108894	01-03-1997	-
2.	Uddhav Abhay Kanoria	00108909	10-08-2006	-
3.	Ahmedali Nalagath	00704341	24-08-2012	12-08-2024
4.	Nirbhay Abhay Kanoria	02558300	01-02-2017	-
5.	Rakesh Parmeshwar Kanyadi	08532438	13-08-2019	07-11-2024
6.	Rohit Choraria	07003583	09-05-2023	-
7.	Jayashree Vijay Ranade	09320683	09-05-2023	30-04-2024
8.	Pradeep Joshi	02713934	12-02-2024	-
9.	Srinivasan Krishnan	08709528	12-02-2024	-
10.	Rani Shokeen	10634071	28-05-2024	

*The date of appointment/cessation is as per the MCA Portal.

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification.

The DIN Status on website of Ministry of Corporate Affairs, New Delhi is "Approved" for all the Directors as on 21.04.2025. None of the Directors are part of "ACTIVE non-compliant company".

This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

CS Raghavendra Naveen B K

Practicing Company Secretary Membership No.: 59814, CP No.: 23728 UDIN: A059814G000217840 ICSI Unique Code: I2020KR2098300 Peer Review Certificate No:6511/2025

Place: Bengaluru Date: 28/04/2025



INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **Anglo French Drugs & Industries Limited** ("the Company", "AFDIL"), which comprise the Balance Sheet as at March 31, 2025 the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate, read with the paragraph below, to provide a basis for our audit opinion on the financial statements.

Emphasis of Matter

- (a) We draw attention to Note 14 to the financial statements regarding loan amounting Rs 751.43 lakhs during the year 2024-25 for purposes of business / providing Working Capital to Dormirbien Private Limited (DPL) incorporated on May 3, 2024 where the directors of the Company are interested in terms of the provisions of Section 185 of the Company. Two directors of the Company are directors of DPL and aforesaid payment is subject to approval by the shareholders through special resolution and disclosure in the explanatory statement in the notice to the ensuing Annual General Meeting is to be given. An agreement on plain paper (instead of non-judicial stamp paper for legal enforceability) was entered on 28th May 2024 for the loan repayable on demand upto an aggregate limit of Rs 952 lakhs payable in tranches.
- (b) Company holds substantive potential voting rights (Rs 7.52 crores loan being convertible into equity through contractual arrangement) that are exercisable or convertible in the near future when Company will be virtually controlling the activities of DPL from the IND AS 110 perspective.

Our opinion is not modified in respect of the above.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon; we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Key audit matters	Principal audit procedures
Formation of Dormirbien Private Limited (DPL) where Directors are interested	The following audit procedures were adopted while considering the matters pertaining to DPL.
Formation of Dormirbien Private Limited (DPL) was incorporated on 3rd May 2024 to whom the company had advanced a loan for working capital/ business purposes amounting Rs 752 lakhs during the FY 24-25 attracting the provisions of Section 185 of the Companies Act, 2013 as the loan was to a Company where the Directors are interested. Two of the directors of the AFDIL happen to be the directors of DPL having equal number of Shares in the Company. Accordingly the related documentation and the required procedures are pending which includes approval by the Shareholders of AFDIL in the forthcoming AGM and disclosure in the explanatory Statement to the Notice to be issued in the ensuing AGM. Company holds substantive potential voting rights (Rs 7.52 crores loan being convertible into equity through contractual arrangement) that are exercisable or convertible in the near future when Company will be virtually controlling the activities of DPL from the IND AS 110 perspective.	 the Year 2024-25 particularly the minutes of the Meeting held on 28-5-2024 where the matter relating to DPL and its profile was placed before the Board. Memorandum and Articles of Association DPL (INC 33 and INC 34) Confirmation of Loan Balance of Rs 7.51 crores from DPL as on 31-3-2025

Key audit matters	Principal audit procedures
Exports division of AFDIL – Challenges encountered	Audit Procedure adopted
The Export Department of AFDIL typically secures regular orders every year. However, due to unforeseen circumstances such as abrupt policy changes and political instability in certain parts of the globe, the company could not secure an expected export order from key customers in that region. In view of these developments, AFDIL recognized the need to establish its own internal export policy framework to better mitigate such external risks in the future period. As a result of the orders lost and the overall decline in export opportunities, the company experienced a significant drop in export sales — from Rs 900 lakhs in the previous year (FY 23-24) to just Rs 93 lakhs in FY 2024–25. (Excluding Deemed Export) To mitigate the impact and ensure a revamp, the Export Department took several proactive measures, including exploring new markets, strengthening relationships with existing clients, and enhancing the competitiveness of its offerings. These efforts have begun to yield results, and the company has already started witnessing an upward turn in export revenue in FY 2025–26.) and related records like Bill of Lading, Bill of Exports for claiming Duty Drawbacks, Packing List, Tax Invoices, Proof of Delivery Interacting with Finance Personnel and also taking inputs from Exports Division

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's

financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based



on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. In this context the matter given in the paragraph emphasis (b) on IND AS 110 may please be referred to.
- e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended: In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - The Company has disclosed the impact of pending litigations on its financial position in its financial statements (refer note 42).
 - The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and

Protection Fund by the Company.

- iv. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- v. The Management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

Based on the audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

- vi. The dividend paid by the Company during the year in respect of the dividend declared in the previous year is in accordance with Section 123 of the Act to the extent it applies to the payment of dividend.
- h) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and the operating effectiveness of the Company's internal financial controls over financial reporting.
- As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in Paragraphs 3 & 4 of the Order.
- j) Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2025 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is in place for the financial year ended March 31, 2025.

For KAMG & ASSOCIATES

Chartered Accountants Firm Reg No.: 311027E

Amitabha Niyogi

Partner M.No. 056720 UDIN: 25056720BMJTAK9365

Date: 02-05-2025 Place: Bengaluru

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' of our report of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED** ("the Company") as of March 31, 2025 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of

the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls *or covertness in regard to purpose for certain material expenses related to the Company*, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, subject to the matter mentioned in *preceding* para above, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For KAMG & ASSOCIATES Chartered Accountants

Firm Reg No.: 311027E

Amitabha Niyogi

Partner M.No 056720 UDIN: 25056720BMJTAK9365

Date: 02-05-2025 Place: Bengaluru



ANNEXURE "B" TO THE INDEPENDENT AUDITORS' REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' of our report of even date)

ii.

- i. (a) (A) The Company has maintained proper records showing full particulars including quantitative details and situation of its Property, Plant and Equipment on the basis of available information.
 - (B) The Company has maintained proper records showing full particulars of the intangible assets.
 - (b) The Company has a regular programme for physical verification of its Property, Plant and Equipment by which its Property, Plant and Equipment are verified in a phased manner on a rotational basis covering all the items over a period of time. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
 - (c) According to the information and explanation given to us by the Management, the Company has disclosed details of all immovable property (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) in the financial statements for which the title deed is in the name of the Company.
 - (d) According to the information and explanation given to us by the Management, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.
 - (e) According to the information and explanation given to us by the Management, there has been no proceedings initiated against or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act 1988 and rules thereunder.

- (a) The inventories have been physically verified by the Management during the year. In our opinion, the frequency of physical verification is reasonable and procedure adopted by the Management for physical verification is reasonable and adequate in relation to the size of the Company and nature of its business. Inclusion of expired and 'near to expiry date' stock in inventory duly reported by us has been provided by the management.
- (b) The Company has been sanctioned working capital limit by Bank in excess of Rs 5 crores on the basis of the 90security of current assets during the year. The statements as required have been submitted to the bank and are in agreement with the books of account other than an item of Stores whose value in the returns is Rs 96.04 lakhs lower as compared to the books due to inclusion of chemicals, consumables and promotional materials in the item as explained by the management.
- iii. During the year, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties other than loans given to the following:
 - (a) The Company has provided unsecured loans during the year as mentioned below:
 - (A) The Company does not have any subsidiary, joint venture, or associates, hence, accordingly the provisions of Clause 3(1)(iii)(a)(A) of the Order is not applicable.
- (B) With respect to advances given to companies other than subsidiaries, the following information was made available to us:

Rs in lakhs

Name of Companies/ Parties	Relation with the Company	Amount provided during the year	Outstanding Balance as on 31.03.2025
A2K Infra	Other Party	90	90
Dormirbien Pvt Ltd	Related Party (a company under Section 2(76)(iv) of the Companies Act, 2013)	752	752

- (b) The loan granted during the year by the Company are as per the terms and conditions which are not prejudicial to the interest of the Company's interest.
- (c) The schedule of repayment of principal and interest has been stipulated and repayment & receipts are regular in case of A2K. However, in case of Dormirbien, the loan shall be repaid as demanded by the Company and interest shall be paid at the rates stipulated in the terms.
- (d) As per information and explanations provided by the management there are no overdue amounts and accordingly the provisions of Clause 3(1) (iii) (d) of the Order is not applicable.
- (e) There are no loan or advance in the nature of loan granted which has fallen due during the year, neither there has been any renewal or extension of any loan, nor fresh loans granted to settle the overdues of existing loans given to the same parties and accordingly the provisions of Clause 3(1) (iii) (e) of the Order is not applicable.

- (f) The Company has granted loan to a related party as defined in clause (76) of section 2 of the Companies Act, 2013, which is a loan repayable on demand, as indicated in clause 3(1)(iii)(a)(B) above which is 90% of the total loan granted during the year by the Company.
- iv. According to the information and explanations given to us by the management the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 ("the Act") other than loan given to Dormirbien Pvt Ltd, a company where the directors are interested, amounting Rs 752 lakhs during the year for which special resolution and disclosure in the Notice to the Shareholders as required is pending. In respect of the investments made by the Company, in our opinion the provisions of Section 186 of the Act have been complied with.
- v. The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

Anglo-French Drugs & Industries Limited

- vi. The maintenance of cost records has been specified by the Central Government under Section 148(1) of Companies Act for the nature of manufacturing activities carried on by the Company. The Company has maintained the prescribed accounts and records. We have not made a detailed examination of those records and have relied on the report of the Cost Auditor.
- vii. (a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees'

State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2025 for a period of more than six months from the date they became payable.

(b) Details of statutory dues referred to in sub-clause (a) above which have not been deposited as on March 31, 2025 on account of disputes are given below:

Name of the Statute	Nature of the dues	Demand (Rs.)	Amount paid (Rs) (in lacs)	Period to which the amount relates	Forum where dispute is pending	Status
Sales tax and VAT laws	Sales Tax/ VAT	13,62,885	4,20,489	2010-11	The Joint Commissioner- Appeals-Dhar Pithampur	Pending in appeal
Sales tax and VAT laws	Sales Tax/ VAT	6,76,432	38,000	2011-2012	MST Tribunal- Mumbai	Appeal posted for hearing
	TOTAL	20,39,317	4,58,489			

xi.

- viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).
- According to the information and explanations given to us, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.
 - (b) According to the information and explanations given to us, the company has not been declared as a wilful defaulter by any Bank or Financial Institution or any other lender.
 - (c) According to the information and explanations given to us, the Company has not obtained any term loans during the year other than two vehicle loans taken during the year which were applied for the purpose for which the loans were obtained. Accordingly, clause 3(ix)(c) of the Order is not applicable.
 - (d) According to the information and explanations given to us, the Company has not raised any short-term funds during the year. Accordingly, clause 3(ix)(d) of the Order is not applicable.
 - (e) According to the information and explanations given to us, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures. Accordingly, clause 3(ix)(e) of the Order is not applicable.
 - (f) According to the information and explanations given to us, the Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies. Accordingly, clause 3(ix)(e) of the Order is not applicable.
- x. (a) According to the information and explanations given to us, the Company has not raised money by way of initial public offer or further public offer (including debt instruments) during the year. Accordingly, clause 3(x)(a) of the Order is not applicable.
 - (b) According to the information and explanations given to us, during the year, the Company has not made any

preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible). Accordingly, clause 3(x)(b) of the Order is not applicable.

- (a) According to the information and explanation given to us, no fraud by the Company or any fraud on the Company has been noticed or reported during the year.
 - (b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
 - (c) In our opinion and according to the information and explanations given to us, the Company has not received any whistle blower complaints during the year.
- xii. The Company is not a Nidhi Company. Accordingly, clause 3(xii)(a) to (c) of the Order is not applicable.
- xiii. In our opinion and according to the information and explanation given to us, the Company is in compliance with Sections 188 and 177 of the Companies Act 2013 where applicable, for all transactions with the related parties and the details of the related party transactions have been disclosed in the financial statements etc as required by the applicable accounting standards.
- xiv. (a) The Company has an internal audit system commensurate with the size and nature of its business.
 - (b) We have considered the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.
- xv. In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with directors or persons connected with him.
- xvi. (a) The company is not required be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi)(a), (b) and (c) of the Order is not applicable.
 - (b) In our opinion, there is no core investment company

within the Group and accordingly reporting under clause 3(xvi)(d) of the Order is not applicable.

- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, reporting under clause 3(xvi)(c) of the Order is not applicable to the Company.
- (d) The Group does not have any Core Investment Company. Accordingly, reporting under clause 3(xvi)(d) of the Order is not applicable to the Company.
- xvii. According to the information and explanation given to us, the Company has not incurred any cash losses in the financial year but has incurred cash losses in the immediately preceding financial year.
- viii. There has been no resignation of the statutory auditors of the Company during the year. Hence the reporting under clause 3 (xviii) of the Order is not applicable to the Company.
- xix. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating

that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. According to the information and explanations from the management and on the basis of verification of records made available to us, provision of Section 135 of the Companies Act, 2013 on Corporate Social Responsibility is not applicable for the Company as on reporting date.

For KAMG & ASSOCIATES

Chartered Accountants Firm Reg No.: 311027E

Amitabha Niyogi

Partner M.No 056720 UDIN: 25056720BMJTAK9365

Date: 02-05-2025 Place: Bengaluru

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2025

(Rs			(Rs. In Lakhs)
Particulars	Note No.	As at March 31st, 2025	As at March 31st, 2024
		Audited	Audited
ASSETS			
Non-current assets			
Property, plant and equipment	3	2,219	1,541
Capital work-in-progress			
Right of Use of Assets	4	409	216
Intangible Assets	5	11	16
Financial Assets			
Investments	6	48	50
Other Financial Assets	7	480	651
Deferred tax assets (Net)	8		
Other Non Current Assets	9		-
Subtotal (A)		3,167	2,474
Current assets			
Inventories	10	1,150	1,160
Financial Assets			
(i) Trade Receivables	11	3,210	4,181
(ii) Cash and cash equivalents	12 (a)	22	9
(iii) Bank balances other than (ii) above	12 (b)	95	240
(iv) Investments	13	9,504	12,469
(iv) Other financial assets	14	2,006	1,302
Current Tax Assets (Net)	15		
Other current assets	16	86	88
Subtotal (B)		16,073	19,448
TOTAL ASSETS(A+B)		19,240	21,922
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	17	113	123
Other Equity	18	12,367	16,967
Subtotal (C)		12,480	17,090
LIABILITIES			
Non Current Liabilities			
Financial liabilities			
Borrowings	19	408	714
Other financial liabilities	20	57	71
Deferred tax liabilities (net)	21	32	96
Other Non Current Liabilities	22	436	266
Long Term provisions	23	192	156
Subtotal (D)		1,125	1,303
Current liabilities			· · ·
Financial Liabilities			
(i) Borrowings	24	1,493	188
(ii) Trade Payables			
a) Total outstanding dues of Micro and Small Enterprises	25	398	254
b) Total outstanding dues other than Micro and Small Enterprises		2,449	1,816
(iv) Óther current financial liabilities	26	1,065	1,090
Short term Provisions	27	50	48
Current Tax Liabilities/ (Asset)	15	180	134
Subtotal (E)		5,635	3,530
TOTAL EQUITY AND LIABILITIES(C+D+E)		19,240	21,923

The accompanying notes form an integral part of the financial statements

As per our report of even date attached

For KAMG & ASSOCIATES Chartered Accountants

Firm's Registration Number 311027E

CA Amitabha Niyogi

Partner M.No.:056720 UDIN: 25056720BMJTAK9365

Date: 2nd May 2025 Place: Kolkata For and on behalf of the Board of Directors of Anglo French Drugs & Industries Limited

Pradeep Vasantrao Joshi Director DIN: 02713934 Nirbhay Kanoria Managing Director DIN : 02558300 Uddhav Kanoria Managing Director DIN : 00108909

Manik Kumar Singh Chief Financial Officer Sriee Aneetha M Company Secretary



STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31ST MARCH 2025

		(Rs. In Lakhs)	
Particulars	Note No.	For the period	For the period
		ended March 31st, 2025	ended March 31st, 2024
CONTINUING OPERATIONS			<u>,</u>
Income			
Revenue from operations	28	8,779	9,520
Other income	29	3,020	465
Total Revenue	·	11,799	9,985
Expenses			
Cost Of Materials Consumed	30	2,271	3,032
Purchases of Stock-in-Trade	31	4,549	3,974
Changes in inventories of Finished Goods, Work in Progress and Stock in Trade	32	(59)	(184)
Employee benefits expense	33	1,844	1,945
Finance costs	34	178	185
Depreciation and amortization expense	35	327	315
Other expenses	36	1,896	1,947
Total Expenses		11,006	11,214
Profit/(loss) before exceptional items and tax		793	(1,229)
Exceptional items			-
Profit before tax		793	(1,229)
Tax expense:			
Current tax	37	135	-
Deferred tax		(64)	12
Tax effect on items reclassified		-	(7)
Profit/ (Loss) for the year		722	(1,234)
Other Comprehensive Income			
A. (i) Items that will not be reclassified to Profit or Loss			
- Remeasurement of Post-employment benefit obligations		(10)	(27)
 Change in equity instruments- Fair value through Other Comprehensive Income 	-	(3)	(8)
Income tax relating to the above			
B. (i) Items that will be reclassified to Profit or Loss			
Income tax relating to the above		-	7
Total Other Comprehensive Income / (Loss)		(13)	(28)
Total Comprehensive Income for the year		709	(1,262)
Earnings per share (Face value Rs.10/-basic and Diluted		62	(99)
[Refer Note 38 to the Financial Statements]			

The accompanying notes form an integral part of the financial statements

As per our report of even date attached

For KAMG & ASSOCIATES **Chartered Accountants**

Firm's Registration Number 311027E

CA Amitabha Niyogi Partner M.No.:056720 UDIN: 25056720BMJTAK9365

Date: 2nd May 2025 Place: Kolkata

For and on behalf of the Board of Directors of Anglo French Drugs & Industries Limited

Pradeep Vasantrao Joshi Director DIN: 02713934

Nirbhay Kanoria Managing Director DIN : 02558300

Uddhav Kanoria Managing Director DIN : 00108909

Manik Kumar Singh Chief Financial Officer Sriee Aneetha M Company Secretary

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH 2025

Particulars	For the period	For the perio
	ended	ende
	March 31st, 2025	March 31st, 202
	Audited	Audite
Cash flow from operating activities		
Profit before tax	793	(1,229
Adjustments for :		
Depreciation and amortisation	327	31
Interest expense	178	18
Interest income	(451)	(240
Gain on termination of ROU	(81)	
(Gain)/loss on Investment	(2,439)	(12)
provision / liability written back	(5)	(30
loss on sale of asset	3	
rent exp 116 IndAS	109	19
Dividend income	(38)	(2)
Operating profit before working capital changes	(1,605)	(95
Adjustments for changes in :		
(Increase)/Decrease Trade Receivables	971	1,73
(Increase)/Decrease Inventories	10	(29
(Increase)/Decrease in Financial Assets (Current)	137	(63
(Increase)/Decrease in Financial Assets (Non-current)	14	8
(Increase)/Decrease in Other assets (Current)	2	10
Increase/(Decrease) in Trade payables	778	15
Increase/(Decrease) in Financial liabilities (Current)	(51)	(1
Increase/(Decrease) in Financial liabilities (Non-current)	(15)	(5
Increase/(Decrease) in employee benefit	39	Ì
Cash generated from operations		
Income tax refund received / (paid) (net)	(89)	14
Net cash flow from operating activities before exceptional items	191	30
Exceptional items		
Net cash flow from operating activities [A]	191	30
Cash flow from investing activities		
Payments for acquisition of assets	(902)	(40
Proceeds from disposal of Property, Plant and Equipment	20	` 1;
Deposit maturity	45	
Investments(Current and Non-current)	5,407	3,79
Investment in bank deposits	146	34
ICD given	(730)	0-
Dividend Received	38	
Interest received	447	24



STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH 2025

		(Rs. In Lakhs)
Particulars	For the period ended	For the period ended
	March 31st, 2025	March 31st, 2024
	Audited	Audited
Cash flow from financing activities		
Changes in long term borrowings	(285)	(982)
Changes in short term borrowings	1,305	(722)
Interest paid - Net	(178)	(185)
Buyback of Shares including Tax thereon	(5,300)	(2,259)
Lease Liability – Principal Payment	(172)	(305)
Dividend paid and tax thereon	(19)	(258)
Net cash flow from financing activities [C]	(4,649)	(4,711)
Net cash inflow / (outflow) D = [A+B+C]	13	(275)
Opening cash and cash equivalents [E]	9	284
Closing cash and cash equivalents F= [D+E]	22	9

The accompanying notes form an integral part of the financial statements As per our report of even date attached

For KAMG & ASSOCIATES

Chartered Accountants Firm's Registration Number 311027E

CA Amitabha Niyogi

Partner M.No.:056720 UDIN: 25056720BMJTAK9365

Date: 2nd May 2025 Place: Kolkata For and on behalf of the Board of Directors of Anglo French Drugs & Industries Limited

Pradeep Vasantrao Joshi Director DIN: 02713934 Nirbhay Kanoria Managing Director DIN : 02558300 Uddhav Kanoria Managing Director DIN : 00108909

Manik Kumar Singh Chief Financial Officer

Sriee Aneetha M Company Secretary

STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2025

A. Equity Share Capital

				(Rs. In Lakhs)
Balance at the beginning of April 1, 2024	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the year 2024-25	Balance at the end of March 31, 2025
123	-	123	11	113

Rs. Lakhs

Rs Lakhs

Balance at the beginning of April 1, 2023	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the year 2023-24	Balance at the end of March 31, 2024
129	-	129	6	123

B. Other Equity

							Rs. Lakhs
		Rese	erves and s	urplus		Other	Total
	Capital Reserve	Securities premium reserve	General Reserve	Capital Redemption Reserve	Retained earnings (Surplus)	Comprehensive income	
Restated Balance at April 1, 2023	43	289	549		19,868	92	20,790
Profit for the year					(1,234)		(1,234)
Other comprehensive income/ (losses) for the year, net of tax					(27)	(8)	(34)
Proposed dividend					(258)		(258)
Changes due to Buyback of shares, Tax and other payments on Buyback					(2,254)		(2,254)
Tax on reclassification of items					7		7
Transfer during the year			(6)	6			
Total comprehensive income for	-	-	(6)	6	(3,781)	(8)	(3,788)
the year							
Balance as at March 31, 2024	43	289	543	6	16,088	84	17,053
Restated Balance at April 1, 2024	43	289	543	6	16,088	84	17,053
Profit for the year					722		722
Other comprehensive income/ (losses) for the year, net of tax					(10)	(3)	(12)
Dividend Paid					(19)		(19)
Changes due to Buyback of shares, Tax and other payments on Buyback					(5,290)		(5,290)
Tax on reclassification of items					-		-
Transfer during the year			(11)	11			
Total comprehensive income for the	-	-	(11)	11	(4,597)	(3)	(4,599)
year							
Balance as at March 31, 2025	43	289	532	17	11,491	81	12,453

The company has bought back 1,06,500 (FY 2023-24: 58,118) shares during the year at a nominal value of Rs.10 per share with a premium of Rs.3990 per share in 14th August 2024 in accordance with section 68 of the Companies Act, 2013 and rules thereunder and in adherence to SEBI (Buyback) Regulations, 2018. The requisite approval of the Board was duly obtained in this regard.

The accompanying notes form an integral part of the financial statements

As per our report of even date attached

For KAMG & ASSOCIATES Chartered Accountants Firm's Registration Number 311027E

CA Amitabha Niyogi Partner M.No.:056720 UDIN: 25056720BMJTAK9365

Date: 2nd May 2025 Place: Kolkata For and on behalf of the Board of Directors of Anglo French Drugs & Industries Limited

Pradeep Vasantrao Joshi Director DIN: 02713934 Nirbhay Kanoria Managing Director DIN : 02558300

Manik Kumar Singh Chief Financial Officer Uddhav Kanoria Managing Director DIN : 00108909

Sriee Aneetha M Company Secretary

51

Notes to Accounts

1 General Information

Anglo French Drugs & Industries Limited ("the company") is a company limited by shares, incorporated and domiciled in India having its Registered Office at Bengaluru. The company is primarily engaged in manufacturing of pharmaceutical formulations, trading, exports and treasury business. As per letter no MSE/LIST/2018/18 dated January 1, 2018 issued by the Metropolitan Stock Exchange, Equity shares of the Company are listed and admitted to dealings on the Exchange w.e.f. January 4, 2018 vide notice number MSE/ LIST/5903/2018 dated January 1, 2018.

The Board of Directors approved the financial statements for the year ended March 31,2025 and authorised for issue on 02nd May 2025

2 Material Accounting Policies

This note provides a list of the material accounting policies adopted in the preparation of these separate financial statements of the company. These policies have been consistently applied to all the periods presented, unless otherwise stated.

2.1 Basis of Preparation and Presentation

(i) Compliance with Ind AS

The Standalone Financial Statements of the Company which comprise the Balance Sheet as at 31st March, 2025, the Statement of Profit and Loss, the Statement of Cash Flows and the Statement of Changes in Equity for the year ended 31st March, 2025, and a summary of the material accounting policies and other explanatory information (together hereinafter referred to as "Standalone Financial Statements") have been prepared in accordance with Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, the provisions of the Companies Act. 2013 ("the Act") to the extent notified, guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India. These financials have been prepared on the assumption of going concern on accrual basis.

(ii) Historical cost convention

The financial statements have been prepared on a historical cost basis, except for the following:

- equity investments in entities other than subsidiary, joint ventures and associate which are measured at fair value;
- Certain financial assets and liabilities that are measured at fair value;
- defined benefit plans plan assets measured at fair value.
- (iii) Use of estimates

In preparing the financial statements in conformity with generally accepted accounting principles, management is required to make judgements, estimates and assumptions that may affect the reported amounts of assets and liabilities and the disclosure of contingent assets & liabilities as at the date of consolidated financial statements and the amounts of revenue and expenses during the reported period. The estimates and assumptions used in the accompanying consolidated financial statements are based upon management's evaluation of facts and circumstances as at the date of the consolidated financial statement. Actual results could differ from those estimates. Estimates and underlying assumption are reviewed on an ongoing basis. Any revision to such estimates is recognised in the period the same is determined.

2.2 PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment is stated at historical cost less accumulated depreciation and impairment losses, if any. Historical Cost represents direct expenses incurred on acquisition of the assets and the share of indirect expenses relating to acquisition allocated in proportion to the direct cost involved. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to statement of profit or loss during the reporting period in which they are incurred.

Transition to IND AS

On transition to IND AS, the company had elected to continue with the carrying value of all property plant and equipment recognized as at April 1, 2016 measured as per the previous GAAP and use that carrying value as the deemed cost of the property plant and equipment.

Depreciation methods, estimated useful lives and residual value

Depreciation on property, plant and equipment is provided on 'Straight Line Method' based on useful life as prescribed under Schedule II of the Companies Act 2013. The residual values are not more than 5% of the original cost of the asset. The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

Derecognition

The carrying amount of an item of property, plant and equipment is derecognised on disposal or when no future benefits are expected from its use or disposal. Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss within other gains/(losses).

2.3 INTANGIBLE ASSETS

Measurement at recognition:

Intangible Assets are stated at acquisition cost, net of accumulated amortisation and accumulated impairment losses, if any. Intangible assets are amortised on a straight line basis over their actual useful lives or upto 6 years whichever is lower. The amortisation period and the amortisation method are reviewed at least at each financial year end. If the expected useful life of the asset is significantly different from previous estimates, the amortisation period is changed accordingly.

The cost of an intangible asset comprises of its purchase price including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities) and any directly attributable expenditure on making the asset ready for its intended use. Expenditure on development eligible for capitalisation are carried as 'intangible assets under development' when such assets are not yet ready for the intended use.

Subsequent Expenditure:

Subsequent Expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the company.

Derecognition:

The carrying amount of an intangible asset is derecognized on disposal or when no future economic benefits are expected from its use or disposal. Gains or losses arising from the retirement or disposal of an intangible asset are determined as the difference between the net disposal proceeds and the carrying amount of the asset and recognised as income or expense in the Statement of Profit and Loss.

2.4 FINANCIAL INSTRUMENTS

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

(i) FINANCIAL ASSETS:

(A) Classification:

The company shall classify financial assets as subsequently measured at amortised cost, fair value through other comprehensive income (FVOCI) or fair value through profit or loss (FVTPL) on the basis of its business model for managing the financial assets and the contractual cash flow characteristics of the financial asset.

(B) Initial recognition and measurement:

A financial asset is classified as measured at

- Amortised Cost;
- FVOCI debt instruments;
- FVOCI equity investment; or FVTPL

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at FVTPL, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trades) are recognised on the trade date, i.e., the date that the company commits to purchase or sell the asset.

Debt instruments:

A 'debt instrument' is measured at the amortised cost if both the following conditions are met:

- a) The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- b) Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method. Amortised cost is calculated by taking into account any discount or premium and fees or costs that are an integral part of the EIR. The EIR amortisation is included in finance income in the profit or loss.

Debt instuments included within the fair value through profit and loss (FVTPL) category are measured at fair value with all changes recognized in the statement of profit and loss.

(C) Derecognition:

A financial asset (or, where applicable, a part of a financial asset or part of similar financial assets) is primarily derecognised (i.e. removed from the company's balance sheet) when the rights to receive cash flows from the asset have expired, or the company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the company has transferred substantially all the risks and rewards of the asset, or (b) the company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates' if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the company continues to recognise the transferred asset to the extent of the company's continuing involvement. In that case, the company also recognises an associated liability. The transferred asset that reflects the rights and obligations that the company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the company could be required to repay.

(D) Impairment:

In accordance with Ind-AS 109, the company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

- (a) Financial assets that are debt investments, and are measured at amortised cost e.g., loans, debt securities, deposits, and bank balance, Lease receivables
- (b) Trade receivables

The company follows 'simplified approach' for recognition of impairment loss allowance on:

Trade receivables which do not contain a significant financing component.

The company assesses on a forward looking basis the expected credit losses associated

with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables only, the company applies the simplified approach permitted by Ind AS 109 Financial Instruments, which requires expected lifetime losses to be recognised from initial recognition of the receivables.

(ii) FINANCIAL LIABILITIES:

(A) Classification:

The Company classifies all financial liabilities as subsequently measured at amortised cost, except for financial liabilities at fair value through profit or loss. Such liabilities, including derivatives that are liabilities, shall be subsequently measured at fair value.

(B) Initial recognition and measurement:

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

(C) Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

(iii) OFFSETTING FINANCIAL INSTRUMENT:

Financial assets and liabilities are offset and the net amount is reported in the balance sheet where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the company or the counterparty.

(iv) INCOME RECOGNITION:

Interest income from debt instruments is recognised using the effective interest rate method. The effective interest rate is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the gross carrying amount of a financial asset. When calculating the effective interest rate, the company estimates the expected cash flows by considering all the contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) but does not consider the expected credit losses.

2.5 CASH AND CASH EQUIVALENTS

Cash and Cash equivalents for the purpose of consolidated Cash Flow Statement comprise cash and cheques in hand, bank balances, demand deposits with banks where the original maturity is three months or less and other short term highly liquid investments. To be classified as cash and cash equivalents, the financial asset must:

- be readily convertible into cash;

- have an insignificant risk of changes in value; and
- have a maturity period of three months or less at acquisition.

Bank overdrafts are repayable on demand and form an integral part of an entity's cash management, and are included as a component of cash and cash equivalents. Bank overdrafts are shown within borrowings in current liabilities in the balance sheet.

2.6 REVENUE RECOGNITION

(A) Sale of goods

The company has applied Ind AS 115 using the modified retrospective approach (cumulative catch up method) and therefore the comparative information has not been restated and continues to be reported under erstwhile Ind AS 18 and Ind AS 11. The new Standard is applied to those contracts which remained in force as at 1st April, 2018. The application of the standard does not have any significant impact on the retained earnings as at 1st April, 2018 or on these financial statements. The details of accounting policies under erstwhile Ind AS 18 and Ind AS 11 are disclosed separately, if they are different from those under Ind AS 115.

Revenue is measured at the transaction price of the consideration received or receivable duly adjusted for variable consideration & customer's right to return the goods and the same represents amounts receivable for goods and services provided in the normal course of business. Revenue also excludes taxes collected from customers. Any retrospective revision in prices is accounted for in the year of such revision.

Revenue is recognised at a point in time on accrual basis as per the terms of the contract, when there is no uncertainty as to measurement or collectability of consideration. When there is uncertainty as to measurement or ultimate collectability, revenue recognition is postponed until such uncertainty is resolved.

When sales discount and rebate arrangements result in variable consideration, appropriate estimates are made and estimated variable consideration is recognised as a deduction from revenue at the point of sale (to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue will not be required). The company typically uses the expected value method for estimating variable consideration, reflecting that such contracts have similar characteristics and a range of possible outcomes.

The contract asset or a contract liability is recognised when either party to a contract has performed, depending on the relationship between the entity's performance and the customer's payment. When the company has a present unconditional rights to consideration, it is recognised separately as a receivable.

Anglo-French Drugs & Industries Limited

(B) Export Incentive

Duty drawback is recognized at the time of exports and the benefits in respect of advance license received by the company against export made by it are recognized as and when goods are imported against them.

(C) Interest Income

Revenue from interest is recognised on accrual basis and determined by contractual rate of interest.

(D) Dividend Income

Dividend income is stated at gross and is recognized when right to receive payment is established.

2.7 EMPLOYEE BENEFITS

The company has various schemes of retirement benefits such as Provident Fund, Superannuation Fund and Gratuity Fund duly recognized.

(i) Short-term obligations

Liabilities for wages and salaries, including nonmonetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

The employees of the company are entitled to leave benefits as per the policy of the company. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. The benefits are discounted using the market yields at the end of the reporting period that have terms approximating to the terms of the related obligation. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in other comprehensive income.

The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

(ii) Post-employment obligations

The company operates the following post-employment schemes:

Gratuity obligations -

Maintained as a defined benefit retirement plan and contribution is made to Gratuity Fund established as Trust maintained by the company. The liability or asset recognised in the balance sheet in respect of defined benefit gratuity plans is the present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets. The defined benefit obligation is calculated annually by actuaries using the projected unit credit method.

The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in employee benefit expense in the statement of profit and loss.

Re-measurement gains and losses arising from experience adjustments and changes in actuarial assumptions are recognized in the period in which they occur, directly in other comprehensive income. They are included in retained earnings in the statement of changes in equity and in the balance sheet. Changes in the present value of the defined benefit obligation resulting from plan amendments or curtailments are recognised immediately in profit or loss as past service cost.

Provident Fund -

The company pays provident fund contributions to a fund administered by Government Provident Fund Authority. The company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

Superannuation Fund -

With respect to Superannuation Fund, which is maintained for few employees is contributed Life Insurance Corporation of India under LIC Superannuation Policy

2.8 LEASES

Transition to Ind AS 116

Ministry of Corporate Affairs ("MCA") through Companies (Indian Accounting Standards) Amendment Rules, 2019 and Companies (Indian Accounting Standards) Second Amendment Rules, has notified Ind AS 116 Leases which replaces the existing lease standard, Ind AS 17 Leases and other interpretations. Ind AS 116 sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. It introduces a single, on-balance sheet lease accounting model for lessees. The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the standard, recognised on the date of initial application (April 1, 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on April 1, 2019.

(i) FOREIGN CURRENCY TRANSLATION

On March 28, 2018, Ministry of Corporate Affairs ("MCA") has notified the Companies (Indian Accounting Standards) Amendment Rules, 2018 containing Appendix B to Ind AS 21, Foreign currency transactions and advance consideration which clarifies the date of the transaction for the purpose of determining the exchange rate to use on initial recognition of the related asset, expense or income, when an entity has received or paid advance consideration in a foreign currency.

The company has adopted amendments prospectively to items in scope of the appendix that are initially recognised on or after the beginning of the reporting



period in which the appendix is first applied (i.e. from 1st April, 2018).

(i) Presentation Currency

These Financial Statements are presented in INR which is the Functional Currency of the company.

(ii) Transactions and balances

The foreign currency balances receivable/ payable as at the year end are converted at the closing rate and exchange difference has been recognized in the statement of Profit and Loss. The company classifies all its foreign operations as integral in nature.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of other financial instruments are recognised in other comprehensive income.

2.9 TAXES ON INCOME

Current income tax is recognized based on the amount expected to be paid to the tax authorities, using tax rates and tax laws that have been enacted or substantially enacted on the date of balance sheet.

Deferred income tax is provided using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

If the company has carry forward unabsorbed depreciation and tax losses, all deferred tax assets are recognised only to the extent there is virtual certainty supported by convincing evidence that sufficient taxable income will be available against which such deferred tax assets can be realised.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

2.10 EARNINGS PER SHARE

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of shares and dilutive equity equivalent shares outstanding during the period, except when results will be anti-dilutive.

2.11 PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

A provision is recognised if, as a result of a past event, the company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. The

provisions are measured on an undiscounted basis.

Provision in respect of loss contingencies relating to claims, litigation, assessment, fines, penalties, etc. are recognised when it is probable that a liability has been incurred and the amount can be estimated reliably.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed, unless the possibility of outflow of resources is remote.

Contingent assets are neither recognised nor disclosed in the consolidated financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

2.12 SEGMENT REPORTING

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker.

2.13 RESEARCH & DEVELOPMENT

Development of expenditure of certain nature is capitalised when the criteria for recognising an intangible asset are met. The revenue expenditure on Research & Development is written off in the year in which it is accrued.

2.14 INVENTORIES

Inventories are valued at the lower of cost (Weighted average basis) and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges. Work-in-progress and finished goods include appropriate proportion of overheads.

2.15 GOVERNMENT INCENTIVES

Government incentives that the company is entitled to on fulfillment of certain conditions, but are available to the company only on completion of some other conditions, are recognized as income at fair value on completion of such other conditions

Incentives that the company is entitled to unconditionally on fulfillment of certain conditions, such incentives are recognized at fair value as income when there is reasonable assurance that the incentives will be received.

2.16 Recent Pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended March 31, 2025,

MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

2.17 Material estimates and judgements

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the company's accounting policies.

Estimates and judgments are continuously evaluated. They are based on historical experience and other factors, including expectations of future events that may have a financial impact on the company and that are believed to be reasonable under the circumstances.

The following are the judgements and estimates that the management have made in the process of applying the company's accounting policies and that have the most material effect on the amounts recognised in the consolidated financial statements.

i) Impairment of trade receivable:

The impairment provisions for trade receivables are based on assumptions about risk of default and expected loss rates. The company uses judgement in making these assumptions and selecting the inputs to the impairment calculation, based on the company's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

ii) Post-employment benefits:

The costs of providing pensions and other postemployment benefits are charged to the income statement in accordance with Ind AS 19 'Employee benefits' over the period during which benefit is derived from the employees' services. The costs are assessed on the basis of assumptions selected by the management. These assumptions include future earnings and pension increases, discount rates, expected long-term rates of return on assets and mortality rates. iii) Sales returns and rebates:

Revenue is recognised when title and risk of loss is passed to the customer, reliable estimates can be made of relevant and all relevant obligations have been fulfilled, such that the earnings process is regarded as being completed.

Gross turnover is reduced by rebates, discounts, allowances and product returns given or expected to be given, which vary by product arrangements and buying companys. These arrangements with purchasing organisations are dependent upon the submission of claims some time after the initial recognition of the sale.

Because the amounts are estimated they may not fully reflect the final outcome, and the amounts are subject to change dependent upon, amongst other things, the types of buying company and product sales mix.

Future events could cause the assumptions on which the accruals are based to change, which could affect the future results of the company.

- iv) Assumptions are also made by the management with respect to valuation of inventories, evaluation of recoverability of deferred tax and contingencies.
- Previous year's figures have been recompanyed / reclassified wherever necessary to correspond with the current year's classification / disclosure
- vi) Rounding off has been done in the relevant notes wherever applicable.



3 NON-CURRENT ASSETS - PROPERTY, PLANT AND EQUIPMENT AND CAPITAL WORK-IN-PROGRESS

FY 2024-25	FY 2024-25 (Rs										
DESCRIPTION	(GROSS CAR	RYING AMOUN	T	C	NET CARRYING AMOUNT					
	As at 01.04.2024	Additions	Adjustments	Balance As at 31.03.2025	As at 01.04.2024	Charge during the year	Adjustments	Balance As at 31.03.2025	Balance As at 31.03.2025		
Freehold land	8			8	-			-	8		
Buildings	873	135		1,008	268	39		308	700		
Plant & equipment	831	638	45	1,424	359	66	35	390	1,034		
Furniture & fittings	335	76		411	138	27		165	246		
Vehicles	343	25	88	281	145	37	75	107	174		
Office equipment	62	8	0	69	51	4	0	55	14		
Computers	336	16		353	285	26		311	42		
Total	2,789	898	133	3,554	1,247	199	110	1,334	2,219		

Previous year (FY 2023-24)

DESCRIPTION	(GROSS CAR	RYING AMOUN	Т	C	EPRECIATION	N / AMORTISAT	NET CARRYING AMOUNT	
	As at 01.04.2023	Additions	Adjustments	Balance As at 31.03.2024	As at 01.04.2023	Charge during the year	Adjustments	Balance As at 31.03.2024	Balance As at 31.03.2024
Freehold land	8			8	-			-	8
Buildings	808	65		873	234	34		268	604
Plant & equipment	751	94	13	831	320	52	13	359	472
Furniture & fittings	204	131		335	120	18		138	197
Vehicles	297	64	18	343	125	38	18	145	198
Office equipment	60	2		62	46	5		51	10
Computers	285	52		336	257	28		285	51
Total	2,413	408	31	2,788	1,102	175	31	1,245	1,541

4 Right of Use Assets-IND AS 116

	FY 2024-25
Right of Use Assets as on 01-4-2024	216
(representing right of use of underlying assets)	
Add: Asset created	515
Less: Asset removed	202
Amortisation Charge	120
Net carrying amount as on 31-3-2025	409

Right of Use Assets-IND AS 116	FY 2023-24
Right of Use Assets as on 31-3-2023	484
(representing right of use of underlying assets)	
Add: Asset created	
Less: Asset removed	133
Amortisation Charge	135
Net carrying amount as on 31-3-2024	216

Note:-

- 1) There are no quaifying assets and accordingly no borrowing costs are capitalised during the year
- 2) There were no Capital work-in-progress at the end of the year
- 3) No revaluation of property, plant and equipment was done during the year as the carrying value is on par with the fair market value as per Management's estimation

4) The Management is of the opinion that there is no impairment of Property, Plant and Equipment, during or as at the end of the year.

5 NON-CURRENT ASSETS - INTANGIBLE ASSETS

FY 2024-25									(Rs. In Lakhs)
DESCRIPTION	GROSS CARRYING AMOUNT				DEPRECIATION / AMORTISATION				NET CARRYING AMOUNT
	As at 01.04.2024	Additions	Adjustments	Balance as at 31.03.2025	As at 01.04.2024	Charge during the year	Adjustments		Balance as at 31.03.2025
Trademarks	-			-	-			-	-
Computer software	30	3		33	14	8	-	22	11
Total	30	3	-	33	14	8	-	22	11

Previous year (FY 2023-24)

DESCRIPTION	(GROSS CAR	RYING AMOUN	Т	DEPRECIATION / AMORTISATION				NET CARRYING AMOUNT
	As at 01.04.2023		Adjustments	Balance as at 31.03.2024	As at 01.04.2023	Charge during the year	Adjustments		Balance as at 31.03.2024
Trademarks	-			-	-			-	-
Computer software	30			30	10	4	-	14	16
Total	30	-	-	30	10	4	-	14	16

Note:- 1) There were no intangible assets under development during the year

2) The Management is of the opinion that there is no impairment of Intangible assets, during or as at the end of the year.

DES	CRIPT	ΓΙΟΝ		As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
6	Non	-Curre	ent investments		
	Α.	Inve	stments in Equity Instruments (fully paid)		
		(i)	Quoted -		
			In Other entities (Equity investments at Fair value through other comprehensive income)		
			5,760 (2023- 5,760) Equity shares of INR 10 each in Industrial Development Bank of India Limited	5	5
			19,400 (2023- 19,400) Equity shares of INR 10 each in Vijaya Bank	2	2
			Note-Vijaya Bank has been merged with Bank of Baroda wef 1st Apr 2019		
			Investments in Shares- Ind As	16	19
		(ii)	Unquoted -		
			1 (2023- 1) Equity share of Rs. 10 each full paid-up in Nysha Mobility Tech Pvt Ltd	0	(
	В.	Inve	stments in Preference Shares (fully paid)		
		(i)	Unquoted -		
			7,850 (2023- 7,850) Compulsorily Convertible Preference Shares of Rs. 10 each (premium of Rs. 308.7 per share) full paid-up in Nysha Mobility Tech Pvt Ltd	25	25
Tota	l non-	currer	nt investments	48	50
Aggr	egate	amoui	nt of quoted investments	7	7
Mark	et val	ue of q	uoted investments	22	26

Annual Report 2024-25

DES	SCRIP [.]	ΓΙΟΝ	As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
7	OTH	IER FINANCIAL ASSETS - NON CURRENT		
	Sec	urity deposits	146	160
	Ban	k deposits with more than 12 months maturity	14	59
	Mar	gin Money	1	1
	Othe	ers- Inter corporate deposit	319	431
Tota	al Othe	er Financial Assets	480	651
8	Def	erred tax assets (Net)		
	Tota	II Deferred Tax assets (Net)	-	-
9	ОТН	IER NON-CURRENT ASSETS		
	Tota	I other non-current assets		-
10	INV	ENTORIES		
	Raw	/ materials	264	274
	Pac	king materials	95	153
	Wor	k-in-progress	79	99
	Finis	shed goods	646	566
	Stor	es, spare parts & chemicals	111	105
	Les	s: Provision for Expired, Near Expiry, Slow-moving and Obsolete Inventory	-45	-37
	Tota	Il inventories	1,150	1,160
	(i)	Raw materials & Packing materials are valued at weighted Average method , WIP & Finished Goods at Standard Price and stores and spares, chemicals & consumables & others at cost		
	(ii)	The Company has made a provision for inventories comprising expired, near- expiry, slow-moving, non-moving, and obsolete items. This provision has been reduced from the gross value of inventories to reflect their net realizable value in accordance with Ind AS 2		
11	Cur	rent Financial Assets-Trade Receivables		
	Trac	de receivables		
	(a)	Considered good - Secured		
	(b)	Considered good - Unsecured	3,365	4,309
	(c)	Trade Receivables which have significant increase in credit risk		
	(d)	Trade Receivables - credit impaired		
	Les	s: Loss allowance		
	(a)	Provision for expected credit loss	87	87
	(b)	Credit impaired	68	41
Tota	al trad	e receivables (current)	3,210	4,181

Trade Receivables - Ageings-FY 2024-25

Part	iculars	Outstand	Total				
		Less than 6 months	6 months- 1 year	1-2 yrs.	2-3 yrs.	More than 3 yrs	
(i)	Undisputed Trade receivables- considered good	2197	110	62	686		3055
(ii)	Undisputed Trade receivables- which have significant increase in credit risk						
(iii)	Undisputed Trade receivables- Impaired				50	105	155
(iv)	Disputed Trade receivables- considered good						
(v)	Disputed Trade receivables- which have significant increase in credit risk						
(vi)	Disputed Trade receivables- Impaired						0
							3210

Trade Receivables - Ageings-FY 2023-24

Part	iculars	Outstandir	Outstanding for following periods from due date of payment						
		Less than 6 months	6 months- 1 year	1-2 yrs.	2-3 yrs.	More than 3 yrs			
(i)	Undisputed Trade receivables- considered good	2185	162	1734	41	59	4181		
(ii)	Undisputed Trade receivables- which have significant increase in credit risk								
(iii)	Undisputed Trade receivables- Impaired								
(iv)	Disputed Trade receivables- considered good								
(v)	Disputed Trade receivables- which have significant increase in credit risk								
(vi)	Disputed Trade receivables- Impaired					128	128		
							4309		

The average credit period allowed to customers is in the range of 30 days and interest on overdue receivables is generally levied at 18% per annum as per the terms of the agreement.

The Company does not have history of defaults in trade receivables. Loss allowance is estimated for disputed receivables based on assessment of each case by obtaining legal advice, where considered necessary.

୍ଷ୍ମିକ

Annual Report 2024-25

Particula	ars	As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
12 a.	Cash and Cash Equivalents		
	Cash in hand	5	1
	Balances with Banks		
	- Dividend A/c	7	6
	- Current Accounts	10	2
		22	9
b.	Other Bank Balances		
- ir	n Deposit account*	95	240
		95	240
	ents deposit with original maturity more than 3 months but less than twelve months deposits which are maturing within 12 months from the reporting date.		
13 CL	JRRENT FINANCIAL ASSETS - INVESMENTS		
Investme	ents in Mutual Funds (Refer Note (i) below)	9,504	12,469
		9,504	12,469

(i) The company had invested in Mutual funds in FY 2022-23 and the investment were stated at Amortized Cost. Accordingly, unrealized gains and losses are not recorded as on the reporting date. The company had strategically invested in these Mutual funds, Equity & debts instruments which is parked temporarily for application by the company in investing and financing activities. The Cost and NAV as on the reporting date are as follows:

Particulars	Cost as on 31.03.2025	NAV as on 31.03.2025
Equity Oriented Funds	4,323	5,683
Debt Oriented Funds	3,536	3,733
Alternative Investment Funds	1,645	1,793
	9,504	11,209

Particulars	Cost as on 31.03.2024	NAV as on 31.03.2024
Equity Oriented Funds	7,191	9,967
Debt Oriented Funds	4,006	4,480
Alternative Investment Funds	1,272	1,441
	12,469	15,887

Part	iculars	As at	As at
		March 31st, 2025 Rs. Lakhs	March 31st, 2024 Rs. Lakhs
14	CURRENT FINANCIAL ASSETS - OTHERS		
	Employee advances	27	42
	Recoverable from Statutory Authorities	806	569
	Advances to suppliers and others	296	657
	Other Financial Assets	36	34
	Other Inter corporate Deposits (Refer Note below)	841	-
		2,006	1,302

Note: Includes Rs. 752 Lakhs paid towards Working Capital to Dormirbien Private Limited, where the two of the directors of the company are interested as directors.

Anglo-French Drugs & Industries Limited

Part	iculars	As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
15	Current Tax Assets (Net)		
	Income Tax (net of provision)		
	Advance Income Tax	6,296	6,236
	TDS Receivables	63	34
	MAT Credit	80	80
	Less: Provision for Income taxes	(6,619)	(6,484)
	Total Current Tax assets	(180)	(134)
16	OTHER CURRENT ASSETS		
	Prepaid expenses	80	73
	Others-Recovery Right Assets	6	15
	Total other current assets	86	88
17	EQUITY SHARE CAPITAL		
	Authorised		
	20,00,000 Equity Shares of INR 10 each	200	200
		200	200
	Issued		
	11,26,882 Equity Shares of INR 10 each	113	123
	(PY: 12,33,382 Equity Shares of INR 10 each)		
		113	123
	Subscribed and fully paid up		
	11,26,882 Equity Shares of INR 10 each	113	123
	(PY: 12,33,382 Equity Shares of INR 10 each)		
		113	123
	Notes:		
	a. Reconciliation of number of Equity shares subscribed		
	Balance as at the beginning of the year	12,33,382	12,91,500
	Add: Shares Issued		
	Less: Shares bought back	1,06,500	58,118
Bala	ance as at the end of the year	11,26,882	12,33,382

b. Aggregate number of shares bought back is 1,06,500 (FY 2023-24 - 58,118)

The Board of Directors of the Company in the meeting held on 29th July 2024 vide Resolution number 03, approved the buy back of shares proposed by the Company at a rate of Rs 4000 per share. A total of 1,06,500 equity shares have been bought back by the company in the second quarter of FY 2024-25 (Face value of Rs. 10 per share and Share Premium of Rs. 3990 per share). The total accepted value for such buyback is Rs. 42,60,00,000/-. and the total amount available for distribution after deduction of costs was Rs. 42,00,76,240/-

The process of buyback concluded on 23rd of September 2024.

c. Rights and preferences attached to equity shares :

The company is having only one class of equity shares carrying a nominal value of INR 10 per share. These shares rank pari passu in all respects including voting rights and entitlement to dividend. Every holder of the equity shares of the Company is entitled to one vote per share held in the event of liquidation of the Company, the equity shareholders will be entitled to receive remaining assets of the Company after the distribution / repayment of all creditors. The distribution to the equity shareholders will be in proportion of the number of shares held by each shareholder.

d. Shareholders holding more than 5% of the total share capital

Name of the Shareholder		As at Marc	h 31st, 2025	As at March 31st, 2024		
		No of Equity shares held	% of holding in that class of shares	No of Equity shares held	% of holding in that class of shares	
(1)	Abhay Kanoria Family Trust represented by Mr. Abhay Kanoria	6,09,823	54.12	6,71,964	54.48	
(2)	Ninaad Finance And Properties Pvt Ltd	-	-	1,29,000	10.46	
(3)	Broach Textiles Mills Limited	1,17,116	10.39	-	-	
(4)	Life Insurance Corporation of India	79,370	7.04	85,977	6.97	

d. Shareholding of Promoters

Name of the Promoter	As at Marc	h 31st, 2025	As at March 31st, 2024	
	No of Equity shares held	% of holding in that class of shares	No of Equity shares held	% of holding in that class of shares
Promoters/Promoters Group				
Abhay Kanoria Family Trust, Represented by Mr. Abhay Kanoria, Trustee	6,09,823	54.12	6,71,964	54
Ninaad Finance and Properties Pvt. Ltd.	-	-	1,29,000	10
Broach Textiles Mills Limited	1,17,116	10.39	-	-
Binod Kumar Kanoria (HUF)	200	0.02	200	0
Prabhadevi Kanoria	3,450	0.31	3,450	0
Total	7,30,589	65	8,04,614	65

The Board of Directors in its meeting held on 28th May 2024, has recommended dividend of 15% (Rs. 1.5/- per equity share of Rs.10/- each) for the year ended 31st March, 2024 and the same was approved by the shareholders at the 101st Annual General Meeting held on 12th August 2024. which resulted in a cash outflow of Rs.18,50,073/-.

18 OTF (a) (b) (a)	CAP SEC GEN CAP SUR OTH Fair Tota	QUITY SERVES AND SURPLUS PITAL RESERVE SURITIES PREMIUM RESERVE NERAL RESERVE PITAL REDEMPTION RESERVE RPLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument of other equity SERVE AND SURPLUS	Rs. Lakhs 43 289 533 16 11,491 12,372 (5) 12,367	Rs. Lakhs 43 289 543 6 16,088 16,969 (2) 16,967
(b)	CAP SEC GEN CAP SUR OTH Fair Tota	PITAL RESERVE CURITIES PREMIUM RESERVE JERAL RESERVE PITAL REDEMPTION RESERVE RPLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument I other equity	289 533 16 11,491 12,372 (5)	289 543 6 16,088 16,969 (2)
	SEC GEN CAP SUR OTH Fair Tota	CURITIES PREMIUM RESERVE IERAL RESERVE PITAL REDEMPTION RESERVE RPLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument I other equity	289 533 16 11,491 12,372 (5)	289 543 6 16,088 16,969 (2)
	GEN CAP SUR OTH Fair Tota RES	IERAL RESERVE PITAL REDEMPTION RESERVE RPLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument I other equity	533 16 11,491 12,372 (5)	543 6 16,088 16,969 (2)
	CAP SUR OTH Fair Tota RES	PITAL REDEMPTION RESERVE PLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument Il other equity	16 11,491 12,372 (5)	6 16,088 16,969 (2)
	SUR OTH Fair Tota RES	RPLUS/(DEFICIT) IN STATEMENT OF PROFIT AND LOSS IER RESERVES Value through Other Comprehensive Income- Equity Instrument Il other equity	11,491 12,372 (5)	16,088 16,969 (2)
	OTH Fair Tota RES	IER RESERVES Value through Other Comprehensive Income- Equity Instrument Il other equity	12,372 (5)	16,969 (2)
	Fair Tota RES	Value through Other Comprehensive Income- Equity Instrument	(5)	(2)
	Fair Tota RES	Value through Other Comprehensive Income- Equity Instrument		
(a)	Tota RES	I other equity		
(a)	RES		12,367	46 065
(a)		ERVE AND SURPLUS		10,307
(a)				
	(1)	CAPITAL RESERVE		
		Opening Balance	43	43
		Closing Balance	43	43
	(ii)	SECURITIES PREMIUM RESERVE		
	. ,	Opening Balance	289	289
		Closing Balance	289	289
	(iii)	GENERAL RESERVE		
		Opening Balance	543	549
		Less: Transfer to Capital Redemption Reserve	11	
		Closing Balance	533	543
	(iv)	Capital Redemption Reserve		
	()	Opening Balance	6	
		Add: Transfer during the year	11	6
		Closing Balance	16	(
	(v)	SURPLUS/ (DEFICIT) IN STATEMENT OF PROFIT AND LOSS		
		Opening Balance	16,088	19,868
		EFFECT OF IND AS		
		Less: Dividend Paid	(19)	(258
		Less: Buyback of shares	(4,249)	(1,796
		Less: Tax and other payments on Buyback of shares	(1,040)	(458
		Add: Profit /(Loss) during the year as per Statement of Profit & Loss	722	(1,234
		Other comprehensive income recognised directly in retained earnings - Remeasurements of post-employment benefit obligation, net of tax	(10)	(24
		- Remeasurements of post-employment benefit obligation, net of tax	11,491	(34 16,08
		Closing Balance	11,451	10,000
(b)	ОТН	IER RESERVE		
(/		IER COMPREHENSIVE INCOME		
		ning Balance	(2)	6
		stments during the year		
	- Re	emeasurements of quoted equity shares	(3)	(8
	Clos	sing Balance	(5)	(2
		lysis of Accumulated OCI		
		nce at the beginning of the year	-2	6
		neasurements of post employment benefit obligations, gain/(loss)		
		me tax effect		
		to change in the rate of tax on opening balance		10
		neasurements of quoted equity shares Ince at the end of the year	(3) (5)	(8 (2



(i) Capital Reserve

Capital Reserve represents the statutory reserve created by the company as per requirement of the Act. This on account of the various transactions like debenture forfeiture, capital receipts and capital subsidary received from the Government during various years.

(ii) Securities premium reserve

Securities premium reserve is used to record the premium on issue of shares. The reserve is utilised in accordance with the provisions of the Companies Act.

(iii) General Reserve

General Reserve is a free reserve, which is in accordance with Indian Corporate law wherein a portion of profit is apportioned to general reserve. Under Companies Act, 2013 transfer of any amount to General reserve is at the discretion of the company.

(iv) Retained earnings :

Retained earnings comprise balances of accumulated (undistributed) profit or loss at each year end.

(v) Capital Redemption Reserve

The nominal value of the shares bought back on 14th August 2024 (FY 2023-24: 26th July 2023) was transferred to Capital Redemption Reserve in consonance with Section 69 of the Companies Act, 2013.

NON CURRENT FINANCIAL LIABILITIES

			(Rs. In Lakhs)
artic	culars	As at March 31st, 2025	As at March 31st, 2024
)	NON-CURRENT BORROWINGS		
	Secured loan		
	HDFC Bank- Loan against property (LAP)	244	413
	Car Loan	52	69
	Inter Corporate Deposit		
	Related Party	112	232
	Total	408	714

PARTICULARS OF BORROWINGS :

- a) Security, Terms of repayment and Interest rate :
 - In respect of Vehicle loans repayments are done by equated monthly installments over 36 to 60 months. Vehicle loans are secured by hypothecation of vehicles.
 - (ii) The company has taken vehicle loan from HDFC Bank during the year which carry interest at the rate of 9.13%, repayable in 39 equal installments. Repayment of the term loan will be completed in March 2028. And from Punjab National Bank @ 9% repayable in 60 equal installments and loan will be completed in August 2029.
 - (iii) Loan from HDFC Bank (LAP) is secured at first ranking and exclusively charged by way of equitable mortgage on residential property of Sudarshan Services Limited & carries interest at the rate of 10%, repayable in 72 equal monthly instalments. Repayment will be completed in July 2027
 - (iv) Inter Corporate Deposits received from Sudarshan services Ltd. carry the interest at the rate of 10.5%. These deposits are repayable on mutually agreed dates.

Part	ticulars	As March 31st, 20 Rs. Lak		As at March 31st, 2024 Rs. Lakhs
20	Other non-current financial liabilities			
	Security deposits		57	71
	Total		57	71

Part	iculars	As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
21	Deferred tax liabilities (net)		
	Deferred Tax Liabilities on account of :		
	Depreciation	156	126
	Total deferred tax liabilities (A)	156	126
	Deferred Tax Assets on account of :		
	Provision for Bonus	(21)	(8)
	Provision for Leave encashment and gratuity	(63)	(21)
	Provision for debts, advances and investments	(40)	(1)
	Total deferred tax assets (B)	(124)	(30)
	Deferred Tax (Assets)/Liabilities (Net - A-B)	32	96
22	Other Non Current Liabilities		
	Lease Liabilities- Ind AS 116 (Refer Note 43)	436	266
	Total	436	266

Long Term Provisions 23

Employee benefit obligations

Employee benefit obligations (Rs. In Lakhs)						
	As at March 31, 2025			As at March 31, 2024		
	Current	Non-current	Total	Current	Non-current	Total
Leave Encashment - Unfunded						
Present value of obligation	6	34	40	9	34	43
Gratuity - Funded						
Present value of obligation	44	270	315	164	122	286
Fair value of plan assets		112	112	126	-	126
Net Liability	44	158	203	38	122	160
Gratuity Liability	44	158	203	38	122	160
Total employee benefit obligations	50	192	243	47	156	203

Defined benefit plans (i)

a) Gratuity

The company provides for gratuity for employees in India as per the Payment of Gratuity Act, 1972. Gratuity plan is a funded plan and the Company makes contributions to Kotak Gratuity Group Plan (UNI-107L010V05).

b) Leave Encashment

(ii) **Defined contribution plans**

The Company makes contributions towards provident fund which are in the nature of defined contribution post employment benefits plans. Under the plan, the Company is required to contribute a specified percentage of payroll cost to fund the benefits.

Annual Report 2024-25

(iii) Movement of defined benefit obligation and fair value of plan assets :

The amounts recognised in the balance sheet and the movements in the net defined benefit obligation over the year are as follows:

Particulars		Leave Encashment		
	Present value	Fair value of	Net amount	Present value of
	of obligation	plan assets		obligation
April 1, 2023	500	281	218	71
Current service cost	19	-	19	12
Prior Service cost				
Interest expense/(income)	19	11	8	-
Total amount recognised in profit or loss	38	11	27	12
Remeasurements				
Loss/(Gain) due to experience	8	-	8	-
Loss due to change in financial assumptions	8	-	8	-
Return on plan assets (greater)/less than discount rate	1	-	1	-
Total amount recognised in other comprehensive income	17	-	17	-
Employer contributions	-	-	-	-
Benefit payments	-	-	-	20
March 31, 2024	555	292	262	63
April 1, 2024	555	292	262	63
Current service cost	21		21	3
Prior Service cost			-	
Interest expense/(income)	19		19	
Total amount recognised in profit or loss	40	-	40	3
Remeasurements			-	
Loss/(Gain) due to experience	8		8	
Loss due to change in financial assumptions	4		4	
Return on plan assets (greater)/less than discount rate	(1)		(1)	
Total amount recognised in other comprehensive income	10	-	10	-
Employer contributions				
Benefit payments				22
March 31, 2025	605	292	312	45

The net liability disclosed above relates to funded and unfunded plan are as follows:

Particulars	March 31, 2025	March 31, 2024
Present value of funded obligations	315	286
Fair value of plan assets	112	126
Deficit of funded plan	203	160
Unfunded plans	0	0
Deficit of Employee Benefit Plans	203	160

(iv) Post-Employment benefits

The significant actuarial assumptions were as follows:

Particulars	March 31, 2025	March 31, 2024
Discount rate	6.99%	7.20%
Salary growth rate	5.00%	5.00%
Expected return on assets	6.99%	7.20%
Mortality	Indian Assured Lives Mortality (2012-14)	Indian Assured Lives Mortality (2012-14)
Withdrawal / attrition rate	5.00%	5.00%

(v) Sensitivity analysis

The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions is:

Particulars	Change in	assumption	Impact on defined benefit obligation				
			Increase by 1%(100bps)		Decrease by 1%(100bps)		
	March 31,	March 31,	March	March 31,	March 31,	March 31,	
	2025	2024	31, 2025	2024	2025	2024	
Gratuity							
Discount rate	1%	1%	(16)	(15)	18	17	
Salary growth rate	1%	1%	15	14	(14)	(13)	
Withdrawal rate	1%	1%	2	2	(2)	(2)	
Leave Encashment							
Discount rate	1%	1%		(3)		3	
Salary growth rate	1%	1%		3		(3)	
Withdrawal rate	1%	1%		0		(0)	

The above sensitivity analyses are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method i.e. projected unit credit method has been applied as that used for calculating the defined benefit liability recognised in the balance sheet.

(vi) The major categories of plan assets are as follows:

Particulars	March	31, 2025	March 31, 2024		
	Amount in lakhs	in %	Amount in lakhs	in %	
Investment funds with Kotak Gratuity Group Plan (UNI-107L010V05)	112	100%	126	100%	
Total	112	100%	126	100%	

The Company pays contribution to Kotak Gratuity Group Plan (UNI-107L010V05) which inturn invests the amount in various instruments. As it is done by Kotak Gratuity Group Plan (UNI-107L010V05) in totality basis along with contributions from other participants, the Company wise investment in planned assets - category / class wise is not available.

(vii) Risk exposure

The defined benefit obligations have the undermentioned risk exposures :

Interest rate risk : The defined benefit obligation is calculated using a discount rate based on government bonds. If bond yields fall, the defined benefit obligation will tend to increase.

Salary Inflation risk : Higher than expected increases in salary will increase the defined benefit obligation.

Demographic risk : This is the risk of variability of results due to unsystematic nature of decrements that include mortality, withdrawal, disability and retirement. The effect of these decrements on the defined benefit obligation is not straight forward and depends upon the combination of salary increase, discount rate and vesting criteria.

(viii) Defined benefit liability and employer contributions

Expected contribution to post employment benefit plan for the year ended March 31, 2025 is 38 lakhs (Year ended 31.03.24 Rs.38 lakhs)

The weighted average duration of the defined benefit obligation is 10.91 years (March 31, 2024 - 10.82 years) in case of Gratuity. The expected maturity analysis of undiscounted gratuity and leave encashment is as follows :

Particulars	Less than a year	Between 1 - 2 years	Between 2 - 3 years	Between 3 - 4 years	Between 4 - 5 years	Beyond 5 years	Total
March 31, 2025							
Gratuity	29	35	22	15	34	135	270
Leave encashment	3	3	2	2	4	15	29
Total	32	38	24	17	38	150	299
March 31, 2024							
Gratuity	29	18	30	19	13	135	244
Leave encashment	4	3	4	3	2	17	33
Total	33	21	33	22	15	152	277



			(Rs. In Lakhs)
Part	ticulars	As at March 31, 2025	As at March 31, 2024
24	CURRENT BORROWINGS		
	SECURED		
	Cash Credit from Banks		
	HDFC Bank *	1,493	-
	YES Bank		188
	Total Current borrowing	1,493	188

PARTICULARS OF BORROWINGS :

1. HDFC Bank

- I) Security
 - (i) The security charge for the loan from HDFC Bank is as follows:
 - a) BhandanDFC Crisil Gift 2028 Index Fund Direct Plan Growth
 - b) Aditya Birla Sun LIFe Nifty SDL Plus Bond Sep 2026 60:40 Index Fund Direct Plan Growth
 - c) Edelweiss Bharat Bond FOF April 2030 Direct Plan Growt
 - d) Aditya Birla SI Crisil SDL Plus AAA PSU APR 2027
- II) Terms of repayment and Interest rate :
 - Loan Against Securities from HDFC Bank carry interest at the rate of 8.75% (From 23.08.2024 to 17.02.2025) & 8.5% from 18.02.2025

* Confirmed as current account by the bank specifying Rs 1785 lakhs limit for the debit balance against the securities pledged as on the reporting date. The amount sanctioned as per HDFC Letter dated 17-4-2024 being Rs 3000 lakhs.

2. Yes Bank

I) Security

- (i) The security charge for the loan from Yes Bank is as follows:
 - a) By way of hypothecation on current assets (CA)
 - b) By way of hypothecation on all movable fixed assets (MFA)
 - c) By way of equitable mortgage on specific building (Factory Land and Building) located at Peenya Industrial Area Building valuing INR 94.17 crores.
- II) Terms of repayment and Interest rate :
 - (i) Cash Credit from YES Bank carry interest at the rate of 9.5%

During the year, the balance in Yes Bank is Rs. 4.36 Lakhs (Dr) as on 31.03.2025 as indicated in note no: 12.

Part	iculars	As at March 31, 2025 (Rs. In Lakhs)	As at March 31, 2024 (Rs. In Lakhs)
25	TRADE PAYABLES		
	Trade payables	2,847	2,070
	Total trade payables	2,847	2,070
	Classification as required by MSME Act		
	Total outstanding dues of Micro Enterprises and Small Enterprises*	398	254
	Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	2,449	1,816
	Total trade payables	2,847	2,070

* Details of dues to Micro Enterprises and Small Enterprises as defined under Micro, Small & Medium Enterprises Development Act, 2006 (MSME Act) are based on information made available to the Company. Credit period as per the purchase orders ranges from 60 to 90 days and most of the bills were raised in February 2024. Hence, the delay of 45 days does not arise as on the reporting date.

Trade Payable ageing schedule as at March 31, 2025

Parti	culars	Outstandi	ing for the follo	wing periods fi	om due date of	lue date of payment			
		Less than 1	1-2 years	2-3 years	More than 3	Total			
		year			years				
(i)	MSME	397	1			398			
(ii)	Others	2435	14			2449			
(iii)	Disputed dues- MSME								
(iv)	Disputed dues- Others								
						2847			

Trade Payable ageing schedule as at March 31, 2024

Part	iculars	Outstand	ing for the follo	wing periods fr	om due date of pa	ayment
		Less than 1	1-2 years	2-3 years	More than 3	Total
		year			years	
(i)	MSME	254				254
(ii)	Others	1811	5			1816
(iii)	Disputed dues- MSME					
(iv)	Disputed dues- Others					
						2070

Disclosure relating to micro and small enterprises

Particulars		As at 31st M	larch, 2025	As at 31st M	arch, 2024
		Current	Non Current	Current	Non Current
(1)	Principal amount outstanding	398	-	254	-
(2)	Principal amount due and remaining unpaid	-	-	-	-
(3)	Interest due on (2) above and the unpaid interest	-	-	-	-
(4)	Interest paid on all delayed payments under the MSMED Act.	-	-	-	-
(5)	Payment made beyond the appointed day during the year	-	-	-	-
(6)	Interest due and payable for the period of delay other than (4) above	-	-	-	-
(7)	Interest accrued and remaining unpaid	-	-	-	-
(8)	Amount of further interest remaining due and payable in succeeding years	-	-	-	-

Part	iculars	As at March 31st, 2025 Rs. Lakhs	As at March 31st, 2024 Rs. Lakhs
26	OTHER CURRENT FINANCIAL LIABILITIES		
	Current maturities of long term debt		
	Car loan	37	31
	HDFC LAP	171	156
	Unclaimed dividend	7	6
	Creditors for Expenses	236	264
	Statutory and other dues	122	23
	Liabilities related to employees	236	222
	Others-Refund Liability	13	30
	Other payables	243	358
	Total current financial liabilities	1,065	1,090
27	SHORT TERM PROVISIONS		
	Employee Benefit Obligations (Gratuity & LE)	50	48
	Total Short Term provisions	50	48

Annual Report 2024-25

				(Rs. In Lakhs)
			For the period ended	For the period ended
			March 31st, 2025	March 31st, 2024
28	RE\	ENUE FROM OPERATIONS		
	a)	Sale of products		
		Pharmaceutical	8,610	9,496
	b)	Other operating revenues		
		Sale of scrap	8	6
		Conversion charges/income from job work	8	10
		Miscellaneous income - Operating Income	153	7
		Total Revenue from Operations	8,779	9,520
9	ОТН			
	Inte	rest from Banks	10	6
	Inte	rest on others	441	234
	Divi	dend income	38	28
	Prov	visions/ Liabilities written back	5	30
	Miso	cellaneous income -non operating	83	36
	DEF	PB Transfer/Duty Drawback	4	5
	Prof	it on sale of Investments (net)	2,439	126
	Prof	it on sale of assets	-	C
	Tota	I Other Income	3,020	465
0	Cos	t Of Materials Consumed		
	a)	Raw Material Consumed		
		Opening Stock	274	167
		Purchases	1,821	2,507
			2,095	2,675
		Less : Closing Stock	264	274
		Raw Material Consumed	1,831	2,400
	b)	Packing Material Consumed		
	,	Opening Stock	153	123
		Purchases	382	662
			535	785
	Les	s : Closing Stock	95	153
		king Material Consumed	440	632
	Tota	al Cost of material consumed	2,271	3,032
1		chases	0.700	0.000
		I Cost of Goods	6,762	6,823
		s:Opening Stock	666	482
		s: Consumption of Materials	2,271	3,032
		: Closing Stock	724	665
	Tota	al Purchases	4,549	3,97

Anglo-French	Drugs	& Industries	Limited
---------------------	-------	--------------	---------

(Rs. In Lakhs			
		For the period	For the period
		ended March 31st, 2025	ended March 31st, 2024
32	Changes in inventories of Finished Goods, Work in Progress and Stock in Trade		
	Opening Inventories of :		
	Finished Goods	566	378
	Work in Progress	99	104
		666	482
	Closing Inventories of :		
	Finished Goods	646	566
	Work in Progress	79	99
		724	665
	Total changes in inventories of finished goods, work in progress and stock-in-trade	(59)	(184)
33	EMPLOYEE BENEFITS EXPENSE		
	Salaries & wages	1,633	1,725
	Contribution to provident and other Funds	129	141
	Staff welfare expenses	82	79
	Total employee benefits expense	1,844	1,945
34	FINANCE COSTS		
	Interest Expense		
	-on borrowing from banks and others	132	149
	Finance Cost-Ind AS 116	46	36
	Total finance costs	178	185
35	DEPRECIATION AND AMORTIZATION EXPENSES		
55	PROPERTY, PLANT AND EQUIPMENT-DEPRECIATION		
	Buildings	39	34
	Plant & equipment	66	52
	Furniture & fittings	27	18
	Vehicles	37	38
	Office equipment	4	5
	Computers	26	29
	oonpatolo	20	20
	INTANGIBLE ASSETS - AMORTISATION		
	Computer software	8	4
	ROU AMORTISATION - IND AS 116	120	135
	Total	327	315

Annual Report 2024-25

	(Rs. In Lakhs)			
		For the period	For the period	
		ended	ended	
		March 31st, 2025	March 31st, 2024	
36	OTHER EXPENSES			
	(a) Operating, administrative & other expenses	04	00	
	Consumption of stores and spares	31	30	
	Rent	111	76	
	Rates & taxes	17	21	
	GST/Sales tax	20	62	
	Repairs & maintenance	-		
	Building	7	3	
	Plant & machinery	73	79	
	Others	49	64	
	Insurance charges	16	12	
	Electricity & water	35	35	
	Factory power & fuel	127	117	
	Job-work charges- manufacturing service charges	-	5	
	Tour & travelling expenses	459	431	
	Vehicle running & maintenance	67	67	
	Conveyance expenses	3	4	
	Legal & professional fee	156	187	
	Membership fee & subscription	38	52	
	Office & general expenses	150	117	
	Postage and telegram	2	2	
	Bank Charges	6	11	
	Printing & stationary	15	24	
	Charity & donations	6	22	
	Security expenses	35	44	
	Telephone & telex charges	15	18	
		34	39	
	Laboratory expenses Research & development	22		
			-	
	Investment Expenses	71	84	
	Directors fee	8	13	
	Trade marks	2	20	
	Loss on Sale of Assets	3	-	
	Exchange Rate (Loss)/ Gain	2	1	
	Auditors remuneration [refer note 36(a)]	5	6	
	(b) Selling & distribution expenses			
	Selling expenses	35	17	
	Advertisement & publicity	-	-	
	Business promotion expenses	18	47	
	Bad debt written off		4	
	Provision for doubtful debts	156	-	
	Clearing, forwarding & freight	23	52	
	Rebates & discount allowed	42	62	
	Insurance expenses- goods-in-transit	0	1	
	Handling expenses	1	1	
	Clearing & forwarding agents commission	39	71	
	Royalty Expenses	1	47	
	Total other expenses	1,896	1,947	
26(-)	Details of Auditors' remuneration			
36(a)	Details of Auditors' remuneration		0	
	Audit fee	3	3	
	For other services such as certification	2	2	
	Total Auditor's Remuneration	5	6	

36 (i) In the preceding financial year, the Company did not meet the criteria under Section 135(1) of the Companies Act, 2013, due to the absence of net profits. Hence, the provisions relating to Corporate Social Responsibility are not applicable for the current year.

(Rs. In Lakhs)				
Par	ticulars	3	Year ended March 31, 2025	Year ended March 31, 2024
37	TAX	EXPENSE		
	(a)	Current tax		
		Tax on profits for the year	135	
		Adjustments for prior periods		
		Total current tax expense	135	0
	(b)	Deferred tax		
		Opening Deferred Tax Liability	96	84
	Add:	Deferred Tax Liability on account of:		
		Change in WDV value of Fixed Assets	156	126
		Tax on Actuarial Gain on Leave Encashment		
	Less:	Deferred Tax Asset on account of:		
		Provision for Bonus	-21	-8
		Provision for Gratuity	-53	-12
		Provision for LE	-10	-9
		Provisionfor doutbful debts	-40	-1
	Net li	ncrease/ (decrease) in deferred tax liability	32	96
		······································	32	96
	Total	deferred tax expense/(benefit)	-64	12
		tax expense	71	12
	Incon	ne tax adjustments (since income tax payable under MAT - u/s 115JB)	0	0
		ayable under MAT - u/s 115JB	0	0
	Incor	ne tax expense as per Income Tax	71	12
Dowt	iculars	··· ··· ··· ··· ···		
9art 38		ings per Share	March 31, 2025	March 31, 2024
		e earnings per share	62	(99)
a b		earnings per share	62	(99)
		culars	March 31, 2025	March 31, 2024
С	Profit	nciliations of earnings used in calculating earnings per share attributable to the equity holders of the company used in calculating basic earnings	722	(1,234)
	per sl Profit	hare attributable to the equity holders of the company used in calculating diluted	722	(1,234)
	earnii	ngs per share		
	Parti	culars	March 31, 2025	March 31, 2024
d	Weig	hted average number of shares used as the denominator		
		hted average number of equity shares used as the denominator in calculating basic ngs per share	11,66,272	12,51,961
	Adju	stments for calculation of diluted earnings per share:		
		hted average number of equity shares and potential equity shares used as the minator in calculating diluted earnings per share.	11,66,272	12,51,961

39 FAIR VALUE MEASUREMENTS

Financial instruments by category

				(Rs. In Lakhs)	
Particulars	As at 31st	As at 31st March 2025 As a		at 31st March 2024	
	FVOCI	Amortised cost	FVOCI	Amortised cost	
Financial assets					
Investments					
-Equity Investments					
-Subsidiaries					
Fixed Deposits		14		240	
Trade Receivables		3,210		4,181	
Cash and cash equivalents		22		9	
Other Bank Balances		95			
Security deposits		146		-	
TOTAL FINANCIAL ASSETS		3,487	-	4,430	
Financial Liabilities					
Borrowings		2,337		1,432	
Security Deposits		57		71	
Trade payables		2,847		2,070	
Other creditors		478		2,070	
Unclaimed Dividend		7			
Others					
TOTAL FINANCIAL LIABILITIES		5,727		3,572	

(i) Financial assets and liabilities measured at fair value - recurring fair value measurements

Particulars	As 31st March 20	s at 025	As at 31st March 2024
	Leve	el 1	Level 1
Financial Assets at FVOCI			
Investment in equity shares			
Industrial Development Bank of India Limited		4	5
Bank of Baroda		18	21
Total Financial Assets at FVOCI		22	25

(ii) Fair Value Hierarchy

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are:

- (a) recognised and measured at fair value and
- (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an indication about the reliability of the inputs used in determining fair value, the company has classified its financial instruments into the three levels prescribed under the accounting standard.

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices. This includes listed equity instruments that have quoted price. The fair value of all equity instruments which are traded in the stock exchanges is valued using the closing price as at the reporting period.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities, security deposits included in level 3.

(iii) Assets and liabilities which are measured at amortised cost for which fair values are disclosed

All the financial asset and financial liabilities measured at amortised cost, carrying value is an approximation of their respective fair value.

(iv) Significant estimates

The fair value of financial instruments that are not traded in an active market is determined using valuation techniques. The company uses its judgement to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period.

40 Financial risk management

The Company's activities expose it to market risk (i.e., currency risk, interest rate risk and market price risk), liquidity risk and credit risk. This note explains the sources of risk which the Company is exposed to and how the Company manages the risk :

The company's risk management is carried out by a treasury department under policies approved by the Board of Directors, Company Treasury identifies, evaluates and hedges financial risks in close co-operation with the company's operating units. The Board provides principles for overall risk management, as well as policies covering specific areas, such as foreign exchange risk, interest rate risk, credit risk, use of non-derivative financial instruments and investment of excess liquidity.

(A) Market risk

(i) Foreign currency risk

The Company operates internationally and is exposed to foreign exchange risk arising from foreign currency transactions. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities denominated in a currency that is not the respective companies' functional currency.

The exposure of the Company to foreign currency risk is not significant. The position of foreign currency exposure to the Company as at the end of the year expressed in USD are as follows :

		(Rs. In Lakhs)	
Currency	Receivables	Payables	
March 31, 2025			
US Dollar (USD)	0.59		
EURO	0.03		
Net exposure to foreign currency risk	0.62	-	
March 31, 2024			
US Dollar (USD)	2		
March 31, 2023	2	-	
US Dollar (USD)	8	-	
Net exposure to foreign currency risk	8	8	
March 31, 2022			
US Dollar (USD)	4	-	
Net exposure to foreign currency risk	4		

(ii) Interest rate risk

The exposure of the company's borrowing to interest rate changes at the end of the reporting period depends on the mix of fixed rate and floating rate of the borrowings and the expected movement of market interest rate. The status of borrowings in terms of fixed rate and floating rate are as follows:

		(in lakhs)
Particulars	March 31, 2025	March 31, 2024
Variable Rate borrowings	415	413
Fixed Rate borrowings	201	489
Total borrowings	616	902

(iii) Price risk

The company's exposure to equity securities price risk arises from investments held by the company in equity securities and classified in the balance sheet as at fair value through profit or loss. However, company does not have a practice of investing in market equity securities with a view to earn fair value changes gain. As per the company policies, whenever any investment is made by the company in equity securities, the same is made either with some strategic objective or as a part of contractual arrangement. Further, at the reporting date company does not hold material value of quoted securities. Accordingly, company is not exposed to significant market price risk.

(A) Credit risk

Credit risk arises when a counter party defaults on contractual obligations resulting in financial loss to the company.

Trade receivables consist of large number of customers, spread across diverse industries and geographical areas. In order to mitigate the risk of financial loss from defaulters, the Company has an ongoing credit evaluation process in respect of customers who are allowed credit period. In respect of walk-in customers the company does not allow any credit period and therefore, is not exposed to any credit risk.

In general, it is presumed that credit risk has significantly increased since initial recognition if the payments are more than 30-120 days past due on case to case basis.

(ii) Reconciliation of loss allowance provision – Trade receivables

Particulars	Rs in Lakhs
Loss allowance as on 31st March 2023	166
Changes in loss allowance	38
Loss allowance as on 31st March 2024	128
Changes in loss allowance	27
Loss allowance as on 31st March 2025	155

(B) Liquidity risk

The Company has a liquidity risk management framework for managing its short term, medium term and long term sources of funding vis-à-vis short term and long term utilization requirement. This is monitored through a rolling forecast showing the expected net cash flow, likely availability of cash and cash equivalents, and available undrawn borrowing facilities.

 (i) Financing arrangements: The position of undrawn borrowing facilities at the end of reporting period are as follows:

		Rs in Lakhs
Particulars	March 31, 2025	March 31, 2024
Floating rate		
Cash credit/WCTL facility	1,493	188

The bank overdraft and cash credit facilities may be drawn at any time and may be terminated by the bank without notice.

(ii) Maturities of financial liabilities

The table below analyses the company's all non-derivative financial liabilities into relevant maturity based on their contractual maturities. The amounts disclosed in the table are the contractual undiscounted cash flows.

Capital management

(a) Risk management

The company's objectives when managing capital are to safeguard their ability to continue as a going concern, so that they can continue to provide returns for shareholders and benefits for other stakeholders, and maintain an optimal capital structure to reduce the cost of capital.

In order to maintain or adjust the capital structure, the company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

Consistent with others in the industry, the company monitors capital on the basis of the following gearing ratio:

Net debt (total borrowings net of cash and cash equivalents) divided by Total 'equity' (as shown in the balance sheet).

RELATED PARTY TRANSACTIONS 41

(a) LIST OF RELATED PARTIES

- Α. Key Management Personnel of the company and close member of Key Management Personnel of the company 7
- 1 Mr. Abhay Kanoria
- 2 Mr. Uddhav Kanoria
- 3 Mr. Nirbhay Kanoria
- 4 Mr. S Krishnan
- 5 Mr. N Ahmedali (upto 12.08.2024)
- 6 Mrs.Rani Shokeen (from 28.05.2024)

- Mrs.Pallavi Kanoria (Wife of Mr Abhay Kanoria)
- 8 Mr. Rakesh P Kanyadi (upto 07.11.2024)
- 9 Mrs. Sriee Aneetha M
- 10 Mr. Manik Kumar Singh (From 29-07-2024)
- 11 Mr. Rohit Choraria
- 12 Mr. Pradeep V Joshi
- Β. Enterprises which are post employment benefit plan for the benefit of employees
 - i) The Anglo French Drug Co. ESTN Ltd Employee's Gratuity Fund
 - ii) Group Supperannuation Scheme under LIC of India

С. Enterprises in which Key Management Personnel and close member of Key Management personnel have joint control.

- 1 Abhay Kanoria Family Trust
- 2 Broach Textile Mills Ltd. (BTM)
- 3 Ekta Tie-up Pvt. Ltd.
- 4 **GBK Charitable Trust**
- 5 Radha Kesari Spinning Mills Ltd.
- 6 AFD Laboratories Private Limited (Merged with BTM 12 dt:12-06-2024)
- Transactions with Related Parties for the year ended March 31, 2025 (b)

							pees in Lacs)
NA	URE OF TRANSACTIONS		s in which	-	agement	Enterpris	
		Key Management Personnel have Joint		Personnel / Relative of Key Management		are post employment benefit plan for the	
			nave som	-	onnel	benefit of	
		2025	2024	2025 2024		2025 2024	
EXF	PENSES:						
i)	Rent paid						
	Mr. Abhay Kanoria			14	13		
	Mrs.Pallavi Kanoria			14	13		
ii)	Receiving of Services – Administrative, Commercial & Accounting service						
	Binod Kanoria Foundation -Donation paid			5	16		
iii)	Interest Paid						
	Sudarshan Services Ltd	17	35				
	Ninand finance & Properties Pvt Ltd	-	7				
iv)	Remuneration Paid						
	Mr. Abhay Kanoria			85	85		
	Mr. Uddhav Kanoria			58	58		
	Mr. Nirbhay Kanoria			47	47		
	Mrs.Pallavi Kanoria			47	44		
	Mr.Harshwardhan Murarka			-	15		
	Ms. Sriee Aneetha			14	13		
	Mr. Rakesh P Kanyadi			25	30		
	Mr Manik Kumar Singh			18	-		

- 7 Sudarshan Exports Ltd. (Merged with BTM dt. 12.06.24)
 - 8 Ninaad Finance & Properties Pvt.Ltd. (Merged with BTM dt:12.06.2024)
 - 9 Shri Binod Kanoria Foundation
 - **Dormirbien Private Limited** 10
 - 11 Sudarshan Services Limited
 - AFD Pharma Private Limited (Merged with BTM dt 12-06-2024)



NAT	URE OF TRANSACTIONS	Enterprises in which Key Management Personnel have Joint Control		Personnel of Key Ma	agement I / Relative nagement onnel	(Rupees in Lacs) Enterprises which are post employment benefit plan for the benefit of employees		
		2025	2024	2025	2024	2025	2024	
V)	Director`s sitting fees Mr. Sanatkumar Shirali Ms.Neha Rajen Gada Mr. N Ahmedali Mr. Rohith Choraria Mrs. Girija Subramanian Mrs. Jayashree Vijay Ranade			- 1.20 1.20 -	2.80 3.20 1.00 0.20 1.00			
	Mr. Rakesh P Kanyadi Mr. Pradeep V Joshi Mr. Srinivasa Krishnan			0.80 2.20 2.60	1.40			
vi)	Interest Received Dormirbien Pvt Ltd	33	-					
INC	OME:							
i)	Rent Received Dormirbien Pvt Ltd	0.54						
ОТН	IER RECEIPTS:							
i)	Inter Corporate Deposit Received Ninaad Finance & Properties Pvt.Ltd	0	80					
ii)	Inter Corporate Deposit Paid Dormirbien Pvt Itd	752	0					
The Emp	Atribution of Gratuity Fund Anglo French Drug Co. ESTN Ltd ployee's Gratuity Fund					-	-	
The	und of Gratuity Anglo French Drug Co. ESTN Ltd ployee`s Gratuity Fund					67	60	

Outstanding Balances as on March 31, 2025

NATURE OF TRANSACTIONS		E OF TRANSACTIONS E OF TRANSACTIONS Key Management Personnel have Joint Control		Personne of Key Ma	agement I / Relative inagement onnel	(Rupees in Lacs) Enterprises which are post employment benefit plan for the benefit of employees	
		2025	2024	2025	2024	2025	2024
PA)	ABLES :						
i)	Inter Corporate Deposit						
	Sudarshan Services Ltd	112	232				
	Ninaad Finance & Properties Pvt Ltd	-	-				
Rec	eivables:						
i)	Inter Corporate Deposit						
	Dormirbien Pvt Itd	752	-				
LO	ANS & ADVANCES AND RECEIVABLES:						
i)	Security Deposit						
	Mr. Abhay Kanoria	12	12				
ii)	Security Deposit Received						
	Dormirbien Pvt Itd	0.50	-				

42 The company had contingent liabilities at March 31, 2025 in respect of:

A (a) Claims against the Company pending appellate/judicial decisions not acknowledged as debts :

		(Rs. In Lakhs)
Particulars	March 31, 2025	March 31, 2024
Value Added Tax/Sales Tax	20	57

- a. The Management believes that the outcome of the above will not have any material adverse effect on the financial position of the company.
- b. The Company does not expect any reimbursements in respect of the above contingent liabilities.
- c. The assessed tax liability is ₹ 20 lakhs towards Value added tax / sales tax are under dispute as at March 31, 2025 based on the favourable decision of the Appellate Authorities and the interpretation of the other relevant provisions, the Company has been advised that the demand raised by the Department may not crystallise into a potential obligation. Accordingly, no provision is considered necessary.
- e. It is not practicable to estimate the timing of cash outflows, if any, in respect of matters above pending resolution of the arbitration / appellate proceedings. Further, the liability above excludes interest and penalty in cases where the company has determined that the possibility of such levy is remote.

(b) Guarantees :

- i. Counter guarantees issued to banks and remaining outstanding INR 4.85 Lakhs (FY 2023-24 INR 20.26 Lakhs).
- ii. Letter of credit opened and remaining outstanding is NIL (FY 2023-24 NIL)

(c) Capital Commitments - Nil

B Additional Regulatory Information

- (i) The Company does not have any benami property, where any proceeding has been initiated or pending against the Company for holding any benami property.
- (ii) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (iii) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (ultimate beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
- (iv) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.
- (v) The Company does not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.
- (vi) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.
- (vii) The Company is not declared wilful defaulter by and bank or financials institution or lender during the year.
- (viii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period
- Quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in agreement with the books of accounts.
- (x) The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was obtained.
- (xi) The title deeds of all the immovable properties, (other than immovable properties where the Company is the lesse and the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in property, plant and equipment and capital work-in progress are held in the name of the Company as at the balance sheet date.
- (xii) The Company does not have any transactions with companies which are struck off



43 Leases

Applicability of Ind AS 116 - As a lessee

Ind AS 116 on "Leases" is mandatory for reporting periods beginning on or after 1st April, 2019 as notified by the Ministry of Corporate Affairs (MCA) vide Companies (Indian Accounting Standards) Rules, 2015 as amended, replacing the existing lease rental recognition criteria. The application of Ind AS 116 has impacted the company's accounting for recognition of leases payments.

Under this standard, amortisation cost and Finance cost have decreased by Rs 15 lakhs and Increased by Rs 10 lakh respectively and corresponding yearly rent has increased by Rs 35 lakhs. The single accounting model introduced by Ind AS 116 recognises a right-of-use asset amounting to Rs 409 lakhs representing its right to use the underlying assets and a lease liability of the Rs. 436 Lakhs representing its obligation to make lease payments.

The following are the leasing arrangements entered into by the Company which has been considered for IND AS 116.

Sr.	Location	Name of Land Lord	Period		Deposit	Rent P.M.	Rent for One
No			From	То			Year
1	Mumbai Office	The Phoenix Mills Limited	01.04.2024	31.03.2025	45,80,180.00	7,74,510.00	92,94,120.00
2	Mumbai Guest House	Minoo Arjandas Melwani	01.08.2023	31.07.2024	12,00,000.00	4,41,000.00	52,92,000.00

During the year, rental payments were made for the Pebble Bay Guest House under lease agreements with a term of less than 12 months. In accordance with Ind AS 116 – *Leases*, these payments have not been recognised as lease liabilities and have been accounted for as Rental expenses in the Statement of Profit and Loss.

Recent Pronouncements :

Ministry of Corporate Affairs (MCA) notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standard) Rules, as issued from time to time. For the year ended March 31, 2025, MCA has notified IND AS 117 Insurance Contracts and amendments to IND AS 116 – Leases, relating to sale and leaseback transactions, applicable to the Company w.e.f April 1, 2024. The Company has reviewed the new pronouncements and based on its evaluation has determined that it does not have any significant impact in its financial statements.

44 (a) Details of Raw Materials Consumed

Description	Units	Current	/ear	Previous Year		
		Quantity	Amount	Quantity	Amount	
PHARMACEUTICALS						
Paracetamol IP& BP	Kgs	1,26,010	353	1,10,417	357.6866015	
Riboflavin IP & BP	Kgs			5,161	225.0251702	
Thiamine Hcl USP	Kgs	9,433	241			
Miscellaneous			1,237		1,816	
(None individually account for more than 10% of total consumption)						
			1,831		2,399	

(b) Value of Raw Materials Stores and Spare Parts consumed:

(in Lakhs)							
Des	cription	Curre	nt Year	Previou	us Year		
		Amount	%	Amount	%		
a)	Raw Materials:						
	Imported			9	0		
	Indigenous	1,831	100	2,390	100		
		1,831	100	2,399	100		
b)	Stores and Spare Parts						
	Imported	0	0	0			
	Indigenous	13	100	10	100		
		13	100	10	100		

(c) Purchase of Stock -in-Trade

						(in Lakhs)	
Description		Units	Curren	it Year	Previous Year		
			Quantity	Amount	Quantity	Amount	
Forr	nulations:						
a)	Tablets	Million	218	2,015	231	1,983	
b)	Liquids	Bottles	98,18,071	1089	84,37,382	943	
c)	Injections	Litres	9,023	140	9,200	110	
d)	Injections	Kgs	946	187	1,326	242	
e)	Capsules	Million	56	459	38	369	
f)	Granules	Kgs	1,307	5	1,136	9	
g)	Powder	Kgs	92,660	114	1,02,189	141	
h)	Ointment	Kgs	32,168	166	29,474	142	
i)	Others	Nos.	11,39,056	366	4,11,141	24	
j)	Gel	Litres	2,444	9	2,987	12	
				4,550		3,975	

(d) Value of Imports on CIF basis

Description		Currei	nt Year	Previous Year		
		USD	Rs. In lakhs	USD	Rs. In lakhs	
i)	Raw Materials	-	-	-	-	
ii)	Components and Spare Parts	-	-	-	-	
	Expenditure in Foreign Currency	52,909	45	87,398	73	
F.O.B Value of Exports						
In Foreign Currency		1,09,641	91	10,51,917	869	

45 Operating Segment

The Holding Company has only one reportable segment i.e. pharmaceticals

		(Rs. In Lakhs)
Particulars	March 31, 2025	March 31, 2024
Information about Geographical Areas:		
Revenue from customers		
In India	8,517	8,601
Outside India	93	895

46	Research and Development Expenses	(Rs. In Lakhs)		
	For the period ended	March 31, 2025	March 31, 2024	
	Material Consumption	3	5	
	Labortary consumption	29	8	
	Employee Benefits Expense	20	14	
	Others	1	1	
		53	28	

47 Revenue Recognition as per Ind AS 115

- i The Company derives revenues primarily from sale of pharmaceutical products and scrap from its contracts with customers. The revenues have been disclosed in Note No.28 "Revenue from Operations
- ii The disaggregation of revenues is as under:

	(Rs. In Lakhs)				
Nature	March 31, 2025	March 31, 2024			
Revenue from contracts with customers					
Revenues from sale of goods	8,610	9,496			
Revenues from sale of scrap	8	6			
(Other operating income)					
	8,618	9,501			

iii. The revenues are further disaggregated into revenues from domestic as well as export market as follows :

(Rs. In Lakh						
Nature	March 31, 2025		March 31, 2024			
	Domestic	Exports (including Deemed Exports)	Domestic	Exports (including Deemed Exports)		
Revenue from contracts with customers						
Revenues from sale of goods	7,178	1,432	7,452	2,044		
Revenues from sale of scrap	8	0	6	0		
(Other operating income)	160					
	7,346	1,432	7,457	2,044		

iv. The movement in Company's receivables, contract assets and contract liabilities are as under:

Nature	Contract Asset	Contract Liabilities
Balance as at the beginning of the year	15	30
Additions	6.50	13
Adjustments	15	30
Balance as at the end of the year	6.50	13

v. The revenue from contracts with customers for the year also includes the impact of customers' right to return the goods of Rs. 13 Lakhs. The same has been deducted from the transaction price. The corresponding cost of materials to be returned to the company amounting to Rs. 6.50 Lakhs has been adjusted with the cost of consumption. The corresponding refund liability and right to recover an asset have been recognised in the financial statements.

48 Critical judgements in applying accounting policies

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosures of contingent liabilities. Uncertainties about these assumptions and estimates could result outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Key Assumptions:

The key assumptions concerning the future and other key estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

a) Estimated useful life of tangible and intangible assets:

The Company has estimated the useful life based on useful life as specified in Schedule-II to the Companies Act, 2013. The Management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used. The estimated useful life and residual values are reviewed at the end of each financial year and if necessary, changes in estimates are accounted. Property, plant and equipment represent a significant proportion of the asset base of the Company. The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of Company's assets are determined by the management at the time the asset is acquired and reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life, such as changes in technical or commercial obsolescence arising from changes or improvements in production or from a change in market demand of the product or service output of the asset.

b) Inventory :

Reviews are made periodically by the management on damaged, obsolete and slowmoving inventories. These reviews require judgement and estimates. Possible changes in these estimates could result in revisions to the valuation of inventories.

Inventories are stated at the lower of cost and net realisable value. Demand levels, exchange rates, technological advances and pricing competition could change from time to time. The company estimates the net realisable value of inventories based on an assessment of sales prices.

The Company's management conducts physical verification of inventories during the year at reasonable intervals. Management was able to perform year end physical verification of inventories, during Mar 24. Management has carried out procedures to validate the existence of its inventory to determine the quantities and value of the inventory at the balance sheet date.

c) Trade Receivable :

The collectibility of receivables is assessed on an on going basis. An allowance for doubtful debts is made for any account considered to be doubtful of collection and also .

Allowance for doubtful debts is made based on a review of all outstanding accounts as at the balance sheet date. A considerable amount of judgement and estimate is required in assessing the ultimate realisation of these receivables, including the creditworthiness, the past collection history of each customer and subsequent collection up to date of report. If the financial conditions of customers of the company were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

d) Impairment of Trade Receivable:

The impairment provision for financial assets is based on the assumption about risk of default and expected loss rates. The Company uses judgments in making these assumptions and selecting the input impairment calculation based on the Company past history as well as forward looking assumptions at the end of each reporting period.

e) Defined Benefit Obligation:

The costs of providing pensions and other post-employment benefits are charged to the Statement of Profit and Loss in accordance with Ind AS 19 'Employee benefits' over the period during which benefit is derived from the employees' services. The costs are assessed on the basis of assumptions selected by themanagement. These assumptions include salary escalation rate, discount rates, expected rate of return on assets and mortality rates. The same is disclosed in Note 23, 'Employee benefits'

f) Fair value measurement :

Fair value measurement of financial instruments When the fair values of financials assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques, including the discounted cash flow model, which involve various judgements and assumptions.

g) Current Tax :

The computation of advance taxes, provision for current/deferred tax are made based on significant judgments and which may get revised pursuant to position taken by the tax authorities.

h) Provision and Contingent Liabilities :

The Company exercises judgement in measuring and recognising provisions and the exposures to contingent liabilities related to pending litigation or other outstanding claims subject to negotiated settlement, mediation, arbitration or government regulation, as well as other contingent liabilities (see note 42 to the financial statements). Judgement is necessary in assessing the likelihood that a pending claim will succeed, or a liability will arise, and to quantify the possible range of the financial settlement. Because of the inherent uncertainty in this evaluation process, actual losses may be different from the originally estimated provision.



Note No 49

Financial Ratios

Particulars	Numerator	Denominator	Ratios		Variance	Change in ratio in excess of 25%	
			For the year ended 31st March 2025	For the year ended 31st March 2024	%	compared to preceeding year	
Current Ratio (in times)	Current Assets	Current Liabilties	2.85	5.51	(48.23)	On account of utilisation of funds from investment for various activities (buyback, Dividend & Tax thereon); Use of Short term Borrowings for Operational purpose.	
Debt Equity Ratio (in times)	Total Borrowings (Non current+Current)	Total Equity	0.15	0.05	188.67	On account of use of Short term Borrowings for Operationalpurpose and utilization of Equity Funds towards Buyback and incidental Expenses.	
Debt Service Coverage Ratio (in times)	Porfit before tax+Depreciation and amortisation expenses+Interest on term loans and debentures	Interest on debentures + Interest on term loans + Scheduled principal repayments of term loans and debentures (i.e. excluding prepayments and refinancing of debts) during the year	9.50	(5.15)	(284.50)	On Account of Profit Earned during the year and reduction of Finance Cost.	
Return on Equity Ratio	Net Profit after tax	Average Networth	0.01	(0.02)	(175.11)	On Account of Profit Earned during the year.	
Inventory Turnover Ratio	Fuel Cost + Stores & Spares Consumed+ Purchase of stock-in-trade	Average inventory	5.91	6.79	13.03	On Account of conscious efforts to reduce overstocking and improve working capital efficiency.	
Debtors Turnover Ratio	Revenue from operations	(Average Trade Receivables + Average unbilled revenue) * No of days in the reporting year	2.38	1.89	(25.96)	On Account of Collection from Debtors.	
Payables Turnover Ratio	Average Trade payables * No of days in the reporting year	Cost of goods sold	0.36	0.28	26.69	On Account of Increase in Creditors.	
Net Capital Turnover (in times)	Revenue from operations	Working Capital	0.84	0.60	40.65	On account of Efficient use of Creditors and Debtors Management.	
Net Profit Margin (%)	Net profit for the year	Total Income	0.06	(0.13)	(147.51)	On Account of Profit Earned during the year.	
Return on Capital Employed (%)	Profit before tax plus Interest on long term loans and debentures	Net worth + Total borrowings + Deferred Tax	0.06	(0.06)	(207.36)	On Account of Profit Earned during the year.	

Note No 50

These financial statements have been adopted by the Board in its meeting dated 2nd May 2025

The accompanying notes form an integral part of the financial statements

As per our report of even date attached

For KAMG & ASSOCIATES Chartered Accountants Firm's Registration Number 311027E

CA Amitabha Niyogi

Partner M.No.:056720 UDIN: 25056720BMJTAK9365

Date: 2nd May 2025 Place: Bengaluru For and on behalf of the Board of Directors of Anglo French Drugs & Industries Limited

Pradeep Vasantrao Joshi Director DIN: 02713934 Nirbhay Kanoria Managing Director DIN : 02558300 Uddhav Kanoria Managing Director DIN : 00108909

Manik Kumar Singh Chief Financial Officer Sriee Aneetha M Company Secretary



Anglo-French Drugs & Industries Limited

Plot no.4, Phase II, Peenya Industrial Area, Peenya, Bengaluru 560058.